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A B S T R A C T 
According to the World Health Organization a third of the world's population is 
infected with Mycobacterium tuberculosis. The unparalleled success of M. 
tuberculosis as a pathogen reflects the bacterium's extraordinary ability to persist 
in its host in spite of eliciting a robust immune response. Currently available 
treatment is inadequate and drug resistance is rapidly spreading. New antibiotics 
are desperately needed. The substrates and metabolic pathways utilized by 
pathogens during infection are largely unknown and represent an under-exploited 
area of investigation. Uniquely, evolution of the genus Mycobacterium has 
involved extensive duplication of fatty acid metabolism genes, including two 
homologs encoding prokaryotic- and eukaryotic-like isoforms of the glyoxylate 
cycle enzyme isocitrate lyase (ICL). The glyoxylate cycle is employed by cells 
when fatty acids are the main carbon source available. Here, we show that these 
enzymes are jointly required by M. tuberculosis for growth on fatty acids and for 
virulence in experimental infections. Although deletion of icll or icl2 had little 
impact on replication of M. tuberculosis in macrophages and mice, deletion of 
both genes abrogated intracellular growth, and resulted in rapid bacterial clearance 
from the lungs. A dual-specificity ICL inhibitor similarly blocked replication of 
M. tuberculosis on fatty acids in vitro and in macrophages. The absence of ICL 
orthologs in mammals, and recent findings implicating the glyoxylate pathway in 
the virulence of other bacterial and fungal pathogens makes this metabolic 
pathway an attractive novel target for drug development. 
A Roxana Elias, mi madre, por su infinita abnegation y amor... 
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" W h e n m e n lack a sense of awe, there will be disaster." 
Lao Tsu 
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P A R T I 
C H A P T E R 1 
Bacterial Persistence: Strategies for Survival 
INTRODUCTION 
Most bacteria cause acute infections that cannot withstand the onslaught of the 
host's adaptive immune response. Less commonly, some bacteria such as 
Salmonella typhi and Mycobacterium tuberculosis cause infections that persist, 
often for the lifetime of the host. Persistence is responsible for the unusual 
epidemic characteristics of diseases like tuberculosis. A relevant metric is the 
"critical community size" (CCS) required for endemicity. The theoretical and 
observed CCS for measles virus is a staggering 250,000 individuals; in smaller 
populations, measles self-extinguishes after exhausting the pool of naive 
susceptible hosts (Keeling & Grenfell 1997; Keeling, 1997). Human populations 
on this scale have existed for only a few thousand years, suggesting that measles is 
a newcomer to the human niche. This view is supported by field studies of 
epidemiologist Francis Black, who found that imported measles did not persist in 
small, isolated human populations — e.g., in the South American Amazon basin 
1 
(Black, 1975). In contrast, tuberculosis was endemic in many of these smaller 
communities. Modeling studies put the CCS for tuberculosis at less than 500 
individuals (McGrath, 1988), perhaps explaining its antiquity as a human disease 
(Daniel et al. 1994; Haas & Haas 1996). Persistence is also reflected in the 
contrasting epidemic dynamics of diseases caused by persistent and non-persistent 
pathogens — e.g., measles epidemics wax and wane over wks or months (Fig. 
1.1 A) (Keeling, 1997), whereas tuberculosis epidemics span centuries (Fig. LIB) 
(Grigg, 1958; Blower etal, 1995). 
M. tuberculosis is not unique in its ability to cause persistent infections. 
Indeed, the roster of persistent pathogens continues to lengthen as technological 
advances allow the identification of previously unknown species. An important 
example is the recognition that gastritis, gastric and duodenal ulcers, and gastric 
neoplasms and lymphomas are often linked to colonization of the human stomach 
by Helicobacter pylori (Dubois et al., 2000). Via mechanisms that are only partly 
understood, this Gram-negative spiral bacterium has evolved to exploit a niche 
that was assumed to be devoid of microbial life. This is a remarkably successful 
strategy — by current estimates, the stomachs of half the global human population 
harbor H. pylori, often for the lifetime of the host (Blaser & Atherton, 2004). As 
the list of persistent pathogens grows, so does our appreciation of the diversity and 
sophistication of the mechanisms that allow these microbial invaders to survive 
"in the face of opposition or adversity." A comprehensive survey of persistent 
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Fig. 1.1 Contrasting epidemic dynamics of measles and tuberculosis. (A) Simulation of a measles 
epidemic initiated by entering one infectious case at time zero into a susceptible population of 
500,000. The simulation illustrates successive waves at -6-12 month intervals (Keeling, 1997). (B) 
Simulation of a tuberculosis epidemic initiated by entering one infectious case at time zero into a 
population of 200,000. It illustrates the relative contribution of 3 types of disease to the overall 
incidence: progressive primary, post-primary, and relapse tuberculosis. A fourth type, exogenous 
reinfection (not included), presumably would increase the peak level and duration of the epidemic. 
Redrawn from Blower et al. (1995). The contrasting epidemic dynamics of measles and tuberculosis 
are also reflected in the "critical community size" (CCS) required for endemicity, which is roughly 
250,000 for measles (Keeling, 1997) and 500 or less for tuberculosis (McGrath, 1988). 
bacterial pathogens is beyond the scope of this chapter, which will focus on a few 
organisms as paradigms of persistence strategies. 
1.1. Treponema pallidum — Why run if you can hide? 
Several spirochetes of the genus Treponema cause persistent infections in humans, 
including Treponema pallidum, the etiologic agent of syphilis. Spirochetes are a 
phylogenetically distinct group of prokaryotes with an outer membrane and a 
periplasmic space, similar to the Gram-negatives; however, the outer membrane of 
treponemes has a higher lipid:protein ratio and lacks the pro-inflammatory 
constituent lipopolysaccharide (LPS) (Radolf et al, 1989; Radolf, 1995). The 
periplasmic space contains the flagella of these highly motile, slender, and 
elongated "corkscrew" bacteria. Syphilis was first recognized in the late fifteenth 
century after the first European explorers returned from the Americas, where the 
disease was probably endemic (Quetel, 1990). When syphilis first erupted in 
Europe, it was highly virulent and usually fatal. As the spirochete spread 
throughout Europe it was rapidly attenuated, and a milder, more chronic form of 
disease became dominant. Why? It may be that the attenuated strains were 
favored because the horrific manifestations of the early, virulent form of syphilis 
were a deterrent to sexual transmission. It is also tempting to speculate that 
attenuated treponemes enjoyed a selective advantage because prolonged survival 
of the infected host ensured greater opportunity for transmission. Field evidence 
in favor of this idea derives from the epidemic of myxomatosis that was 
introduced into the feral rabbit population of Australia in 1950/51 (Fenner & 
Fantini, 1999). Following an initial period of high host mortality, attenuated 
strains of myxoma virus emerged and became dominant. Rabbits infected with 
attenuated viruses were protected against superinfection with the virulent parental 
virus, and, because they lived longer and were more active, dissemination of the 
attenuated strains was favored. 
The incidence of syphilis has declined steeply since the introduction of 
penicillin in 1943. However, the disease continues to pose a significant health 
problem worldwide. The steady decline in the incidence of syphilis from 1991 to 
the present in the United States should not necessarily be interpreted as a victory 
for public health because syphilis epidemics display naturally periodic dynamics 
with approximately ten-year cycles. Recently, these cycles, which previously had 
been attributed to changes in "environmental" factors such as sexual behavior, 
have been shown to be due to intrinsic host immunity-pathogen interactions 
(Grassly et al, 2005). The immunity that follows syphilis, though imperfect, 
allows for exhaustion of susceptible individuals after an epidemic, leading to a 
decline in incidence (Morgan et al, 2003). However, this period is typically 
followed by a surge in the number of cases as a new supply of susceptible 
individuals becomes available. The periodic dynamics of syphilis epidemics 
underscores the need for unceasing vigilance in case detection and treatment 
(Garnett & Brunham, 1999). 
Syphilis is a slowly progressing, multistage disease (Singh & Romanowski, 
1999). Infection is transmitted horizontally by sexual contact and vertically by 
transplacental migration of treponemes. During sexual intercourse, spirochetes 
present in the genital tract of the donor invade the recipient through small 
abrasions in the mucous membranes or skin of the genitalia. Replication of the 
organism at the site of entry triggers massive leukocyte infiltration, blood vessel 
damage, and tissue necrosis, resulting in the appearance of a primary lesion or 
"chancre." In most patients, the chancre heals spontaneously after a few weeks 
and disease progression is arrested. In the less fortunate minority, dissemination 
from the primary lesion occurs a few weeks after initial infection, leading to 
generalized infection of almost every tissue of the body, with a notable tropism for 
the vascular system. The onset of secondary syphilis is marked by the appearance 
of nodular lesions or papules at these metastatic sites of infection. In most cases 
of primary and secondary syphilis, infection is resolved spontaneously by the 
adaptive immune response usually in less than 6 months post-exposure (Garnett et 
al, 1997). However, small populations of treponemes may persist in a few 
isolated lesions and eventually give rise to tertiary syphilis, a chronic disease that 
usually endures for the lifetime of the host. Treatment of primary or secondary 
syphilis with penicillin is highly effective, but once disease progresses to the 
tertiary or latent stages it becomes refractory (Ghinsberg & Nitzan, 1992). Tertiary 
syphilis is characterized by the persistence of mature granulomatous lesions 
("gummas") containing small numbers of spirochetes. Gummas may occur in 
almost any organ system, causing gradual physiological deterioration. Persistent 
infection of the CNS can lead to destruction of neural tissue, loss of motor activity, 
and paresthesia, as in the jerking movements and paroxysmal pains that are 
characteristic of tabes dorsalis (sclerosis of the posterior columns of the spinal 
cord). Gummas occurring in other regions of the CNS may give rise to the most 
dreaded manifestations of syphilis — insanity and generalized paralysis. It is not 
clear how treponemes damage tissues. No bacterial toxins have been identified, 
and it is possible that the pathology is due to chronic inflammatory host responses 
to persistent spirochetes. 
In the pre-chemotherapy era, longitudinal studies of untreated syphilis 
revealed that the great majority of patients do not progress beyond the primary 
stage (Gjestlaand, 1955), and reinoculation studies established that syphilitic 
patients were partially protected against reinfection (Fitzgerald, 1981). Both 
humoral and cellular adaptive immune responses play a role in resistance to T. 
pallidum (Rich et al, 1933). Passive immunization of rabbits with immune serum 
before infection with T. pallidum delays the appearance of syphilitic lesions and 
attenuates their severity (Bishop & Miller, 1976a), and resistance to re-infection is 
correlated with the appearance of anti-treponemal antibodies (Bishop & Miller, 
1976b). Antibodies from immune rabbit serum promote complement-mediated 
killing of treponemes (Blanco et al, 1984) and block the interaction of T pallidum 
with extracellular matrix components (fibronectin, laminin, and collagen), which 
could interfere with the invasion and dissemination of spirochetes (Fitzgerald et 
al, 1984). Syphilitic patients typically develop IgM and IgG responses to a slew 
of treponemal antigens (Baker-Zander et al, 1985). 
A role for cellular immunity is suggested by the dramatic infiltration of 
lesions by mononuclear leukocytes, which occurs as early as one week post-
infection in the rabbit model (Lukehart et al, 1980a; Sell et al, 1980). The 
cellular infiltration peaks by two weeks post-infection and is composed 
predominantly of mononuclear phagocytes and T cells, with Treponema-specific T 
cells emerging early in the course of infection (Lukehart et al, 1980b; Baker-
Zander et al, 1988; Arroll et al, 1999). Lesions of syphilitic patients contain 
activated CD8+ cytolytic T lymphocytes (van Voorhis et al, 1996a) and show 
evidence of a dominant type-1 CD4+ T cell cytokine response — i.e., IFN-y, IL-
12, and IL-2, but not IL-4 (van Voorhis et al, 1996b). Activation of macrophages 
by type 1 cytokines is thought to be important for treponemal clearance and lesion 
resolution (Sell et al, 1980; Lukehart et al, 1980a; Lukehart, 1982). Degraded 
treponemes are found inside the phagolysosomal compartments of infiltrating 
macrophages in regressing syphilitic lesions (Ovcinnikov & Delektorskij, 1972), 
and rabbit peritoneal macrophages are capable of phagocytizing and killing 
treponemes in vitro (Lukehart & Miller, 1978; Baker-Zander & Lukehart, 1992), 
particularly in the presence of opsonizing antibodies (Baker-Zander et al, 1993). 
However, both opsonized and non-opsonized treponemes are unusually resistant to 
phagocytosis by macrophages, which presumably enhances bacterial survival in 
inflammatory lesions (Alder et al, 1990; Lukehart et al, 1992). 
In the rabbit model of syphilis, long-lasting immunity to T. pallidum does 
not develop until about three months post-infection, and fails to develop altogether 
if the course of infection is interrupted by antibiotic therapy (Fitzgerald, 1981). 
Although adaptive immunity curtails further disease progression, sterilization does 
not occur, and "immune" animals continue to harbor viable treponemes 
indefinitely. There is a clear parallel to human disease, in which tertiary syphilis 
may occur years or decades after initial infection. Two key questions arise: why 
does acquired immunity develop so slowly in syphilis, and why is the pathogen 
not eliminated? Poor immunogenicity and immune evasion by treponemes may 
provide partial answers. 
Persistent treponemes harvested from rabbits at later stages of infection, 
after >99% of the bacteria have been cleared, are less susceptible to phagocytosis 
by macrophages (Lukehart et al, 1992), suggesting that persistent infection may 
be due to a subpopulation of treponemal persistent bacteria that evade 
opsonization and phagocytosis. It has been suggested that this type of bacteria 
might adopt a "stealth" strategy in vivo, altering their surface composition in order 
to reduce their antigenicity (Radolf, 1994). Indeed, ultrastructural studies reveal 
that the outer membrane of T. pallidum is largely devoid of membrane-associated 
proteins (Radolf et al, 1989), and intact treponemes are poorly reactive with 
immune rabbit serum unless the outer membrane is removed or damaged (Cox et 
al, 1992). A number of cell wall-associated T. pallidum lipoprotein antigens have 
been identified, but these are apparently localized to the inner (plasma) membrane 
rather than the outer membrane (Radolf, 1994; Radolf, 1995). 
T. pallidum is a highly invasive pathogen (Haake & Lovett, 1990), so the 
paucity of surface-exposed proteins begs the question, what are the ligands that 
allow the organism to attach and invade after entering the host? These presumably 
surface-exposed bacterial components are likely targets of the adaptive immune 
response. Two proteins termed Trompl and Tromp2 (^Treponema pallidum rare 
outer membrane proteins") were identified by freeze-fracture electron microscopy 
(Blanco et al, 1997). Although localization of Tromps to the outer membrane is 
disputed (Akins et al, 1997), anti-Tromp antibodies are treponemicidal and 
correlate with protective immunity in rabbits (Lewinski et al, 1999). The 
sequence of the T. pallidum genome reveals another group of potentially surface-
exposed molecules comprising a novel twelve-member gene family termed tpr 
{"Treponema pallidum repeat") (Fraser et al, 1998). The Tpr proteins contain 
central domains of variable length and sequence flanked by conserved N- and C-
terminal domains, including conserved hypothetical transmembrane domains in 
some family members. One of these, TprK, is surface-exposed and targeted by the 
protective immune response in rabbits (Centurion-Lara et al, 1999). Antiserum 
from rabbits that are immunized with TprK is opsonizing for phagocytosis and 
TprK-immunized animals are partially protected against challenge with virulent 
treponemes. The role of the Tpr proteins in treponemal pathogenesis is not 
known, but these studies suggest that they could be attractive subunit candidates 
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for a vaccine. Strain differences in tprK copy number and sequence have been 
identified, suggesting that variation of TprK might contribute to immune evasion 
(Centurion-Lara et al, 2000). Possibly, the advent of a subpopulation of antigenic 
variants during infection could account for the failure of adaptive immunity to 
eliminate small numbers of persistent bacteria, resulting in the prolonged periods 
of latency that can be observed during syphilis. 
1.2. Borrelia spp. — Antigenic variation: a change of face wins the race 
Many microbial pathogens control gene expression by programmed 
rearrangements of specific DNA sequences (Borst & Greaves, 1987). These 
"contingency loci" (Moxon et al, 1994) affect processes at the host/pathogen 
interface, including colonization, invasion, adaptation to different tissue 
environments, and evasion of immune defenses (Deitsch et al, 1997). 
Programmed rearrangement of genes encoding surface antigens ("antigenic 
variation") is essential for the evasion of humoral immunity by extracellular 
pathogens such as the Borrelia spp. that cause relapsing fever and Lyme disease. 
1.2.1. Relapsing fever. Relapsing fever (RF) is characterized by recurrent febrile 
episodes, which correspond to intervals of high bacteremia (Fig. 1.2A) (Barbour & 
Hayes, 1986). The causative agents are arthropod-transmitted spirochetes of the 
genus Borrelia. The RF borrelias persist at titers of up to ~108 bacteria per ml of 
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Fig. 1.2. Antigenic variation in Relapsing Fever and Gonorrhoeae. (A) Relapsing Fever. Spikes of 
fever are accompanied by waves of spirochetemia. In each successive wave, a new antigenic variant 
dominates (indicated by different shapes). As the bacteria are cleared by the specific humoral 
response, the fever subsides. However, expansion of a newly emergent variant brings about another 
febrile episode within a few days. (B) Antigenic variation of pili in Neisseria gonorrhoeae. Pilin is 
encoded by one or two pilE expression loci. Variant pilin sequences are stored in silent pilS cassettes, 
which lack the 5' coding and promoter sequences required for expression. Nonreciprocal 
recombination between pilS and pilE sequences gives rise to expression of variant pilin subunits. 
Modular recombination can generate mosaic pilE loci containing sequences derived from several 
distinct pilS loci. 
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blood, which ensures transmission of the pathogen to the insect vector during a 
blood meal. However, extracellular bacteria residing in the blood are exposed to 
the onslaught of the humoral immune response; survival in this perilous 
environment requires the pathogen to keep one step ahead of the host, which the 
RF borrelias accomplish by means of antigenic variation (Barbour, 1990). 
Referring to the spirochete-specific antibodies generated during an episode of RF, 
Meleney (1928) wrote: "These substances [antibodies] are specific for the strain of 
spirochetes which was present during the preceding attack, but have no influence 
on the spirochetes of the succeeding relapse. The spirochetes of the relapse give 
rise, in turn, to immune substances which are specific for them but not for the 
spirochetes of the first attack." A key question was whether a single bacterium 
could give rise to the observed waves of variants, or whether relapses were due to 
simultaneous infection with a mixture of variants that were expanded and 
eliminated in succession. This issue was resolved by infection of rats with a single 
bacterium (B. turicatae) and recovery of antigenically distinct relapse populations 
(Fig. 1.2A) (Schuhardt & Wilkerson, 1951). The population dynamics of borrelial 
antigenic variation were clarified by the application of serotype-specific immune 
sera to identify relapse isolates of B. hermsii, which arose at frequencies of ~ IO"3 
to IO"4 per generation (Stoenner et al, 1982). Only a small proportion of the 
spirochete population converted to other serotypes; this switch was abrupt and 
coincided with the clearance of the dominant (parental) population. Given the 
high rate at which serotype switching occurred, it was (and still is) puzzling that 
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only one or a very small number of serotypes were found in each relapse. 
Inhibition of antibody production had no effect on the emergence of serotype 
variants, demonstrating that humoral immunity was not driving the generation of 
new spirochete serotypes, but merely selecting against pre-existing types. The 
serotype-specific antibodies responsible for spirochete clearance recognize a 
family of surface-exposed and serotype-specific lipoproteins, the "variable major 
proteins" (VMPs) (Barbour et al, 1982). 
The high-frequency variation of VMPs was later shown to result from 
programmed rearrangements of the vmp genes (Meier et al, 1985). The DNA 
sequences encoding a serotype-specific VMP variant are present in all serotypes, 
including those that express a different VMP variant (Plasterk et al, 1985). 
However, serotypes that express a particular VMP contain not one but two DNA 
loci encoding that variant, i.e., duplication of a given vmp is associated with its 
expression. Duplication occurs via a non-reciprocal recombination event between 
a silent vmp "cassette" and a unique, unlinked "expression site". Recombination 
between these non-homologous loci is targeted by homologous regions flanking 
the expressed and silent vmp genes. The repertoire of vmp genes is carried on 
multi-copy, linear plasmids, with silent and expressed loci located on different 
plasmids (Saint Girons & Barbour, 1991; Kitten & Barbour, 1992; Wilske et al, 
1992). This arrangement allows recombination to occur at high frequency without 
jeopardizing chromosomal integrity. Interestingly, the vmp expression site is 
linked to the telomere of the linear plasmid that carries it (Kitten & Barbour, 
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1990). Although the significance of telomere linkage is unclear, it is shared by the 
system responsible for high-frequency variation of the immuno-dominant "variant 
surface glycoprotein" (VSG) antigen in Trypanosoma brucei (Rudenko et al, 
1998). 
Two additional mechanisms contribute to antigenic variation in B. hermsii. 
The first involves activation of a pseudogene downstream of an expressed vmp by 
intra-plasmid (rather than inter-plasmid) recombination (Restrepo et al, 1994). 
The second involves the selective hyper-mutation of expressed vmps by an 
unknown mechanism; polymorphisms in expressed vmp genes accumulate with 
time and are absent in silent vmp genes (Restrepo & Barbour, 1994). 
None of the vmp genes is expressed in the insect vector, suggesting that the 
vmp system has evolved to promote bacterial survival exclusively in the vertebrate 
host (Schwan & Hinnebusch, 1998). What is the role of the VMP system in 
pathogenesis? Is it simply to offer a constantly changing face to the vertebrate 
immune system? Or do the VMPs contribute directly to infection and 
dissemination within the host? Emerging evidence suggests that VMP variation 
may influence the organ tropism and dissemination properties of individual 
spirochetes (Cadavid et al, 1994; Cadavid et al, 1997; Pennington et al, 1999). 
It is tempting to speculate that these "knock-on" effects of VMP variation could 
promote the adaptation of Borrelia spp. to previously unavailable niches, possibly 
including new host species. 
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1.2.2. L y m e disease. Lyme disease (LD) is a chronic syndrome caused by the 
tick-borne spirochete Borrelia burgdorferi. The ecological cycle of the pathogen 
is complex, involving several small and intermediate-sized vertebrate reservoirs, 
which transmit bacteria to the insect vector during blood meals (Gern & Humair, 
1998). Humans are thought to be a "dead end" host. LD can be divided into three 
clinical stages (Steere, 1989; Evans, 1999). The first stage is marked by a 
transient skin lesion at the site of inoculation (erythema migrans). In the second 
stage, lasting up to six months, dissemination of the spirochetes gives rise to 
secondary skin lesions and other intermittent and variable pathologies, such as 
muscular and skeletal pain, meningitis, and carditis. These signs and symptoms 
often resolve spontaneously, leading to a subclinical or latent phase of variable 
duration. The third stage of disease, occurring months to years after initial 
infection, is characterized by chronic arthritis, cardiomyopathy, and neurological 
abnormalities. Borrelial persistence has been documented in clinical studies of LD 
patients (Fikrig et al, 1994; Kuiper et al, 1994) and in animal models (Barthold et 
al, 1993; Pachner et al, 1995; Roberts et al, 1995; Gylfe et al, 2000). The 
mechanism(s) that allow B. burgdorferi to cause persistent infection - whether 
chronic or latent - remain poorly understood. 
Although LD patients typically produce antibodies against a broad range of 
B. burgdorferi antigens, antibody production may be significantly delayed (Steere, 
1989). Studies in animal models of infection also suggest that B. burgdorferi may 
in some cases induce a non-protective immune response. In different strains of 
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mice, susceptibility seems to correlate with production of the "type 1" cytokine 
interferon-y (IFN-y), whereas resistance correlates with production of the "type 2" 
cytokine interleukin-4 (IL-4) (Sigal, 1997). This association has also been noted 
in Lyme disease patients (Oksi et al, 1996), and may reflect the importance of 
antibody-mediated mechanisms of protection against borreliosis (Hu & Klempner, 
1997), since type 2 cytokines are associated with dominant humoral immune 
responses. 
There is accumulating evidence that B. burgdorferi evades the humoral 
response by antigenic variation of surface-exposed lipoproteins encoded by vis 
genes (for "vmp-like sequence") (Zhang et al, 1997). The parallel to the vmp 
system of the RF borrelias is striking: the vis coding sequences are carried on a 
linear plasmid, and serotype switching occurs by non-reciprocal recombination 
between silent vis cassettes and an expressed copy (vlsE) that is telomere-linked 
(Zhang & Norris, 1998a, 1998b). Because recombination between vlsE and 
segments of the silent vis cassettes is combinatorial, the number of unique VlsE 
variants that could arise by shuffling of cassette segments is potentially enormous. 
Antigenic variation of VlsE in mice is associated with loss of seroreactivity, and 
the rate of variation is higher in immune-competent mice than in immune-deficient 
SCID mice (Zhang & Norris, 1998b). These observations suggest that VlsE 
variation may be an important mechanism of immune evasion. However, the rate 
of VlsE variation in SCID mice, although relatively low, is still much higher than 
observed during in vitro passage, suggesting that VlsE variation may play an 
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adaptive role in vivo in addition to its probable role in immune evasion. This idea 
is supported by the observation that spirochetes lacking the vslE plasmid are less 
infective to both immune-competent and SCID mice (Norris et al, 1995). 
Interestingly, the fact that while most of the bacterium's chromosome is -25% 
G+C in content while the vlsE region is about ~50% G+C, suggests that this 10 kb 
region might not be autoctonous to B. burgdorferi species (Casjens et al, 2000). 
The genome of B. burgdorferi potentially encodes as many as 150 different 
lipoproteins (Fraser et al, 1997). Lipoproteins of the outer surf ace proteins family 
(OspA through OspG) are immuno-dominant and elicit potent inflammatory 
responses (Sigal, 1997). B. burgdorferi does not display high-frequency variation 
of Osp proteins during infection, suggesting that Osps probably do not undergo 
antigenic variation (Barthold, 1993; Persing et al, 1994; Stevenson et al, 1994). 
However, selection of low-frequency, spontaneous, escape mutants has been 
observed in vivo, and could account for the considerable polymorphism of Osps 
within natural populations of spirochetes (Fikrig et al, 1993; Marconi et al, 1993; 
Livey et al, 1995). Strain variation in Osp serotypes could play an important role 
in enhancing survival during infection of a host who had previously been exposed 
to a different antigenic variant. 
In addition to high-frequency variation and population-level heterogeneity 
of borrelial antigens, antigenic "modulation" may also play a role in persistence. 
Expression of surface lipoproteins, e.g. OspA and OspC, fluctuates as the bacteria 
travel from vector to host and back again (Philipp, 1998). Spirochetes express 
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high levels of OspA in the gut of the flat tick, but precipitously down-regulate its 
expression as they begin their migration to the salivary glands of the feeding tick 
(de Silva et al, 1996). While levels of OspA remain low in the course of infection, 
expression of OspC is increased and sustained. However, this expression is not 
uniform: Bacteria not expressing ospC are selected in vivo just as anti-OspC 
antibodies titers emerge -17 days post-infection. Interestingly, these bacteria can 
regain expression of ospC in culture or when transferred to naive mice. Thus, 
differential expression of ospC might represent an important mechanism of 
immune evasion in Lyme disease (Liang et al, 2002). Several other genes of B. 
burgdorferi that are expressed in the host but not in the tick vector or in vitro have 
been identified (Suk et al, 1995; Das et al, 1997; de Silva & Fikrig, 1997), some 
of which are induced specifically during the persistent phases of infection (Fikrig 
et al, 1999), but their role in the host-pathogen interaction remains to be 
elucidated. 
Some late manifestations of LD may not be related to persistence of viable 
spirochetes. Some LD patients develop refractory arthritis. It is not clear whether 
arthritis is due to local persistent infection or to autoimmune disease initiated by 
infection but maintained in the absence of viable bacteria (Klempner & Huber, 
1999; Evans, 1999; Hemmer et al, 1999). The controversy stems from the fact 
that many patients with Lyme arthritis do not respond to antibiotic therapy and 
may not have detectable borrelial DNA in their synovial fluid. 
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The persistence strategies of the R F and L D borrelias are markedly similar, 
but several important differences should also be noted. Both pathogens cause 
septicemia, but the spirochete blood load in RF is much higher than in LD. The 
waves of spirochaetemia and fever that are the signature of RF are not seen in LD. 
Antigenic variation and immune selection of variants occur at much lower rates in 
LD than in RF. These differences likely reflect the divergent ecologies of the 
causative spirochetes, their vectors, and their intermediate hosts. 
1.3. Neisseria gonorrhoeae — Traveling incognito to escape recognition 
Gonorrhea, caused by the Gram-negative diplococcus Neisseria gonorrhoeae, is 
one of the most prevalent sexually transmitted diseases of humans — every year, 
78 million infections occur worldwide (WHO, 1995). Gonorrhea is usually a self-
hmiting, uncomplicated acute infection of the urethra or the cervix with localized 
inflammation, which usually resolves within a weeks of exposure (Garnett et al, 
1999). However, in some instances, acute infection is followed by more serious 
sequellae, such as epididymitis in men, and pelvic inflammatory disease (PID), 
salpingitis, and endometritis in women (Paavonen, 1998). Damage to the upper 
reproductive tract in women can lead to infertility and ectopic pregnancy. 
Mucosal colonization and invasion results in disseminated gonococcal infection 
(DGI) in ~ 0.5-3.0% of cases, leading to arthritis, dermatitis, tenosynovitis, and 
(rarely) carditis or meningitis (Kerle et al., 1992). Gonoccocal arthritis is the most 
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common type of joint infection in sexually active adults (Cucurull & Espinoza, 
1998). 
"Gonorrhea in the male, as well as in the female, persists for life in certain 
sections of the organs of generation, notwithstanding its apparent cure in a great 
many instances" (cited in Oriel, 1991). Thus, the persistent nature of gonorrhea 
was recognized by the noted veneorologist Emil Noeggerath in 1872, seven years 
before Albert Neisser identified the gonococcus as the etiologic agent. Persistent 
infection can be symptomatic or subclinical; the high frequency of asymptomatic 
carriers is a major obstacle to prevention and treatment. In clinical studies, 
approximately half of infected males who were examined because their sexual 
partners were known to have gonorrhea were aymptomatic (Handsfield et al, 
1974; Crawford et al, 1977), and asymptomatic infection rates may be even 
higher in women (McCormack et al, 1977). 
The persistence of N. gonorrhoeae in a population is largely possible 
because infection, despite eliciting massive inflammation, uniformly fails to 
generate an immune response capable of conferring immunity to reinfection 
(Gray-Owen et al, 2001). Infection initiates with entry of iV. gonorrhoeae into the 
lower urogentital tract. Rapid attachment to the mucosal epithelium of the genital 
tract is mediated by surface appendages called pili (Nassif & So, 1995). Loose 
attachment is followed by a more intimate association involving the surface-
exposed opacity (Opa) proteins (Dehio et al, 1998). Certain Opa proteins also 
promote the transmigration of gonococci across the epithelial layer to the 
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submucosa. Colonization of the (sub)mucosa is followed by extensive bacterial 
multiplication and shedding of bacteria into the genital secretions, triggering the 
massive localized inflammation that is responsible for the clinical signs and 
symptoms of gonorrhea. The inflammatory response begins with a massive 
infiltration of phagocytes, predominantly polymorphonuclear cells (PMNs), in 
response to pro-inflammatory cytokines and chemokines such as interleukin-1 (IL-
1), IL-6, IL-8, and tumor necrosis factor-a (TNF-a (Naumann et al, 1997). These 
are produced locally in response to factors released or triggered by the bacteria, 
including bacterial cell-wall peptidoglycan and lipooligosaccharide (LOS), and 
complement component C5a. 
PMNs phagocytize and kill gonococci by the oxidative burst, and other 
mechanisms such as defensins, cathepsin G, and other cationic antimicrobial 
proteins (Shafer & Rest, 1989). Gonococci may, however, be able to counter 
these defenses. Neisserial cell-wall porins inhibit phagocytosis and degranulation 
by PMNs (Bjerknes et al, 1995) and interfere with both the classical and 
alternative pathways of complement activation (Ram et al, 1999; Vogel & Frosch, 
1999). The critical role of complement in host defense against Neisseria spp. is 
evidenced by the hyper-susceptibility of individuals with heritable complement 
deficiencies to infections by these species (Figueroa & Densen, 1991). Virtually 
all patients develop specific, opsonizing antibodies to the major surface proteins of 
the gonococcus (Jarvis, 1995), but these do not necessarily prevent re-infection 
(Brooks & Lammel, 1989). In part, re-infection may reflect the ability of the 
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gonococcus to subvert humoral immunity. Like several other mucosal pathogens, 
N gonorrhoeae produces an IgAl-specific serine protease that cleaves the hinge 
region of IgA antibodies (Kilian et al, 1988; Kilian et al, 1996). The IgAl 
protease may also promote the intracellular survival of gonococci by cleaving the 
lysosome-associated membrane protein 1 (LAMP-1) (Lin et al, 1997), which 
could be important for transcytosis of gonococci across the genital epithelium 
(Hopper et al, 2000). 
Antigenic variation also plays an important role in survival of N. 
gonorrhoeae in the face of adaptive immunity. Variation of several cell-surface 
components of the gonococcus — notably, the pili, outer membrane Opa proteins, 
and LOS — is controlled by distinct and complex mechanisms. In addition to 
immune evasion, the organism's ability to invade and colonize different 
anatomical niches may also be determined by changes in surface components. 
Furthermore, recent evidence suggests that some of these surface proteins might 
be involved in active suppression of T-cell responses, which could be the reason 
why infection by N. gonorrhoeae is not followed by immunity that protects from 
reinfection with bacterial strains of the same serotype (Hobbs et al, 1999). 
Pili. Pioneering experiments in human volunteers established the essential 
role of pili in infection (Kellogg et al, 1963). Pili promote the initial colonization 
of the urethral tract by mediating adherence to the genital epithelium (Swanson, 
1973) via the CD46/MCP receptor (Kallstrom et al, 1997, 1998). Pili are 
immuno-dominant antigens and antibodies directed against them block gonococcal 
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adherence to epithelial cells (Rothbard et al, 1985). However, high-frequency 
variation of the pilin subunits that comprise pili occurs throughout the course of 
human infection, including early stages before the emergence of the adaptive 
humoral immune response (Hagblom et al, 1985; Seifert et al, 1994). These 
observations suggest that pilin variation might play two roles in the gonococcal 
life cycle: persistence in an infected individual by evasion of the adaptive immune 
response, and persistence at the community level by permitting transmission to 
individuals who had previously encountered the parental serotype. The 
mechanism of pilin variation in Neisseria is remarkably similar to the mechanisms 
used by the Borrelia to vary their surface antigens (Segal et al, 1985; Seifert, 
1996). The gonococcal genome encodes a large number of sequence-variable pilin 
genes, but only the pilin gene present at an expression locus (pilE) is actually 
transcribed and translated into protein (Fig. 1.2B). The silent pilin loci {pilS) are 
pseudogenes that lack the 5'-terminal coding sequences and the promoter 
sequences required for transcription. A pilin switch occurs when sequences stored 
at a pilS locus are transferred to a pilE locus by non-reciprocal recombination. 
Thus, the pilE gene that is expressed at any given time is a mosaic of sequences 
derived from various pilS cassettes, which can be endogenous or exogenous in 
origin, since Neisseria are naturally transformable (Gibbs et al, 1989). Pili can 
also undergo on/off/on... phase variation by imprecise recombination between pilS 
and pilE generating aberrant forms of pilin that are not assembled and exported 
(Seifert, 1996). Phase variation of pili can also occur by on/off/on... switching of 
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PilC, a minor constituent of pili that is essential for pilus assembly and maturation. 
Phase variation of pilC occurs by "slipped-strand replication" mediated by runs of 
G residues near the 5' end of the gene. In addition to immune evasion, phase 
variation of pili might play a role in traversal of the genital epithelium, because 
pili interfere with invasion of epithelial cells and transcytosis of epithelial barriers 
(liver et al, 1998). If non-piliated gonococci are responsible for mucosal 
invasion, then reversion to the piliated state must occur rapidly, because gonococci 
present in the blood of DGI patients are uniformly piliated. 
Opacity (Opa) proteins. The surface-exposed Opa proteins are encoded 
by a family of related but unlinked genes; a single isolate of N. gonorrhoeae may 
encode as many as twelve opa genes and may express zero, one, or multiple Opa 
proteins (Dehio et al., 1998; Nassif et al, 1999). Gonococci isolated from human 
patients or volunteers are predominantly Opa-positive, even when initial infection 
was with Opa-negative bacteria, and simultaneous expression of multiple Opa 
proteins is apparently favored (Swanson et al, 1988; Jerse et al, 1994). The Opa 
repertoire expressed by a given bacterium affects invasiveness as well as tissue 
tropism (Kupsch et al, 1993; Dehio et al, 1998; Nassif et al, 1999). Opa proteins 
phase vary in vitro at a frequency of IO"3 to IO"4 (Stern et al, 1984, 1986) and the 
mechanisms involved in this variation include "strand slippage" during DNA 
replication, and intergenic recombination of opa genes, from both intra- and extra-
genomic sources. This promiscuous reshuffling of coding sequences is 
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presumably responsible for the enormous repertoire of opa alleles observed in 
natural populations of gonococci (Meyer et al, 1990). 
Opa proteins might also play a role in the suppression of T-cell responses 
during gonoccocal infection. Binding of bacteria expressing OPA to CEACAM1, 
a surface molecule present on lymphocytes, blocks CD4+ T cell activation and 
proliferation in vitro (Boulton & Gray-Owen, 2002). This likely occurs via 
signaling through ITIM motifs found in the cytoplasmic tails of CEACAM1 
molecules, which can recruit SHP1 and SHP2 phosphatases that can antagonize 
the kinase-dependent signaling required for lymphocyte activation (Ravetch & 
Lanier, 2000). 
Lipo-oligosaccharide (LOS). The outer-membrane lipooligosaccharide 
(LOS) of Neisseria spp. differs from the typical lipopolysaccharide (LPS) of 
Gram-negative bacteria in that it lacks the repetitive O-antigen moiety. In addition 
to its structural role in the cell wall, LOS is thought to facilitate mucosal invasion 
and survival of gonococci (Dehio et al, 2000). The resemblance of the 
carbohydrate moieties of LOS to host glycosphingolipids may promote immune 
evasion by "molecular mimicry" (Mandrell & Apicella, 1993; Moran et al, 1996). 
Extensive variation of LOS oligosaccharide moieties can result in expression of 
several structurally distinct LOS molecules by a single bacterium (van Putten & 
Robertson, 1995; Minor & Gotschlich, 2000). LOS variation is determined by 
phase-variable expression of the LOS glycosyltransferases that sequentially add 
sugars to the LOS variable chain (Gotschlich, 1994; Minor & Gotschlich, 2000). 
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Individual Igt genes contain poly-G tracts that expand and contract by slipped-
strand replication, resulting in on/off/on... expression of the corresponding LOS 
glycosyltransferase (Danaher et al, 1995; Yang & Gotschlich, 1996; Minor & 
Gotschlich, 2000). Certain LOS variants are sialylated by a bacterial sialyl 
transferase using host CMP-NANA (van Putten & Robertson, 1995). This 
modification promotes survival by blocking the bactericidal activity of normal 
human serum and specific antibodies against cell-surface antigens such as porins 
or LOS itself (Parsons et al, 1989; Smith et al, 1995; Ram et al, 1999). On the 
other hand, LOS sialylation interferes with invasion of epithelial cells and 
transcytosis across mucosal barriers, suggesting that modulation of LOS 
sialylation could be advantageous at different stages of infection (van Putten, 
1993). This idea is supported by studies in human volunteers, where sialylation 
levels were low during early stages of infection (facilitating mucosal invasion) but 
high after colonization and traversal of the mucosal barrier (conferring serum 
resistance) (Schneider et al, 1991). This temporal modulation of surface 
components in the course of infection is one of the more striking examples of the 
sophistication with which the Neisseria have learned to blindside the defense 
mechanisms of the host. 
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1.4. Salmonella typhi — Chronic carriers, a galling problem 
Typhoid fever is major threat to human health anywhere treatment of sewage and 
drinking water is inadequate. The etiologic agent is the Gram-negative bacillus 
Salmonella typhi. Over 16 million people suffer from the disease annually, and 
about 0.6 million die from it (Pang et al, 1998). Antibiotics are available but 
resistance is increasing — some regions in India report rates of multi-drug 
resistance in excess of 50% (Rowe et al, 1997). A vaccine based on the capsular 
polysaccharide antigen Vi is effective but its application has not been sufficiently 
widespread (Hessel et al, 1999). S. typhi is an exclusively human pathogen so 
transmission depends on contact with an infectious case, either an acutely infected 
individual or a chronic carrier. Because infection occurs via the oral route, 
transmission is often mediated via contaminated foodstuffs, as in the infamous 
case of Mary Mallon ("Typhoid Mary") (Scherer & Miller, 2001). 
Ingested bacteria invade the intestinal wall by transcytosis of enterocytes or 
M cells in Peyer's patches. Bacterial replication in the submucosa is followed by 
entry into the bloodstream and dissemination throughout the body. Replication 
within macrophages in the spleen and liver leads to release of bacteria into the 
bloodstream. Signs and symptoms of typhoid include enterocolitis, diarrhea, 
anorexia, fever, convulsions, and delirium. Much of the pathology of typhoid fever 
is attributed to the massive release of cytokines triggered by bacterial LPS. 
Invasion of the gallbladder leads to shedding of bacteria into the intestine. High 
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fevers, accompanied by constant severe abdominal pain, persist for about four 
weeks, followed by slow convalescence with continued shedding of bacteria in the 
feces (Hornick et al, 1970). Both humoral and cell-mediated immunity have been 
implicated in the protective immune response (Jones & Falkow, 1996; Jones, 
1997). Most individuals recover fully and clear the infection; however, about 1% 
to 5% of those infected become asymptomatic chronic carriers and continue to 
shed bacteria in their stool and urine for the remainder of their lives. Although 
chronic carriers have none of the signs and symptoms of acute typhoid, they are at 
increased risk of developing cancer (Dutta et al, 2000; Shukla et al, 2000). 
S. typhi has adopted a novel strategy to evade destruction by the host 
immune response: by invading and adapting to an immune-privileged anatomical 
niche (the gallbladder), the organism puts itself out of harm's way. Little is 
known about its survival in the bilious environment of the gallbladder. Curiously, 
persistence of S. typhi in the gallbladder is more likely if gallstones are present — 
indeed, S. typhi can often be cultured from gallstones. The gallbladder also seems 
to provide a safe haven from the onslaught of chemotherapy. Antibiotics, 
although generally effective in treating acute infection, often fail at eliminating 
infection from chronic carriers: About 25-50% of carriers are never cured despite 
long-term chemotherapy, and relapses are common, particularly in those with 
biliary or gallbladder calculi (Hornick, 1985; Gilman, 1989). In clinical studies of 
chronic carriers, subsets of patients had negative stool cultures for up to two years 
after chemotherapy yet eventually relapsed (Kaye et al, 1967; Johnson et al, 
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1973). This largely undetected source of contagion poses a formidable obstacle to 
public health efforts to eliminate typhoid. Therefore, it is rather disheartening that 
the carrier state has received scant attention from the scientific community. 
A major obstacle to the study of typhoid fever and the carrier state has been 
the lack of a suitable animal model. The related species S. typhimurium, a 
significant source of food-borne gastro-enteritis in humans, produces a disease in 
mice that resembles typhoid in humans. Extrapolations from studies in the mouse 
model to human typhoid must be made with caution, since it is not yet clear 
whether the mechanisms of persistence are conserved between two bacterial 
species. When mice are infected with S. typhimurium orally, survival en route 
from the stomach to the intestine is dependent on the "acid tolerance response" 
(ATR) controlled by the alternative sigma factor RpoS (Foster., 1995; Slauch et 
al, 1997). The intestinal mucosa is breached by invasion of bacteria into 
enterocytes or M cells lining the Peyer's patches. Bacterial "invasion factors" are 
injected into the cytoplasm of the target cell by a type III secretion system encoded 
by the "Salmonella pathogenicity island 1" (SPI1) (Ochman et al, 2000). Injected 
factors include SopE (Hardt et al, 1998) and SptP (Fu & Galan, 1999), which 
function as a GDP/GTP exchange factor (GEF) and a GTPase-activating factor 
(GAP), respectively, for GTPases Cdc42 and Rac-1. The sequential 
activation/deactivation of Cdc42/Rac-1 directs the transient actin cytoskeleton 
reorganization and membrane ruffling that accompany invasion. Once bacteria 
breach the mucosa they invade and replicate within macrophages in the underlying 
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submucosa. Alternatively, bacteria may be phagocytized on the lumenal face of 
the intestinal wall and ferried across to the submucosa, thus bypassing the SPI1-
mediated invasion pathway altogether (Vazquez-Torres et al, 1999). 
Once the intestinal wall is breached, the infection is rapidly generalized 
throughout the reticuloendothelial system, especially in the liver and spleen. The 
pathogenesis of Salmonella hinges on the ability to survive and replicate within 
phagocytes of the monocyte-macrophage lineage. Salmonella inhabits a "loose" 
vacuole that acidifies to the normal phagolysosomal pH of 4.5-5.0 (Rathman et al, 
1996), but whether this compartment is a true phago-lysosome or a modified 
vacuole is controversial (Rathman et al, 1997; Sinai & Joiner, 1997). Functions 
required for survival and replication within macrophages are encoded by a second 
"Salmonella pathogenicity island", SPI2, which also encodes a second type in 
secretion system, Spi/Ssa (Ochman et al, 1996), whose expression is activated 
intracellularly (Valdivia & Falkow, 1997). The SPI2 type Ul secretion system 
translocates the bacterial protein SpiC from the Salmonella vacuole into the 
cytoplasm of the host cell, where it interferes with phagosome-lysosome fusion 
(Uchiya et al, 1999). SPI2 also encodes the PhoP/PhoQ two-component 
regulatory system that controls expression of Pho-activated genes (pag) and Pho-
repressed genes iprg), which are critical for intracellular survival (Groisman & 
Ochman, 1997). SPI2-encoded factors are responsible for evasion of the oxidative 
burst via exclusion of the NADPH-dependent phagocyte oxidase complex from 
the membrane of the Salmonella vacuole (Vazquez-Torres et al, 2000). The 
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foregoing discussion highlights the important contributions of the susceptible 
mouse model of typhoid to our current understanding of the molecular basis of 
invasion, intracellular survival, and dissemination of Salmonella spp. This model, 
however, has shed little light on the asymptomatic carrier state, a key aspect of 
human typhoid that merits more attention. 
In the past, some attempts were made to model certain aspects of persistent 
Salmonella infections in susceptible mice. For instance, certain strains of S. 
typhimurium are capable of causing a persistent infection in the intestine, spleen, 
liver, and occasionally even the gallbladder of these mice that can last for up to 
two months, thus allowing the study of some aspects of the immune response to a 
more chronic infection (Sukupolvi et al, 1997). More recently, a significant step 
toward the development of a model of prolonged persistent infection was taken by 
simply shifting the study of Salmonella pathogenesis from the historically-
preferred Salmonella-sensitive mouse strains to resistant ones. Monack et al. 
(2004) demonstrated that infection of mice carrying the wild-type Nrampl allele 
(resistant) infected orally with wild-type S. typhimurium bacteria resulted in a 
chronic infection: bacteria lingered in the organs of these mice for upto a year, 
mostly in macrophages of the mesenteric lymph nodes. Interestingly, IFN-y-
dependent immunity was found to be required for maintaining the bacteria in 
check. Though, no persistence-specific bacterial genes have yet been found, two 
genes, mig-14 and virK, are apparently important in both the acute and persistent 
phases of the infection using this newly developed Salmonella persistence model 
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(Brodsky et al, 2005). These factors promote bacterial survival in macrophages 
through inhibition of the bactericidal effects of the anti-microbial peptide 
(CRAMP), which is highly expressed in IFN-y-activated macrophages. 
1.5. Biofilms — Staying alive by staying put 
Pathogens persist in their hosts via phenotypic adaptation to a multitude of 
different tissue environments. Studies of these processes in bacteria have focused 
on the behavior of individual cells, but accumulating evidence suggests that this is 
an overly reductionist view (Costerton et al, 1999). Many bacterial species 
fluctuate between planktonic growth and sessile growth within biofilms, which 
typically complex and highly structured microbial communities (Costerton et al, 
1995), frequently composed of several species engaged in symbiotic relationships. 
Bacteria living in biofilm communities appear to be strikingly different in their 
physiology and metabolism from those growing planktonically (Costerton et al, 
1995; Costerton et al, 1999). 
Biofilms begin to form when bacteria growing in nutrient-rich 
environments develop adhesive behavior, leading to attachment to a surface and 
the formation of a monolayer of cells, followed by aggregation into characteristic 
micro-colonies (Fig. 1.3) (Costerton et al, 1995; Pratt & Kolter, 1999). These 
micro-colonies secrete highly hydrated exo-polysaccharides (EPS), which 
compose up to 80-90% of a mature biofilm's mass (Lawrence et al, 1991) and 
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Biofilm Dissolution: Programmed Disruption, Shear Forces, etc. 












via HSL (lasl) 
EPS matrix 
synthesis 
Fig. 1.3. Biofilm life cycle. Planktonic bacteria swim to a surface via flagellar motility and attach 
(mediated by flagella and nutrient sensing mechanisms). Replication on the surface leads to the 
formation of a monolayer of cells, which aggregate by twitching motility (mediated by type IV pili) 
and adhere to each other, forming surface-attached microcolonies. These microcolonies become 
embedded within a thick layer of secreted exopolysaccharides (EPS). A s cell density increases, 
quorum sensing via homoserine lactones (HSLs) synthesized by Lasl triggers the developmental 
changes required for formation of the correct architecture and thickness of the fully mature biofilm. 
The mature biofilm is penetrated by fluid-filled channels that deliver nutrients and remove waste. 
Bacteria within the biofilm are less susceptible to antibodies, phagocytes, and antimicrobials than 
planktonic cells. The steps leading to dissociation of biofilms and reversion to the planktonic form are 
poorly understood, but m a y involve environmental sensing and programmed disruption, or simple 
physical forces such as shear stress from fluid flow. Adapted from Costerton et al. (1999). 
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form an architecturally complex EPS matrix which is essential for biofilm 
formation and structure (Watnick & Kolter, 1999; Yildiz & Schoolnik, 1999), as 
well as resistance to environmental insults, antimicrobials, and predation by free-
living protozoa or, in the case of biofilm infection, by host phagocytes (Jensen et 
al. 1990; Costerton et al, 1995). The EPS matrix is penetrated by a complex 
system of fluid-filled channels that mediate nutrient distribution, elimination of 
metabolic waste products, and chemical communication between micro-colonies 
in the biofilm. Nutrient availability is an important determining factor in the early 
stages of biofilm formation. In Pseudomonas aeruginosa, the carbon metabolism 
sensor Cre controls the expression of functions required for biofilm genesis, such 
as the type IV pili that mediate twitching motility (Wall & Kaiser, 1999; O'Toole 
et al, 2000). Both flagellar motility and twitching motility are required for the 
early stages of biofilm formation by P. aeruginosa and Vibrio cholera (O'Toole & 
Kolter, 1998; Watnick & Kolter, 1999). Flagella are required for initial bacteria-
surface contacts, while type IV pili promote the aggregation of surface-adherent 
bacteria into micro-colonies. 
The mechanisms that control the later stages of biofilm development 
remain largely unknown, but quorum sensing via secreted homoserine lactones 
(HSLs) seems to play a critical role. In P. aeruginosa, the lasl locus responsible 
for HSL synthesis is dispensable for the formation of a nascent and structurally 
simple biofilm, but essential for its further maturation (Davies et al, 1998). 
Apparently, bacteria within the developing biofilm must talk to each other in order 
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to coordinate the events that generate the complex architecture of the mature 
biofilm. Production of HSLs has been demonstrated in naturally-occurring 
biofilms from aquatic environments (McLean et al, 1997) and from urethral 
catheters removed from patients (Stickler et al, 1998). The latter observation 
suggests the possibility that inhibitors of HSL production or function might be 
useful for preventing biofilm formation on indwelling medical devices. 
Little is known about the mechanisms that mediate the dissolution of 
biofilms and reversion to planktonic growth. Recent work in V. cholera suggests 
that quorum sensing is also involved in this process. During V. cholera infection, 
bacteria in an apparently superinfectious state in biofilm-like structures (Merrel et 
al, 2002) are ingested orally. After passage through the gut (the biofilm state is 
needed to withstand the stomach's acidity), they must be able to exit the biofilm in 
order colonize the intestine. Quorum sensing is apparently essential for the 
formation of a biofilm of just the right thickness so that rapid dissociation can take 
place once the bacteria get to the intestine because mutants of the quorum sensing 
regulator hapR, which overexpress the vps genes of EPS biosynthesis and make 
thick biofilms, are poor colonizers, despite having increased acid resistance (Zhu 
& Mekalanos, 2003). 
One of the most relevant aspects of bacterial biofilms vis-a-vis infections is 
the increased resistant of biofilm bacteria to killing by antimicrobials (Costerton et 
al, 1999). Inadequate drug penetration may contribute to the problem, as well as 
the altered physiology of bacteria within biofilms. The heterogeneous architecture 
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of biofilms creates chemical micro-environments that support slow- and non-
growing bacterial populations (Costerton et al, 1995), which are known to be less 
susceptible to antimicrobials (Eng et al, 1991; Evans et al, 1991). Indeed, the 
drug susceptibility and growth rate of biofilm bacteria are inversely related 
(Gilbert et al, 1990). 
Among medically relevant biofilm formers, P. aeruginosa is the best 
understood. This Gram-negative opportunistic pathogen afflicts immune-
compromised individuals, including burn victims, neutropenic patients on cancer 
chemotherapy, and particularly cystic fibrosis (CF) patients (Govan & Deretic, 
1996). Inherited defects in the chloride ion channel CFTR (cystic fibrosis 
transmembrane regulator) cause CF patients to suffer from buildup of dehydrated 
mucus in the respiratory tree, defective mucociliary function, and other defects in 
lung defenses. CF patients are unusually prone to develop chronic pulmonary 
infections by opportunistic pathogens, most of which respond to antibiotic therapy. 
However, virtually all CF patients are eventually colonized by P. aeruginosa, 
which resist eradication. 
Flagella are required for the early stages of Pseudomonas biofilm formation 
(see above) and for virulence in mouse models of burn wound sepsis (Drake & 
Montie, 1988) or pulmonary infection (Feldman et al, 1998). However, flagella 
can also promote non-opsonic phagocytosis of bacteria by neutrophils and 
macrophages (Mahenthiralingam & Speert, 1995). This conundrum might be 
resolved by temporal modulation of flagella expression in the course of infection. 
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In a prospective clinical study, bacteria isolated from C F patients at early stages of 
disease were flagella-positive, motile, and sensitive to phagocytosis, whereas 
bacteria isolated from persistently infected patients were flagella-negative, non-
motile, and resistant to phagocytosis (Mahenthiralingam et al, 1994). Flagella 
phase variation could be accelerated by the emergence of hyper-mutable 
subpopulations of P. aeruginosa in the CF lung (Oliver et al, 2000). 
Hyper-mutation might also promote the replacement of non-mucoid strains, 
which are responsible for initial colonization, by mucoid variants, which dominate 
later stages of infection. Mucoid variants arise by spontaneous mutations in genes 
controlling synthesis of alginate, an EPS matrix component, and their appearance 
is correlated with a poor prognosis for the patient. The alginate matrix shields the 
bacterial micro-colonies from both arms of the host immune response -humoral 
and cellular. Some variants that spontaneously arise during infection have been 
shown to have an enhanced ability to form biofilms as well as resistance to 
multiple antibiotics (Drenkard & Ausubel, 2002). These variants, which can 
readily be selected upon antibiotic exposure in vitro, might be selected in vivo by 
antibiotic exposure itself or as a result of exposure to host-mediated stresses. 
Most CF patients develop high levels of specific antibodies to P. 
aeruginosa, but these are ineffective against bacteria buried in the alginate matrix 
(Govan & Deretic, 1996; Costerton et al, 1999). Indeed, deposition of immune 
complexes on the surface of Pseudomonas biofilms is believed to contribute to 
lung inflammation and pathology in CF. Lung damage may also result from the 
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chronic influx of neutrophils, which are unable to clear the infection because the 
alginate matrix interferes with phagocytosis and killing. Bacterial communication 
(quorum sensing) within the biofilm is apparently required for optimal induction 
of protective mechanisms, including the superoxide dismutases (Mn-SOD and Fe-
SOD) and catalase (KatA) that detoxify phagocyte-generated ROI (Hassett et al, 
1999). Interestingly, the biofilm also supports the appearance of variants that 
The study of microbial biofilms and their role in persistent infections is still 
at an early stage. The environmental signals that promote biofilm formation and 
dissolution, and the signals that the bacteria use to communicate with each other, 
are just beginning to be deciphered. In addition to species-specific signals, a 
common language of secreted pheromones is apparently used for inter-species 
communication (Bassler, 1999). Elucidation of the signalling pathways that 
control biofilm dynamics could point the way to novel interventions targeting not 
individual bacterial cells, but their collective behavior as biofilms. 
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C H A P T E R 2 
Tuberculosis a n d the tubercle bacillus 
I N T R O D U C T I O N 
Mycobacterium tuberculosis is arguably the single most successful pathogen 
humankind has ever known. As Koch (1882) put it in The Etiology of 
Tuberculosis: "If the number of victims is a measure of the significance of a 
disease, then all disease, even the most dreaded infectious diseases, such as plague 
or cholera, must rank far behind tuberculosis." Today, 120 years later, President 
Mandella tells us: "We cannot cure AIDS without curing TB." 
The unparalleled penetrance of TB in the human population reflects the 
extraordinary ability of M. tuberculosis to cause a lifelong persistent infection, a 
peculiarity which most likely is the result of a long dynamic interaction with its 
host, one that may have begun before modern civilization (Morse et al, 1964; Salo 
et al, 1994). Though microbial infections including those caused by highly 
pathogenic bacteria tend to run an acute course, with infectious cycles of a few 
weeks, mycobacterial infections such as leprosy and TB are unusually protracted 
due to these pathogens' proclivity to persist in their hosts (Fig. 2.1) (Gomez & 















M. tuberculosis (active) 
M. tuberculosis (latent) 
Months 
Fig. 2.1. Acute vs. chronic active and latent bacterial infections. Acute infections are rapidly 
cleared by a sterilizing immune response that often protects from reinfection. Chronic infections last 
much longer, can be controlled, but usually are not eradicated by immunity, which seldom protects 
from reinfection. M. tuberculosis causes both chronic active and latent infections. 
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occur in the form of chronic active disease and latent infection; in either form, the 
biology of M. tuberculosis persistence is poorly understood (Manabe & Bishai, 
2000; Gomez & McKinney 2004; Boshoff & Barry, 2005). Because available 
antibiotics are inefficient in eradicating persistent bacteria, treatment must be 
extended, and often lasts between 6 and 9 months. In spite of the inherent 
difficulties in implementing these sorts of regimens, antibiotics have effectively 
led to a scale back of TB in most of the industrialized world, however, they have 
had a much smaller impact in the rest of the world, where lack of resources make 
implementing such cumbersome drug treatments considerably more difficult (Dye 
et al, 1999). Most people live in the "developing" world," and it is in this other 
'forever-developing' world -where poverty is extreme, public health deplorable, 
and malnutrition and overpopulation widespread - where TB relentlessly and 
inexorably continues to exact its deadly toll (Farmer etal, 1991). 
Though it is clear that combating the current TB epidemic would be greatly 
facilitated by the development of new and more efficient drugs and vaccines, and 
that in order to generate these, a better understanding of the biology of M. 
tuberculosis during infection would be greatly beneficial (McKinney, 2000; 
Andersen, 2001; Flynn, 2004; Mitchison, 2004), the major obstacle in dealing with 
TB and other major infectious diseases such as malaria and HIV is the 
uwillingness of the industrialized world to make the investments that would be 
needed to facilitate drug discovery (Nathan, 2004) and the affordable and efficient 
distribution of already available drugs (Farmer, 1996; Farmer & Campos, 2004). 
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2.1. Global burden of tuberculosis 
2.1.1 Epidemiology. Despite improvement in the prognosis of TB in affluent 
nations, the disease continues to be the leading cause of death among bacterial 
infections worldwide (Dye et al, 1999; Dye et al, 2002). Furthermore, it has 
been estimated that close to 2 billion people harbor latent tubercle bacilli, 
constituting a reservoir that will result in about 100 million cases of reactivation 
TB (Raviglione et al, 1995). According to WHO estimates, of circa 50 million 
deaths occurring per year, approximately 2 million are from TB, and over 95% of 
those deaths occur in the developing world (WHO, 2004). 
TB epidemics are extremely slow, typically expanding over centuries 
(Blower, et al, 1995) (Fig. LIB). Though the incidence of TB worldwide was in 
a downtrend since the 1950's, this changed considerably in recent times: from 
1985 to 1992 the incidence of TB rose by 20% in the United States (Bloom & 
Murray, 1992), and a considerable percentage of the cases were drug resistant 
(Moore et al, 1996). Among the most important reasons for such reversal were 
the AIDS pandemic, reduction in public health resources in inner cities, and 
continued immigration from areas of high TB prevalence (Zuber et al, 1997). 
2.1.2. TB and AIDS. AIDS in HIV-infected individuals, e.g., low CD4+ T cells, 
is one of the most important contributors to the development of TB in co-infected 
individuals in many parts of the world including the United States (Chaisson et al, 
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1987; Modilevsky et al, 1989). The low CD4+ T cell counts translate into 
suboptimal macrophage activation and an inability to mount a protective response. 
HIV-coinfection is the greatest single risk factor for progression from M. 
tuberculosis infection to disease. The risk of developing disease after infection 
with M. tuberculosis in an HIV-coinfected person is about 5-15% per year, 
compared to a lifetime risk of developing active TB after infection of about 10% 
in immuno-competent individuals. Furthermore, the inability to mount an 
effective adaptive immune response leads to a more progressive course of TB in 
HIV-infected individuals (Sepkowitz, 1995; Corbett et al, 2003; Aaron, 2004). 
Miliary TB, a highly disseminated form of TB that can affect multiple organs 
(Mert et al., 2001), is also more frequent in AIDS patients (1990). Furthermore, 
some evidence suggests that the interaction might be reciprocal, since active TB 
might stimulate viral replication, thereby accelerating the onset of AIDS (Whalen 
et al, 1995), perhaps through TNF-a, which induces viral transcription, and/or 
activation of the CD4+ T cells that support viral replication (Fauci, 1996; Bafica et 
al, 2003). Current estimates indicate that there are about 11 million individuals 
coinfected with HIV and M. tuberculosis worldwide. A recent study found that of 
an estimated 1.8 million deaths from TB, 12% were attributable to HIV, and 
similarly, TB was responsible for 11% of all deaths due to AIDS in adults (Corbett 
et al, 2003). 
The emergence of drug resistant strains of M. tuberculosis is another 
important factor modifying the current TB epidemic (Farmer et al, 1998). In 
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general, a strain is considered multiple drug resistant ( M D R ) if it is resistant to at 
least isoniazid and rifampicin, the two most effective drugs for TB. Rapidly 
spreading MDR M. tuberculosis strains, that are resistant to all four first line TB 
drugs, including isoniazid, rifampin, pyrazinamide and embuthal, have already 
emerged (Bifani et al, 2002; Post et al, 2004). According to WHO estimates, 
circa 5% of all active TB cases worldwide are caused by MDR strains. In some 
parts of the world, MDR strains represent a much higher percentage of the TB 
cases; in Estonia, for instance, MDR TB represents close to 15% of all cases, 
while in Russia, -25% of all TB cases are MDR (Farmer, 2001). 
2.2. The tubercle bacillus 
Mycobacterium tuberculosis belongs to the class Actinobacteria, order 
Actinomycetales, suborder Corynebacterineae, family Mycobacteriaceae. The 
suborder Corynebacterineae encompasses other high G+C Gram-positive bacteria 
including members of the Nocardia, Rhodococcus and Corynebacterium families. 
M. tuberculosis bacilli are non-motile rod-shape bacteria with general dimensions 
ranging from 1 and 4 \im in length and 0.3 to 0.6 urn in diameter. Some forms of 
bacilli that are smaller and round have been observed in histopathological studies 
(Reviewed in Lurie, 1939a). Though M. tuberculosis requires oxygen for growth, 
it can grow at low oxygen tensions and can survive complete oxygen deprivation 
(Wayne & Hayes, 1996). 
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2.2.1. Mycobacterial growth rates. Mycobacteria are notorious for being very 
slow growers. M. smegmatis, a fast growing innocuous mycobacterial saprophyte 
used as a surrogate to study M. tuberculosis, has a division time of about 3 hr in 
axenic culture and takes 3-4 days to form a colony on agar. M. tuberculosis has a 
doubling time of about 20 hours in culture and formation of a colony on agar 
requires 18-21 days (Wayne, 1994). Pathogenic mycobacteria have adapted to 
slow growth at many levels. For example, M. tuberculosis takes about 10 hours to 
replicate its genome, while E. coli can do it in 0.5 hours; and while E. coli has 
seven rRNA operons, M. tuberculosis has only one (Cole et al, 1998). 
2.2.2. Mycobacterial cell wall. One of the most striking features of 
mycobacterial cells is their tremendously complex lipid-rich envelope, which 
weigths half of the cell's dry weight. This property causes mycobacterial cells to 
aggregate into clumps in culture, making their experimental manipulation difficult. 
Limited studies suggest that mycobacterial cells might be relatively less permeable 
to hydrophilic substrates due to the presence of mycotic acids and mycosides; this 
impermeability could prevent transport of hydrophilic substrates into the cell. 
This lipid "shield," which causes M. tuberculosis to retain Carbol fuchsin dye 
despite acid treatment ("acid fastness"), plays an important protective function 
from physical and chemical stress, and accumulating evidence indicates that its 
components mediate complex interactions with the host immune response (Manca 
et al, 2004; Reed et al, 2004; Karakousis et al, 2004). These properties might 
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also limit the ability of certain drugs to efficiently enter the mycobacterial cell 
(Barry & Mdluli, 1996; Kolattukudy et al, 1997, Brennan, 2003). 
The peptidoglycan of mycobacterial cell walls has alternating N-
acetylglucosamine and muramic acid residues. The muramic acid residues are N-
acylated with glycolic acid rather than acetic acid. Arabinogalactan, a branched-
chain polysaccharide made up of a galactose and an arabinose chain, is attached to 
the peptidoglycan. Some of the arabinose units are linked to penta-arabinose 
units, which are esterified with mycolic acids. Mycolic acids, long-chain 1-alkyl 
2-hydroxy fatty acids, are essential for formation of the mycobacterial cell wall 
(Brennan, 2003). 
2.2.3. Mycobacterial genomes. The first M. tuberculosis genome sequenced was 
that of the virulent laboratory strain H37Rv (Cole et al, 1998). A recent clinical 
isolate, termed CDC 1551, was sequenced shortly after (Fleischman, 2001), and a 
third clinical isolate (strain 210) is near completion. The sequencing of the 
genomes of several other mycobacteria has been completed or is near completion 
(Gamier et al, 2003; NCBI). This wealth of information has uncovered unique 
aspects about mycobacterial biology. The constant G+C content of -65% 
throughout mycobacterial genomes suggests the absence of horizontally acquired 
pathogenicity islands, which are widespread in other pathogenic bacteria. 
Mycobacterial genomes have several novel multigene families and an unusually 
high number of duplicated 'housekeeping' genes, as well as repetitive insertion 
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sequences (Brosch et al, 2001). Interestingly, though the proportion of the 
genome that has arisen through gene duplication is not particularly high (-51%), 
the duplicated genes show low divergence, which might contribute to functional 
overlap or outright redundancy. 
The most salient characteristic of the M. tuberculosis and other 
mycobacterial genomes so far sequenced is the presence of a vast number of genes 
dedicated to lipid metabolism, including catabolic and anabolic functions (Cole et 
al, 1998; Fleischman, 2001; Gamier etal, 2003). Over 8% of the M. tuberculosis 
genome is made up of genes encoding proteins putatively involved in some aspect 
of lipid metabolism and considering that near 40% of the dry weight of the 
mycobacterial cell wall (Anderson, 1940) is made up of lipids, it is reasonable to 
conclude that lipid metabolism plays a major role in the biology of mycobacteria. 
2.3. Clinical tuberculosis 
M. tuberculosis contagion occurs when a susceptible person inhales bacilli-
containing infectious droplets that have been expelled from the lungs of a 
tuberculous individual by sneezing, coughing or simply talking. Of those infected, 
only a minority (-10%) will develop disease; about half will do so within a few 
months to a couple of years immediately following infection (primary TB), while 
the other half will do so only after an indeterminately long period of latency (post-
primary TB) (Comstock, 1982). 
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2.3.1. Primary TB. After reaching the alveoli, phagocytosis of the bacilli by 
resident macrophages (Ernst, 1998; North & Jung 2004) is followed by 
unrestricted bacterial exponential intracellular growth. Uptake of bacteria by 
dendritic cells (DCs) and migration of infected DCs to the draining lymph nodes 
for antigen presentation likely contributes to the lympho-hematogenous 
dissemination of bacteria to extrapulmonary organs and uninfected parts of the 
lung, leading to the formation of secondary lesions (Lurie, 1964; Dannenberg & 
Rook, 1994a). Exponential bacillary growth is thought to continue in primary and 
secondary lesions until a specific T-cell response is generated around each lesion, 
curtailing bacillary growth and likely killing some of the bacteria within 
macrophages as these become mycobacterio-static or -cidal after activation (Flynn 
&Chan, 2001) (Fig. 2.2). 
The caseous centers of newly formed lesions are surrounded by activated 
macrophages. Presumably bacterial antigens being released by the bacteria 
(Beatty & Russell, 2002) or captured from them are constantly being processed 
and presented to surrounding T cells in the context of IL-12 and other cytokines 
that induce a Thl type of immune response. Constant presence of antigen likely 
contributes to expansion of the T cell populations and continued activation of 
macrophages, which avidly ingest and inhibit/kill bacilli that accumulated during 
the acute phase of the infection. In a lesion where the bacteria are effectively 
controlled by CMI, the caseous center becomes surrounded by a capsule, forming 
a protective granuloma. Overtime, the number of viable bacilli in these 
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granulomas likely diminishes. Old caseous foci of this sort contain little to no 
bacilli, and some of the old lesions can ossify and be reabsorbed (Sweany et al, 
1943; Opie & Aronson, 1927). The interactions just described result in control of 
the infection in most infected individuals. 
For reasons poorly understood, some individuals fail to generate the 
protective type of immune response just described. In these cases, bacteria 
continue to replicate and the granulomas become increasingly necrotic. It is 
believed that part of the tissue damage that occurs is the result of 
immunopathology, i.e., an excessive host-mediated inflammatory response to 
bacillary antigens (Dannenberg & Rook, 1994a). When the centers of granulomas 
undergo caseating necrosis, the sheaths of monocytes and T cells which normally 
suppress the intracellular growth of the bacilli can also become necrotic; as the 
bacteria continue to replicate in nonactivated macrophages at the periphery of the 
lesion, progressive destruction of lung tissue ensues, ultimately leading to the 
death of the host. Massive inflammation and tissue damage can also be caused 
directly by some components of the bacterial cell wall as well as by secreted lipids 
and proteins; lipoarabinomannan (LAM), for instance, triggers TNF-ct secretion 
by macrophages, while some secreted lipids lead to secretion of proinflammatory 
IL-6 (Karokousis et al, 2003). 
Although M. tuberculosis is not an obligate intracellular pathogen, it is 
unclear whether it is capable of extracellular growth in the acellular necrotic 
centers of caseous lesions. In contrast, solid caseum that has undergone 
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Fig. 2.2. Cellular immune response to M . tuberculosis infection. Depicted are some aspects of the 
innate and adaptive cellular immune responses to infection by M. tuberculosis as inferred from 
studies using ex-vivo and in-vivo models of TB. The bacteria are assumed to reside mostly within 
vacuoles in macrophages. Not shown are CTL- and gd T cell-mediated proposed mechanisms of 
protection. 
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liquefaction is believed to be permissive for bacillary replication. The coughing 
up of this highly infectious material is in fact responsible for the transmission of 
the bacilli. These observations illustrate how pathology is a necessary step in the 
life cycle of M. tuberculosis infection in humans. 
2.3.2. Latent TB infection and reactivation. Little is known about the factors 
that determine whether an individual that is exposed to M. tuberculosis will go on 
to develop primary TB or become latently infected. That the immune status of the 
host is involved in both the establishment and maintenance of latency can be 
inferred from the observation that HIV-M. tuberculosis coinfected individuals 
have a much higher risk of developing TB after infection. 
The only sign of infection in individuals with latent TB infection (LTBI) is 
the appearance (between 2-6 wks post-exposure) of a detectable delayed type 
hypersensitivity reaction to a mycobacterial purified protein derivative (tuberculin) 
(PPD). By taking necropsy specimens of lung lesions from immune-competent 
individuals who had died of causes other than TB and inoculating them into 
guinea pigs to determine the presence of infectious bacilli, it was shown that some 
individuals can harbor viable tubercle bacilli for many years without showing any 
symptoms of disease (Opie & Aronson, 1927). In these early studies, it was found 
that while specimens from encapsulated or calcified lesions rarely were infectious, 
those isolated from caseous lesions in the lung's apex generally were. 
Unexpectedly, apparently healthy tissues were also often infectious. Several other 
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studies from the pre-antibiotic era have confirmed that lung lesions from 
asymptomatic individuals can harbor viable bacilli to different degrees (Feldman 
& Baggentoss, 1938; 1939; Sweany et al, 1943; Manabe & Bishai, 2000; Gomez 
& McKinney, 2004). Recent evidence of potential LTBI in normal human lung 
tissue was provided by the finding that about 30-50% of samples from individuals 
from endemic regions (Mexico and Ethiopia) could harbor M. tuberculosis DNA 
(Hernandez-Pando et al, 2000). Molecular evidence of endogenous LTBI 
reactivation LTBI comes from a recent case study in Denmark concerning an 
individual who had become infected 30 years prior with the same strain shown to 
be responsible for the reactivation and development of active TB (Lillebaek et al, 
2002). 
Perhaps the most compelling evidence for the prevalence of LTBI has come 
from the observed increased rates of TB in AIDS patients, as well as the high 
reactivation TB associated with the intake of TNF-a inhibitors prescribed for 
rheumatoid arthritis. These observations indicate that many individuals with LTBI 
accomplish life-long suppression of the bacillus, but never actually achieve 
sterilization. 
Reactivation TB usually presents clinically as a slowly progressive, chronic 
condition; an individual with chronic sub-acute TB may infect scores of contacts 
without realizing that (s)he has the disease (Hoge et al, 1994; Valway et al, 
1998). Patients with cavitary TB are particularly infectious because they shed 
enormous numbers of tubercle bacilli in their sputa. Cavitation is caused by the 
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liquefaction of necrotic tuberculous tissue and its expulsion via the airways; 
liquefaction is linked to a strong DTH response and is an important example of 
immuno-pathology in TB (Dannenberg & Rook, 1994a). The molecular basis of 
cavity formation has not been determined, nor is it clear whether the immune 
mechanisms responsible for pathogenesis and protection are the same. 
2.4. Experimental studies of tuberculosis 
The Mouse model of chronic tuberculosis. Animals infected with M. 
tuberculosis — mice, guinea pigs, or rabbits — typically develop a chronic, 
progressive form of the disease which varies in severity depending on the species, 
the guinea pig being the most susceptible, the rabbit the most resistant, and the 
mouse somewhere in between. 
The mouse has become the animal of choice in the study of TB. In fact, 
Koch himself employed mice in his pioneering experiments over 100 years ago. A 
chronic infection in mice can be established by inoculation of bacilli by 
intravenous injection (Hart & Rees, 1950; McCune & Tompsett, 1956) or by 
aerosol exposure (Orme & Collins, 1994). The bacilli multiply logarithmically 
during the first 2-4 wks post-infection and then stop increasing in numbers in the 
lung and start to slowly decline in numbers in the liver and spleen. Depending on 
the titer of the initial inoculum, the chronic infection can last from months to over 
a year (Rhoades et al, 1997). The model is useful in that it allows host-M. 
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tuberculosis interactions to be studied in the context of a prolonged persistent 
infection. The maintenance of a relative high bacterial load, accompanied by 
accumulating pathology, might pertain to human active TB, while the apparent 
lack of bacterial replication might be relevant to both active TB and LTBI. 
Among the limitations of the mouse model are differences in the composition and 
organization of the granulomatous structures compared to those formed in human 
lungs, and in the location of the bacilli in the infected lungs - almost exclusively 
intracellular in mice, considerably more extra-cellular in humans. 
Spontaneous M. tuberculosis latency in animals only occurs in nonhuman 
primates (Capuano et al., 2003; Flynn et al, 2003). A drug-induced model of 
latency known as the "Cornell model", in which M. tuberculosis-infected mice are 
sterilized by drug treatment, and then allowed to reactivate spontaneously or by 
immunesuppression, was developed in the 1950's (McCune & Tompsett 1956; 
McCune et al. 1956, 1966a, 1966b). This model allows host-pathogen interactions 
to be studied in the context of an infection where very low numbers of bacteria are 
present and has been used to study host factors involved in establishing and 
maintaining this type of "latency" (Scanga et al, 1999; Botha et al., 2002; Botha 
& Ryffel, 2003). However, the relevance of the model to true latency awaits 
validation. 
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2.5. Host-pathogen interactions in T B 
Bacilli reaching the lung alveoli are phagocytosed by resident macrophages (Lurie 
& Zappasodi, 1942) via mannose, complement (Schlesinger et al, 1990; 
Schlesinger, 1993)), and Fc receptors (in differentiated macrophages) (Malik et 
al, 2000). Uptake through Fc receptors increases phagolysosomal fusion 
(Armstrong & Hart, 1975) and triggers the oxidative burst (Kobzik et al, 1990), 
leading to killing of bacteria in human macrophages (Malik et al, 2000; Malik et 
al, 2001). Regardless of the receptor involved, uptake apparently requires 
recruitment of cholesterol to the phagosome (Gatfield & Pieters, 2000). Uptake by 
dendritic cells occurs via DC-SIGN (Tailleux et al, 2003). 
2.5.1. Cellular interactions leading to a protective immune response. A 
protective immune reponse to M. tuberculosis is mediated mainly by T-cells 
(CMI) (Suter et al., 1961; MacKaness, 1968; Murray, 1999; Flynn & Chan, 2001; 
North & Jung, 2004) (Fig. 2.2). As early as one wk post-infection, bacteria-
specific CD4+ and CD8+ T cells migrate to the lung (Serbina & Flynn, 1999), 
peaking in numbers at around 4 wks post infection (Feng et al, 1999). Studies in 
immune-deficient mice have established that IFN-y (Cooper et al, 1993; Dalton et 
al, 1993; Flynn et al, 1993; Kamijo et al, 1993), TNF-a (Flynn et al, 1995; 
Adams et al, 1995), and IL-12 (Flesch et al, 1995; Cooper et al, 1997) are the 
main ytokines involved in a protective immune response. The relevance of 
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IFN-y and IL-12 in antimycobacterial immunity is supported by human genetic 
data (Altare et al, 1998); the recent association between administration of TNF-a 
inhibitors used to treat rheumatoid arthritis and the reactivation of LTBI has 
underscored the protective role of this cytokine in control of M. tuberculosis in 
humans (Nunez-Martinez etal, 2001). 
The initiation of the immune response occurs via presentation of M. 
tuberculosis antigens, presumably by dendritic cells (DCs) (Guermonprez et al, 
2002), on MHC class I and II molecules to naive T cells, which in the context of 
IL-12 and IL-23 (Flesch et al., 1995; Fulton et al, 1996; Cooper et al, 2002; 
Verreck et al, 2004) produced by infected macrophages and DCs themselves, are 
instructed to differentiate into IFN-y-secreting cells (T helper type I, Thl) cells 
(Trinchieri, 2003) (Fig. 2.2). Both CD4+ and CD8+ T cells contribute to the 
activation of infected macrophages via IFN-y secretion (Tascon et al., 1998), 
while CD8+ T cells might additionally contribute to protection by causing 
apoptosis of infected macrophages through the Fas-FasL pathway, as well as via 
secretion of granulysin and other microbicidal molecules (Stenger et al, 1998; 
Serbina et al, 2000). However, the relative contribution of CD8+ T cells to the 
overall protective CMI might not be as significant as that by CD4+ T cells since M. 
tuberculosis-infected mice deficient in the former live almost as long as infected 
wild-type mice, while those deficient in the latter are significantly more 
susceptible (Sousa et al, 2000; Mogues et al, 2001). 
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Natural killer (NK) cells might contribute to the early control of M. 
tuberculosis replication by generating IFN-y and granulysin during the first few 
days of the infection (innate phase), however since their depletion does not affect 
bacterial loads, it is likely that other innate sources of IFN-y exist (Junqueira-
Kipnis et al, 2003). In addition to NK cells, the rapid early activation of 
'bystander' CD8+ T cells has been implicated as an early source of IFN-y during 
bacterial infections (Lertmemongkolchai et al, 2001). The lack of early CD8+ T 
cell-derived IFN-y could explain why in the lungs of CD8+ T cell-deficient mice 
M. tuberculosis bacilli replicate to 1 logio higher than in wild-type mice, before 
their numbers stabilize (Mogues et al, 2001). Later on in the infection NK cells 
might also help control the infection by producing granulysin or by inducing 
apoptosis in infected monocytes, via a Fas-FasL independent mechanism (Brill et 
al, 2001). 
Mice lacking CD4+ T cells are highly susceptible to M. tuberculosis 
infection (Caruso et al, 1999), and exhibit reduced macrophage activation, which 
is associated with lower IFN-y production (Barnes et al, 1993; Orme et al, 1993). 
Even though CD8+ T cell production of IFN-y can compensate and restore the 
concentrations of IFN-y back to normal levels in CD4+ T-defecient mice, the latter 
still succumb to the infection earlier than wild-type mice, suggesting a role for 
CD4+ T cell-derived IFN-y early in the infection, or perhaps an IFN-y-independent 
mechanism that is important early in the infection (Caruso et al, 1999). An IFN-
y-independent CD4+ T cell-mediated mechanism dependent on NOS2 has recently 
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been shown in vitro and suggested to be important in vivo by the demonstration 
that IFN-y-deficient mice can be effectively protected by BCG vaccination in a 
CD4+ T cell-dependent manner (Cowley & Elkins, 2003). 
CMI to M. tuberculosis promotes the formation of granulomas - infected 
macrophages surrounded by antigen-specific lymphocytes, multinucleated giant 
cells, and a ring of fibrous deposition (Dannenberg & Rook, 1994b). Granulomas 
typically encompass the entire infection foci and effectively isolate the bacilli 
from the rest of the healthy lung. Granuloma formation is largely dependent on 
TNF-a and GM-CSF (Kindler et al, 1989; Shibata et al, 2001), which are 
produced by infected macrophages, T cells (Saunders et al, 2003), and other 
hemaetopoetic cells, and drive tissue-resident stromal cells to produce 
macrophage-inflammatory protein-ip (MIP-ip), MlP-la (Czermak et al, 1999) 
and other chemokines (Algood et al, 2003) needed to recruit neutrophils, 
lymphocytes, and monocytes to the site of infection. TNF-a"A mice infected with 
M. tuberculosis fail to form organized granulomas, are incapable of controlling M. 
tuberculosis replication, and succumb to M. tuberculosis within 20-30 days post 
infection (Flynn et al, 1995; Bean et al, 1999). The levels of TNF-a must be 
tightly regulated since overproduction can lead to excessive pathology (Bekker et 
al, 2000). Likewise, GM-CSF-deficient mice are highly susceptible to M. 
tuberculosis infection (mean-time to death, 35 days) (Gonzalez-Juarrero et al, 
2005). 
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2.5.2. Survival of M . tuberculosis in the macrophage. Pathogenic mycobacteria 
reside and readily replicate within tight vacuoles of non-immune-activated 
macrophages (Armstrong & Hart, 1971; Rusell, 2001). Pioneering studies by 
D'Arcy Hart and co-workers showed that tubercle bacilli prevent the fusion of 
lysosomes to M. tuberculosis-containing vacuoles, which prevents their normal 
acidification and facilitates bacterial survival and replication (Armstrong & Hart, 
1971, 1975). Vacuoles containing live virulent M. avium have a relatively high 
pH (6.3-6.5), which correlates with a lower density of vesicular H+ ATPase pumps 
on their membranes (Sturgill-Koszycki et al, 1994). Mycobacterial vacuoles 
reside within the recycling/sorting endosomal compartment — markers of early 
endosomes (Rab5) are retained, markers of late endosomes (Rab7) and lysosomes 
(LAMP1-1 and LAMP-2) are largely excluded; communication with the 
cytoplasmic membrane appears to be maintained as suggested by the cycling of 
transferrin in and out of the vacuoles (Clemens & Horwitz, 1996; Sturgill-
Koszycki et al, 1996). Diversion of the mycobacterial phagosome from the 
normal maturation pathway correlates with retention of the actin-binding coronin 
"TACO" on the phagosomal membrane (Ferrari et al, 1999). 
Active evasion of phagolysosomal fusion by M. tuberculosis involves 
bacterial "effectors" such mannose-capped lipoarabinomannan (ManLAM) which 
interferes with phagolysosomal fusion by blocking the acquisition of the 
lysosomal cargo and syntaxin 6 from the trans-Golgi network (Fratti et al., 2003). 
LAM alone can specifically block the cytosolic Ca2+ increase necessary for a 
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signaling cascade involving phosphatidylinositol (PI)3 kinase hVPS34, which is 
needed for production of PI 3 phosphate (PI3P) on phagosomes (Vergne et ah, 
2003). 
The importance of type-1 cytokines in human immunity to M. tuberculosis 
infection has been confirmed by studies of naturally occurring polymorphisms in 
the genes encoding type-1 cytokines and their receptors in humans (Atare et al, 
1998; Ottenhoff et al, 2002). The principle role of type-1 cytokines in anti-TB 
immunity is to activate the anti-microbial functions of macrophages. IFN-y 
activation and infection of murine macrophages with M. tuberculosis results in the 
differential expression of some 40% of the macrophage genes, an indication of just 
how dynamic the host-M. tuberculosis interaction is (Ehrt et al, 2001). Many of 
these differentially-expressed genes likely encode functions involved in the 
curtailment of growth and killing of the intracellular bacilli. 
2.5.3. Effector mechanisms of the immune-activated macrophage. Schaible 
and colleagues (1998) found that upon activation of M. avium-infected 
macrophages with IFN-y and LPS, the mycobacterial vacuoles fuse to each other, 
become more acidic (pH 5.3), and as a result of fusion with lysosomes accumulate 
hydrolases. These and other changes in the intracellular milieu lead to stasis and 
killing of the bacilli. 
One of the facilitators of phagolysosomal fusion and acidification 
downstream of IFN-y that has been shown to be essential for protection in TB is 
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L R G 4 7 (Feng et ah, 2004; MacMicking et ah, 2003), a member of a family of 
IFN-y-dependent GTPases that mediate fusion events in endosomal networks 
(Taylor et ah, 1996). That these GTPases play different functions in response to 
infection by different pathogens is suggested by the findings that IGTP-/~ and IRG-
47_/_ mice, which are susceptible to infection by viral, bacterial, and eukaryotic 
pathogens (Taylor et ah, 2000; Collazo et ah, 2001), are resistant to infection by 
M. tuberculosis. In contrast, LRG47"7" mice succumb to infection by M. 
tuberculosis with kinetics similar to those of NOS2_/" mice, the other major 
pathway of antimycobacterial immunity (Chan et ah, 1992; Chan et ah, 1995; 
MacMicking et ah, 1997). 
The immune system relies on chemically reactive micromolecules as well 
as enzymes to neutralize and eliminate invading pathogens and their products. 
Some of the most efficient of these reactive molecules in killing and controlling 
M. tuberculosis include the reactive nitrogen intermediates derived from nitric 
oxide produced by nitric oxide synthase 2 (Nathan, 1992). M. tuberculosis is 
killed by murine peritoneal macrophages and cell lines activated with IFN-y and 
either LPS or TNF-a via RNI production, and IFN-y and TNF-a synergistically 
increase NO synthesis by macrophages (Flesch & Kaufmann, 1991; Chan et ah, 
1992; MacMicking et ah, 1997a; Nathan & Shiloh, 2000). The demonstration that 
NOS2"A mice are highly susceptible to M. tuberculosis infection provides clear 
functional genetic evidence that NOS2 is essential for the protective immune 
response against M. tuberculosis (MacMicking et ah, 1997b; Scanga et ah, 2001). 
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Even though macrophage activation and resulting RNI production result in 
bacteriostasis, M. tuberculosis is nonetheless able to resist eradication in mouse 
lungs and in activated macrophages in tissue culture, despite the fact that in vitro 
reagent NO is a potent mycobactericidal (Nathan & Ehrt, 2003). Having evolved 
to infect the mammalian lung, M. tuberculosis appearently has ways of countering 
the nossive effects of NO and related RNI. One such mechanism involves the 
product of the mpa gene, which forms hexamers that have ATPase activity, and is 
believed to be associated with a mycobacterial proteosome. Ampa M. tuberculosis 
bacteria are attenuated in wild-type mice and show some revertion to virulence in 
NOS2_/" (Darwin et al, 2003). It remains to be shown whether Ampa M. 
tuberculosis bacteria have defects in protein degradation via this presumptive 
proteasome, and whether this proposed function is involved in protecting the 
bacteria from RNI. An additional strategy adopted by M. tuberculosis to deal with 
RNI appears to be simple avoidance of NOS2. Recent, microscopy studies 
indicate that M. tuberculosis might be able to prevent NOS2 from being recruited 
to bacteria-containing phagosomes (Miller et al, 2004). 
The role of NO in protection against M. tuberculosis in humans is 
somewhat controversial (Nathan & Ehrt, 2003). While some investigators have 
reported NOS2 protein induction, NO, which is measured by determining the 
concentration of its breakdown products nitrate (N03) and nitrite (N02), cannot be 
consistently detected in M. tuberculosis-infected cultures of human 
monocytes/macrophages (MacMicking et al, 1997; Nathan & Ehrt, 2003). 
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Furthermore, no mutations in nosl in humans have yet been associated with 
susceptibility to M. tuberculosis. However, patients with active TB apparently 
exhale high levels of NO, which correlate with high expression of NOS2 and 
spontaneous production of nitrite by alveolar macrophages (Wang et al, 1998). 
Another reactive micromolecule that is a potent antimicrobial effector of 
the immune response is the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (PHOX)-mediated production of reactive oxygen intermediates 
(ROIs) - reduction products of 02 such as superoxide, hydrogen peroxide, and 
hydroxyl radical (Nathan & Shiloh, 2000). ROI generation is an effective 
antimicrobial defense against many bacterial pathogens including Salmonella 
(Vazquez-Torres & Fang, 2001) and Burkholderia cepacia (Segal & Holland, 
2003). However, the protective role of ROI in TB appears to be less prominent 
than during Salmonellae infections. CGD patients which lack phagocyte oxidase 
have not been reported to be more susceptible to M. tuberculosis infection (Nathan 
& Ehrt, 2003). Furthermore, gp91(phox/) mutant mice, which lack a functional 
phagocyte oxidase are not more susceptible to M. tuberculosis than wildtype mice 
(Hisert et ah, 2004; Ng et ah, 2004), while mice lacking the gp47 subunit of 
PHOX are less able to control M. tuberculosis replication only transiently (Cooper 
et ah, 2000). Furthermore, M. tuberculosis appears to be able to effectively 
counteract the damaging effects of ROIs. ROI detoxification mediated by the 
KatG catalase is essential for bacterial persistence in mice following induction of 
adaptive immunity (Li et ah, 1998; Pym et ah, 2002), and an M. tuberculosis 
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mutant of katG is attenuated in wild-type mice, but reverts to wildtype levels of 
virulence in mice lacking PHOX (Ng et ah, 2004). The product of katG is also a 
peroxynitritetase, thus it may protect M. tuberculosis from botrh RNI and ROI 
(Wengenack et ah, 1999). At least one of the superoxide dismutases of M. 
tuberculosis contributes to intracellular survival (Piddington et ah, 2001). 
2.5.4. Immunity during M. tuberculosis chronic infection. Several of the 
components that are important for generating a protective immune response to M. 
tuberculosis infection are also important for maintaining the equilibrium between 
host and pathogen during the chronic phase of the infection. As expected, Thl 
maintainance is important for controlling M. tuberculosis during the chronic phase 
of the infection and sustaining this type of response requires IL-12 (Feng et ah, 
2005). Neutralization of TNF-a by antibodies or by infection with an adenovirus 
expressing a soluble TNF-a receptor resulted in marked increases in bacterial 
loads and exacerbation of disease in the mouse model of chronic TB and in a 
variation of the Cornell model of drug-induced latency (Adams et ah, 1995, 
Scanga et ah, 1999; Mohan et ah, 2001). Also using the Cornell model of TB, 
IFN-y has been shown to be involved in preventing reactivation (Scanga et ah, 
1999). Similarly, chemical inhibition of NOS2 in chronically infected mice 
resulted in rapid increases in lung bacterial loads (Flynn et al, 1998). NOS2-
inhibiton also reactivated M. tuberculosis in variations of the Cornell model of 
latency (Scanga et al, 1999; Botha et ah, 2002). 
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2.6. M . tuberculosis mechanisms of immune evasion 
Some of the bacterial mechanisms M. tuberculosis uses to directly protect itself 
from ROI/RNI effectors of the immune response have already been discussed. 
But like many persistent pathogens, M. tuberculosis has evolved mechanisms to 
evade and subvert host immune responses at many levels (Flynn & Chan, 2003). 
In addition to directly blocking phagosome maturation (See above), M. 
tuberculosis interferes with IFN-y signalling via STAT1 (Ting et ah, 1999). 
STAT1 deficiency in humans has been associated with increased susceptibility to 
mycobacterial infection. Down-regulation of antigen-presenting (MHC class II 
and CD1) and costimulatory (B7) molecules on infected macrophages may affect 
activation of IFN-y-secreting T cells (Wojciechowski et al, 1999; Flynn & Chan, 
2003). Macrophage activation, antigen presentation, and T cell activation may 
also be inhibited by cytokines secreted by macrophages as a result of the infection 
such as IL-10 (Murray, 1999), IL-6 (van Hyningen et ah 1997; Nagabhushanam et 
ah, 2003), and transforming growth factor-p (TGF-p) (Vanham et ah, 1997). In 
addition to blocking antimicrobial signaling pathways, many pathogens prolong 
their survival by triggering apoptosis of leukocytes (Weinrauch & Zychlinsky, 
1999). However, in M. tuberculosis infection apoptosis of the infected 
macrophage has been implicated as a mechanism of host protection which could 
deprive the bacterium of its intracellular niche of replication (Oddo et ah, 1998; 
Gil et ah, 2004). Indeed accumulating evidence suggests that pathogenic 
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mycobacteria may interfere with apoptosis of infected macrophages in order to 
perpetuate their intracellular "safe haven" (Fratazzi et ah, 1999; Komfeld et ah, 
1999; Keane etal., 2000). 
2.7. Extracellular persistence of M. tuberculosis in vivo 
In the human lung M. tuberculosis is thought to reside both intracellularly and 
extracellularly, depending on the type of lesion (Grossett, 2003; Kaplan et ah, 
2003; Boshoff & Barry 2005). Pioneering work by Lurie (1964) and continued by 
Dannenberg (Dannenberg & Rook, 1994b) in the rabbit model showed the 
existence of extra-cellular M. tuberculosis in caseous necrotic lesions. Since 
immunity to TB was thought to be mainly mediated by activated phagocytes 
which kill intracellular bacteria (Mackaness, 1968; North, 1974), it was suspected 
that the extra-cellular milieu represent a safe heaven for bacterial replication and 
perhaps persistence. In order to study this population of bacteria directly, Lurie 
devised a very ingenious method of cultivating bacteria extracellularly in vivo: 
Parlodion-film encased silk bags that were impervious to host cells, but not to 
plasma, were inoculated with bacilli, and then implanted subcutaneously in 
rabbits. These "extracellular" bacteria replicated unhindered during the first two 
wks of infection, but then leveled off at circa 2 wks post infection. When 
immunized animals were used, bacteria stopped growing earlier and were killed 
more efficiently than in naive counterparts, strongly implicating acquired 
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immunity in controlling the growth of extracellular bacteria. Since control of 
growth correlated with a more rapid mobilization of mononuclear cells toward the 
encased focus of infection, it was proposed that factors secreted by activated 
macrophages rendered the fluids entering the infection foci inimical to bacterial 
replication (Lurie, 1939a,b). 
Recently, Karakousis and collagues (2004) adapted Lurie's strategy to the 
widely used model of murine TB: M. tuberculosis was encapsulated in cell-
impermeable hollow fibers, and these were implanted subcutaneously into mice 
for in vivo cultivation. As expected, an initial period of bacterial replication was 
followed by curtailment of growth, followed by a considerable decline in numbers, 
and, interestingly, an eventual stabilization of the counts. These stationary-state 
CFU counts, similarly to those in the equilibrium that characterizes the chronic 
phase of infection in the mouse model of chronic TB (Rees & Hart, 1961; Mufioz-
Elias et ah, 2005) represented a somewhat static scenario: they found that about 
half of the encapsulated bacilli were alive by differential staining; a highly 
dynamic equilibrium would have resulted in a large accumulation of dead bacteria 
and a decreasing proportion of live ones. Furthermore, indirect analysis -
comparison of ATP utilization and CFU at corresponding time points - indicated 
that soon after implantation, bacteria decreased their metabolism. The rapid 
cessation of multiplication and rather swift reduction in metabolic activity suggest 
that innate defenses or perhaps immune-independent mechanisms prompt these 
adaptations. This was also suggested by Lurie's studies using vaccinated animals, 
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which implicated an unknown plasma factor in bacterial growth inhibition. This 
factor could be nitric oxide, which is known to block M. tuberculosis replication in 
vitro by inhibiting bacterial respiration (Voskuil et ah, 2003). Careful analysis of 
the hollow-fiber's contents in this extracellular model of persistence in vivo, 
including concentrations of NO, oxygen, essential elements, and nutrients might 
be of value. 
2.8. Chemotherapy: drug tolerance and resistance 
2.8.1. Chemotherapy and drug tolerance. Current antibiotic treatment regimens 
for active pulmonary TB are costly and burdensome, typically consisting of an 
early phase of daily treatment with four drugs (isoniazid, rifampin, pyrazinamide, 
and ethambutol or streptomycin) for two months, and a prolonged four-month-
long phase of isoniazid and rifampin treatment. However, even when adequate 
antibiotic therapy is completed, persistent bacilli may not be eradicated completely 
(Kopanoff, 1988), and relapses are relatively frequent, especially among HIV+ 
individuals (Perriens et ah, 1995). Most drugs currently used to treat TB target 
functions that are required for bacterial growth and division; see Table 2.1 for a 
list of available drugs and their proposed targets. 
2.8.2. Drug Resistance. The long duration and complexity of currently available 
TB drug regimens contribute to high levels of non-compliance and the emergence 
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of widespread drug resistance and multiple-drag resistant ( M D R ) strains of M. 
tuberculosis. The global prevalence of MDR-TB has recently been estimated at 
4.3% (Heymann et al, 1999); alarmingly, almost 80% of MDR-TB strains 
worldwide are resistant to 3 of 4 first-line drugs. In some eastern European and 
former USSR nations, MDR-TB has reached epidemic proportions (Farmer et ah, 
1998; TB alliance, 2005 report; tballiance.org). 
2.8.3. Drug tolerance in vivo. It is not clear why treatment of TB is so difficult 
and slow. The same antimicrobials that take months to cure a patient or to sterilize 
the tissues of an experimentally infected animal, will sterilize a culture of M. 
tuberculosis in vitro within days (Fig. 2.3B&C) (McDermott, 1958; McKinney, 
2000; Mitchision, 2004). Drug penetration might be a problem, though apparently 
at least for isoniazid adequate penetration does occur (Barclay et ah, 1953). 
Neither increasing drug dosages (McDermott, 1958), nor giving patients more 
drugs (Mitchison, 1980), led to increases in rates of killing in vivo. 
Drug tolerant bacterial populations. One influential model of persistence 
in the face of chemotherapy posits that the phenomenon results from physiological 
heterogeneity of mycobacteria in the tissues, which might include slow- and non-
dividing bacteria which resist killing by antimicrobials (Mitchison 1979, 1980). 
Supporting evidence for this model was provided by a remarkable clinical study in 
which tuberculous lung lesions were cultured from patients who had received 
prolonged multi-drug chemotherapy (Fig. 2.3A) (Vandiviere et ah, 1956). Lesions 
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Fig. 2.3. In vivo drug tolerance. (A) Resected lung lesions from patients on chemotherapy were 
cultured. "Open" and active cavitary lesions, with patent connections to the airways, yielded drug-
resistant tubercle bacilli in the normal timeframe (less than 2 months' incubation). "Closed" and 
dormant encapsulated lesions, with no apparent connections to an airway, yielded drug-sensitive 
bacteria only after extended incubation (3 to 10 months). Adapted from Vandiviere et al. (1956) by 
Munoz-Elias & McKinney (2002). (B) In vivo drug tolerance in mice. Mice infected with M . 
tuberculosis (Erdman) were put on I N H monotherapy from w k 4-12 post-infection (empty) or not 
(solid). (C) In vitro vs in vivo susceptibility of M . tuberculosis isoniazid (INH) and rifampin (RTF); 
(Fig. C: courtesy of J.D. McKinney). 
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that were "open" and active yielded colonies of drug-resistant tubercle bacilli in 
the normal time frame of 3-8 wks; in contrast, lesions that were "closed" and 
inactive yielded colonies only after 3-10 months of incubation, and these 
"resurrected" bacteria were fully drug susceptible. 
These clinical findings parallel pioneering experiments in the mouse model 
of TB by McCune, McDermott, and Tompsett (McCune & Tompsett 1956; 
McCune et ah 1956, 1966a, 1966b) who established the Cornell model of drug-
induced latency (See above). McDermott (1958) defined in vivo "persisters" as 
those "microorganisms which are drug susceptible when tested outside the body 
[but] are nevertheless capable of surviving within the body despite intensive 
therapy". Importantly, these persisters are not genotypically resistant (do not have 
higher minimal inhibitory concentrations, MICs) and are not genotypically tolerant 
(do not have mutations that allow survival in the absence of replication). Thus, the 
nature of these persisters largely remains an enigma. 
The nature of 'persisters.' This type of bacterial persistence was first 
recognized by Bigger (1944), who observed that penicillin treatment of a growing 
culture of Staphylococcus aureus consistently failed to kill a fraction of the 
population (106). Remarkably, these bacteria, which he called "persisters," could 
survive exposure to multiple antibiotics and stresses and were therefore postulated 
to be in a modified state in which they were neither able to replicate, nor 
permanently incapacitated since they retained the ability to grow like wild-type 
when cultured in the absence of antibiotics. 
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One important question regarding the nature of "persisters" is whether they 
generate spontaneously or are induced by exposure to antibiotics. Recently, 
Balaban et ah, (2004) took advantage of two previously described E. coli strains 
which formed high numbers of persisters, hipA7 (Moyed & Bertrand, 1983) and 
hipQ (Wolfson et ah, 1990), and microfluidic devices which allowed the analysis 
of the history of individual cells after subjecting the population to antibiotic-
mediated killing, to demonstrate the existence of at least two types of persisters, 
both of which were shown to be present in the population prior exposure to 
antibiotic. Type I persisters are a preexisting subpopulation of non-growing cells 
generated at stationary phase. The size of the population of type I persisters is 
directly proportional to the number of stationary phase cells inoculated into a 
culture. Type II persisters are a subpopulation of cells that multiply more slowly 
than the majority of the cells in the culture, a state that appears to be inherited for 
several generations. Since type II persisters are constantly generated during 
exponential growth, the number of type II persisters present in a growing culture 
increases in step with the population, and is not influenced by the size of the 
inoculum. 
Since these persisters survive treatment with antibiotics but their generation 
is independent of exposure to them, they are probably generated during natural 
infections and might play a role in persistent infections including TB. How might 
these persisters arise during M. tuberculosis infection? Most bacteria in the 
sputum of TB patients are susceptible to killing by antibiotics, as suggested by 
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rapid conversion to sputum negativity soon after onset of chemotherapy; thus it is 
unlikely that many of these bacteria are persisters. Since M. tuberculosis infection 
involves the inhalation of infectious droplet nuclei containing between 1-10 
bacilli, natural transmission of persisters is unlikely. Persisters could be generated 
as the infection progresses. Type II persisters could be generated during the initial 
period of replication before the onset of CMI and probably in smaller numbers 
during periods of active replication throughout the chronic phase of the infection. 
Type I persisters could be generated during periods of no replication, which might 
be similar to stationary-phase. If bacterial replication resumes sporadically during 
latency, only to be curtailed by the protective immune response, type I persisters, 
by virtue of their lag in coming out of stationary phase, might be protected from 
such killing and enriched for. Both types of persisters would be intrinsically 
tolerant to the cidal action of antibiotics, but type II persisters would be expected 
to be more sensitive to killing by antibiotics than type I persisters because 
replication and cell division require macromolecular synthetic processes that are 
targeted by currently available drags. 
But why is M. tuberculosis so recalcitrant to eradication by the host and by 
antibiotics compared to other bacteria that also have the ability to form persisters? 
One reason might be its intrinsic resistance to chemical and physical stress, which 
could act as a barrier to the efficient penetration by drugs. Additionally, M. 
tuberculosis might have evolved a high rate of generation of persisters. The 
existence of high persistence mutants in other bacteria indicates that the ability to 
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form persisters is under genetic control and therefore subject to evolution. 
Bacterial species might have evolved specific rates for generation of persisters, 
which fit their particular life styles, e.g., it is possible that bacterial species that 
spend a lot of time in biofilms have a high basal rate of persister generation, and 
that the resistance to killing displayed by bacteria in a biofilm might be due to this 
high fraction of persisters. M. tuberculosis, having evolved to cause chronic and 
latent infections in humans, would likely benefit from having an intrinsically high 
persister generation rate. In LTBI, acquired immunity, which effectively controls 
and kills most of the infecting bacteria, might fail in eradicating all the bacteria 
because surviving cells might be persisters that are phenotypically resistant to host 
antibacterial chemical compounds (ROIs, RNIs, acid, hydrolases, etc) as well as to 
commonly used antibiotics. Interestingly, recent modeling suggests that high 
persister generation might be a physiological adaptation well suited to life in 
environments where antibiotics (stresses) are intermittently encountered, while 
low rates of persister generation might be better suited for life in an environment 
where exposure to anbiotics (stresses) is rare (Kussell et ah, 2005). Generation of 
persisters may be important for pathogens like M. tuberculosis which depend on 
long-term survival in the dynamic environment of the immune-aware host for 
transmission. Whether environmental signals might influence the manifestation of 
the persister phenotype is unknown; there could be significant interplay between 
the myriad of mechanisms involved in stress survival by bacteria and the 
mechanism(s) of persister generation. 
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C H A P T E R 3 
Bacterial Metabolism in vitro 
I N T R O D U C T I O N 
We have learned much about the metabolism of bacteria since the observation of 
these animacules under Leeuwenhoek's crafty lenses, and their early cultivation in 
Pasteur's expertly sterile hands (de Kruif, 1926). Most of this knowledge has been 
gained from the study of a handful of species, mostly the enterics Escherichia coli 
and Salmonella enterica serovar typhimurium, and has resulted in our vast current 
understanding of physiology and metabolism. However, since most of these 
studies were and continue to be conducted in the laboratory, generally under 
artificially optimized conditions, much less is known about the physiology and 
metabolism of bacteria living in their natural environments. This void in our 
understanding extends to those few species that are arguably the most relevant 
ones, those bacteria that as part of their intended or accidental life cycles inhabit 
and cause malaise in humans, and occasionally their death. This chapter is a 
general discussion of bacterial metabolic pathways with an emphasis on carbon 
metabolism, largely drawing from the work on enterics; however, an effort has 
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been made to highlight what is known to occur or might occur in M. tuberculosis 
and other mycobacterial species. 
3.1. General metabolic considerations 
In order to sustain themselves, chemotrophic bacteria need a number of elements 
in varying quantities. Some elements such as carbon (C), oxygen (O), hydrogen 
(H) and nitrogen (N), which are abundant constituents of cells, as well as calcium 
(Ca), chloride (CI), iron (Fe), phosphorous (P), potassium (K), magnesium (Mg), 
and sulfur (S), which are needed for various cell functions, are required in 
relatively high concentrations (>100 \iM). A number of other elements such as 
manganese and zinc are needed in trace amounts. All of these elements are 
generally found in substances referred to as nutrients, which are also energy 
sources since their catabolism can lead to ATP generation, the energy currency of 
the cell. Some of this ATP can be produced directly from metabolic intermediates 
containing high-energy phosphoryl bonds by the transferring of this group to ADP 
(substrate-level phosphorylation). However, most ATP molecules are generated 
through respiratory chains in which the flow of electrons from negative redox-
potential donors to more positive redox-potential acceptors is linked to the transfer 
of the phosphoryl groups to ADP molecules. ATP is employed to activate 
metabolic intermediates for further chemical reactions necessary for cell 
maintainance, growth, and genetic perpetuation. While the electron donor can be 
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either an organic or an inorganic compound, the electron acceptor is in most cases 
oxygen, though other electron acceptors such as carbon dioxide, nitrate, and 
sulfate are sometimes used. 
In addition to the elements so far listed, different types and amounts of a 
variety of compounds must sometimes be obtained from the environment, 
depending on whether the bacteria can synthesize them themselves. These include 
prosthetic groups of various enzymes such as nicotinic acid (precursor of 
coenzymes NAD+ and NADP+), lipoic acid, riboflavin B2 (precursor of flavin 
mononucleotide, FMN), flavin adenine dinucleotide (FAD) and thiamine 
(precursor of thiamine pyrophosphate), as well as other vitamins and some amino 
acids. 
3.2. Substrate uptake 
Passively diffused substrates (oxygen, C02) get into cells without interaction with 
cell membrane components until equilibrium is established; their transport does 
not involve energy expenditure. Similarly, facilitated diffusion requires no 
energy, but does involve a membrane carrier. Active transport, in contrast, is 
substrate specific and requires energy. One type of active transport involves the 
electron transport chain or ATP hydrolysis at the membrane and its coupling with 
the carrier's ability to bind and transport the substrate into the cell. Another type 
involves substrate-specific binding proteins, which usually hydrolyse ATP. Group 
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translocation by chemical modification of the transported substrate via formation 
of a phosphate ester is also common and in this case the donor is a phosphorylated 
substrate specific enzyme that traps the substrate in the membrane and frees it into 
the cytoplasm in the phosphorylated form. The transport of sugars in E. coli 
occurs through this mechanism via the phosphoenolpyruvate:glucose 
phosphotransferase system (PTS), where the phosphate donor is phosphoenol 
pyruvate (PEP). This pathway is found mostly in facultative and obligate 
anaerobic bacteria and is apparently absent in mycobacteria (Romano, 1970). 
3.3. Carbon catabolism and cellular biosynthesis 
Bacteria can either use organic (carbon heterotrophs) or inorganic compounds 
(carbon autotrophs) to generate energy and cell constituents. Mycobacteria are 
heterotrophs and can use a variety of carbon substrates as sources of carbon and 
energy. In addition to chemotrophy, mycobacteria are also capable of 
chemolithotrophy since they all contain a CO dehydrogenase and can grow on CO 
(Park et ah, 2003). Bacteria can grow on a number of carbohydrates including 
glucose, fructose, lactose, and pentoses, on several organic acids including 
pyruvate, malate, and succinate, as well as on a number of amino acids, and fatty 
acids of different lengths, including acetate and propionate. Carbon utilization 
studies in vitro have shown that M. tuberculosis and other mycobacteria can 
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oxidize a number of carbon substrates including carbohydrates, lipids, and amino 
acids (Wheeler, 1984). 
Carbon substrate catabolism provides the bacterial cell with energy in the 
form of reducing equivalents to generate ATP, and with essential biosynthetic 
precursors. Glucose-6-P, fructose-6-P, 3-P-glycerate, PEP, pyruvate, acetyl-CoA, 
oxaloacetate and alpha-ketoglurate are all precursors of monomers such as sugar 
phosphates, amino acids, vitamins, fatty acids, and nucleotides, which are then 
assembled into macromolecular cellular components such as proteins, 
polysaccharides, lipids, and nucleic acids that make up the cell. A partial list is 
provided in table 3.1. 














mannose-6-P, hexoseamines (N-acetylglucosamine 
of LPS and peptidoglycans) 
Phospholipids 
Glycine, Serine, Cysteine 
Phenylalanine, Tryptophan, Tyrosine 
Alanine, Valine, Leucine 
Fatty acids 
Fatty acids 
Arginine, Glutamate, Glutamine, Proline 
Porphyrins 
Asparagine, Aspartate, Isoleucine, Lysine, 
Methionine, Threonine 
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3.4. Pathways of carbohydrate catabolism 
Sugars such as glucose and other hexoses are used by many bacteria as sources of 
carbon and energy. Glucose is not only a highly versatile biosynthetic precursor, 
but thanks to its relatively high potential energy, it is also an excellent fuel for 
ATP generation. A typical bacterial cell uses half of the glucose available to it for 
biosynthetic purposes and the other half for ATP generation (Fraenkel, 1996). In 
several bacteria, the transport of glucose into the cell is linked to its 
phosphorylation via the PTS, which is unique to bacteria (Anderson and Wood, 
1969). Searches of the M. tuberculosis genome with the glucose-specific (or 
fructose-specific) phosphotransferase enzyme IIA or other components of the PTS 
systems yielded no homologues. Some bacteria, including E. coli and Salmonella 
have a hexokinase (glk) and while glk mutants grow normally on glucose medium, 
PTS-deficient bacteria grow slowly on glucose relying on this hexokinase. M. 
tuberculosis does not have a clear glk homologue (possibly Rv0650), but it does 
have a clear polyphosphate glucokinase homolog, and transposon mutants of 
ppgK, encoding this putative sugar transporter, grow slowly on glycerol/dextrose-
containing plates (Sassetti et ah, 2003). 
The three main pathways of sugar intermediary metabolism are the 
Embden-Meyerhof pathway (glycolysis), the pentose phosphate pathway, and the 
Entner-Doudoroff pathway (Romano & Conway, 1996; Peekhaus and Conway, 
1998). 
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3.4.1. Entner-Doudoroff pathway. Some bacteria metabolize sugars through 6-
phosphogluconate via the Entner-Doudoroff pathway (EDP) (Fig. 3.1) (Entner & 
Doudoroff, 1952). Though the EDP is widely distributed and apparently one of 
the most ancient in evolution, its significance in carbon catabolism is only 
beginning to be understood (Romano & Conway, 1996). Studies carried out over 
the past few decades, most of which analyzed E. coli grown in bactch cultures and 
high glucose concentrations, indicated that the EDP played a minor role in 
carbohydrate metabolism. In contrast, recent functional genetic analyses suggest 
that the EDP is heavily employed and is essential for the survival of E. coli in the 
mammalian intestine (Chang et ah, 2004). Furthermore, recent analysis of 
bacterial species not routinely studied in the laboratory is uncovering a much more 
central role for the EDP in bacterial sugar catabolism than previously realized 
(Fuhrer et ah, 2005). Genes encoding enzymes of the EDP, namely glucose 
oxidase (gcd), 6-P-gluconate dehydrase (edd), and 2-keto-3-deoxy-6-P-gluconate 
aldolase (edd) are not found in M. tuberculosis or M. leprae genomes as 
determined by BLASTP searches with the E. coli sequences. Likewise homologs 
of genes involved in the transport of gluconate (gluconate permeases: gntP and 
gntT) or its activation (gluconate kinase: gntK) are also missing. 
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Fig. 3.1. Carbohydrate metabolism pathways. The best-characterized pathways of carbohydrate 
catabolism are glycolysis, the pentose phosphate pathway (PPP), and the Entner Doudoroff pathway 
(EDP). Glucose anabolism occurs via gluconeogenesis. Enzymes c o m m o n to glycolysis and 
gluconeogenesis are indicated by thick double-headed arrows. Irreversible reactions: 
phosphofructokinase and pyruvate kinase (glycolysis), and fructose-1,6-biphosphatase and P E P 
synthase (gluconeogenesis). pts, PEP:glucose phosphotransferase system; glk, glucose kinase; pgi, 
phosphoglucose isomerase; pflc, phosphofructokinase; fbp, fructose- 1,6-bisphosphatase; fba, 
fructose-1,6-bisphosphate aldolase; tpi, triosephosphate isomerase; gap, glyceraldehyde 3-
phosphatedehydrogenase; pgk phosphoglycerate kinase; pgm, phosphoglyceratemutase; eno, 
enolase; pyk, pyruvate kinase; pps, P E P synthase; ppdk, pyruvate phosphate dikinase; gcd, glucose 
dehydrogenase; gntK, gluconate kinase; zwf, glucose-6-phosphate dehydrogenase; pgl, 6-
phosphogluconolactonase; edd, 6-phosphogluconate dehydratase; eda, 2-keto-3-deoxy-6-
phosphogluconate aldolase; gnd, 6-phosphogluconate dehydrogenase; rpe, ribulose-5-phosphate 
epimerase; tkt, transketolase; tal, transaldolase. Genes absent in mycobacteria are indicated by 
parenthesis/dashed arrows (Modified from Fraenkel, 1996). 
84 
3.4.2. The pentose phosphate pathway. The pentose phosphate pathway (PPP) 
(Fig. 3.1) allows the oxidation of one molecule of glucose to 3 of C02 and 1 
glyceraldehyde-3-P with the concomitant generation of NADPH; NADPH is 
required for reactions in which NADH cannot act as co-enzyme. The PPP also 
generates pentose phosphates, which are precursors of nucleotide biosynthesis, 
and erythrose-4-P, which together with phosphoenol pyruvate (PEP), are 
precursors of aromatic amino acids (Romano & Conway, 1996). In B. abortus the 
PPP alone can be used for sugar metabolism. M. tuberculosis has homologs of the 
genes of the PPP, including glucose-6-P dehydrogenase (zwfl and zwfl), 
phosphogluconolactonase (pgl), 6-phosphogluconate dehydrogenases (gndl and 
gndl), transaldolase (tal) and transketolase (tkt). E. coli oxidize up to a third of 
the glucose available throuhg the PPP, and the rest through glycolysis. However, 
other species use the PPP mostly for biosynthetic purposes. Importantly, the PPP 
pathway can function as a cycle and allow aerobic growth on carbohydrates in the 
absence of a functional TCA cycle (Fig. 3.1). Glucose-6-phosphate 
dehydrogenase activity (GND) was long ago demonstrated in extracts from fast 
and slow growing mycobacteria (Sharma et ah, 1985), and M. tuberculosis 
transposon mutants in several PPP genes (gndl, tkt, tal) are impaired for growth 
on standard mycobacterial medium (Sassetti et ah, 2003). 
3.4.3. Embden-Meyerhof-Parnas pathway (Glycolysis). Glycolysis (Fig. 3.1) is 
widely used for the degradation of glucose-6-P to pyruvate (Fraenkel, 1996). 
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Lacking a PTS, M. tuberculosis likely activates glucose by phosphorylating it via 
polyphosphate glucokinase (PPGK). In E. coli, the inter-conversion of glucose-6-
P and fructose-6-P is catalyzed by P-glucose isomerase (pgi). Apgi E. coli grow 
slowly on glucose, and do so relying on the PPP since deleting either zwf or gnd in 
apgi-nnll background abrogates growth (Fraenkel & Levisohn, 1967). Similarly, 
PGI-deficient M. smegmatis grow on glucose but at a lower rate and after a 
protracted lag phase (Tuckman et ah, 1997). M. tuberculosis pgi mutants are also 
impaired for growth on glucose-containing media (Sassetti et ah, 2003). 
Fructose-6-P is converted to Fructose-1,6-P2 by phosphofructokinase (pfk). 
E. coli has two PFK isoenzymes, neither of which is essential for growth on 
glucose, however, pfkA appears to encode the main PFK in this species since pfkA 
mutants are more markedly impaired for growth on glucose than mutants in pfkB 
(Doelle, 1975; Vinopal & Fraenkel, 1975; Vinopal et ah, 1975). Similarly, M. 
tuberculosis has two putative PFKs, which appear to overlap functionally (Sassetti 
et ah, 2003). Interestingly, E. coli ApfkAIApfkB mutants cannot grow on glucose, 
but constitutivity of the glyoxylate cycle (GC), an anaplerotic pathway normally 
employed during growth on even-chain fatty acids (C2 substrates), as a result of a 
mutation in the GC regulator iclR, can compensate for the partial loss of PFK 
(ApfkA) (Vinopal & Fraenkel, 1974), which suggests that when there is reduced 
flow of carbon into into the lower part of glycolysis, the GC might supply 
sufficient PEP via PEP carboxykinase (PCK) (Romberg & Smith, 1970). 
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Fructose-1,6-P2 aldolase (fba) splits fructose-1,6-P2 into 
dehydroxyacetone-P and glyceraldehyde-3-P, and interconversion of these two 
products is catalyzed by triose-P-isomerase (tpi) (Bai et ah, 1982). As expected, 
M. tuberculosis tpi mutants do not grow well on standard 7H10 plates where 
glucose and glycerol are the main carbon sources (Sassetti et ah, 2003). When E. 
coli use glycerol as a carbon source, its conversion to dihydroxyacetone-P must be 
accompanied by its isomerisation to glyceraldehyde-3-P to avoid the production of 
methylglyoxal, which can be toxic to cells (Cooper & Anderson, 1970). This 
might not be an issue during glycerol catabolism in mycobacteria because 
methylglyoxal synthase (mgsA) seems to be absent in these species. 
Glyceraldehyde-3-P is converted to glycerate-l,3-P2 by glyceraldehyde-3-P 
dehydrogenase (gap); glycerate-l,3-P2 can be interconverted to 3-P-glycerate by 
P-glycerate kinase (pgk), which can be interconverted to 2-P-glycerate by P-
glycerate mutase (gpm), of which several homologues exist in M. tuberculosis. 2-
P-glycerate is dehydrated to PEP by enolase (eno). Though functional TPI, GAP, 
PGK and ENO enzymes are required for growth on either glycerol or succinate 
alone, if both substrates are provided, these steps are dispensable (Anderson & 
Wood, 1969; Fraenkel, 1996). Up until this point in glycolysis, the only 
irreversible reaction dicussed is that catalyzed by PFK. 
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3.5. Conversion of P E P to pyruvate and the fate of pyruvate 
Conversion of PEP to pyruvate by pyruvate kinase (PYK) is coupled to ATP 
generation (Clark, 1989). E. coli lacking PYK (PYKI and PYK2) grows slowly on 
glucose, relying on the PPP for sugar catabolism and energy, the PTS system for 
pyruvate generation, and PEP carboxylase (PPC) for replenishment of 
oxaloacetate (Ponce et ah, 1998; Peng & Shimizu, 2003). PYK-deficient E. coli 
can only grow on sugars that are transported by the PTS because pyruvate is 
formed when the phosphoryl group of PEP is donated (Anderson & wood, 1969). 
B. subtilis PYK-deficient mutants grow slowly on glucose (Fry et ah, 2000) 
despite lacking a PPC, likely because their PTS provides the necessary pyruvate. 
Since M. tuberculosis lacks both a PTS and PPC, a PYK-deficient mutant 
should not grow on sugars. While M. tuberculosis has a functional PYK enzyme, 
the related species M. bovis lacks this activity (Gamier et ah, 2003) and cannot 
grow on glycerol or dextrose (Keating et ah, 2005). M. bovis grows well on 
several C2 and C3 (odd chain fatty acids) substrates in vitro (unpublished, E.J.M.). 
Most commonly, pyruvate is oxidized through decarboxylation to acetyl-
CoA via the pyruvate dehydrogenase (PDH) complex, which is composed of 
pyruvate dehydrogenase (El), a dihydrolipoamide acetyl (succinyl-) transferase 
(sucB, E2), which liberates the acetyl-CoASH molecule, and dihydrolipoamide 
dehydrogenase LPD (E3), which regenerates the dihydrolipoic acceptors 
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covalently attached to lysine residues on the E2 acetyl (succinyl-) transferase 
component (Argyrou & Blanchard, 2001). The PDH complex is present in almost 
all aerobic heterotrophs so far studied (Neveling et ah, 1998). The LPD subunit is 
the same as that in the E3 of 2-ketoglutarate dehydrogenase (a-KGDH). M. 
tuberculosis LPD and the SUCB components of PDH/a-KGDH apparently 
participate in the detoxification of peroxynitrite in vitro (Byrk, et ah, 2002). 
3.6. The tricarboxylic acid cycle (TCA cycle) 
The TCA cycle is the predominant cycle of intermediary metabolism in animal 
tissues, where it oxidizes acetyl-CoA to C02 and provides several important 
biosynthetic precursors. However, the TCA cycle is generally more widespread in 
eukaryotes than it is in prokaryotes; bacterial genomes often lack one or more 
genes of the pathway, most commonly an a-ketoglutarate dehydrogenase 
component (Cordwell, 1999). 
In the TCA cycle, oxaloacetate (oxaloacetate) (a C4-dicarboxylic acid) 
condenses with acetyl-CoA (high potential-energy C2 compound) yielding citrate 
(C6 compound) (Fig. 3.2) (Cronan & LaPorte, 1996). The cycle then oxidizes this 
C6 compound back to the C4 releasing two C02 molecules and gaining ATP, GTP, 
NADH+, and FADH2 molecules in the process. Acetyl-CoA, which can originate 
from sugars (glycolysis and PDHC), fatty acids (P-oxidation), or through direct 
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Fig. 3.2. Tricaboxylic Acid Cycle. The T C A cycle allows the oxidation of acetyl-CoA to C 0 2 with 
concomittant gain of reducing equivalents. Quantity and type of carbon substrate, as well as oxygen 
levels, affect expression of T C A cycle enzymes; induction of the T C A cycle is most pronounced 
when bacteria grow on C 2 substrates under aerobic conditions. Gene names are those used for M . 
tuberculosis (H37Rv annotation) (TubercuList: http://genolist.pasteur.fr/TubercuListA 
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condensation with oxaloacetate by action of citrate synthase. M. tuberculosis has 
three genes that could encode this activity (gltAl, gltAl, citA). The isomerization 
of citrate to isocitrate is catalyzed by a two step reaction carried out by aconitase 
(ACN, acs), which first dehydrates citrate to the enzyme-bound form cis-aconitate, 
and subsequently adds a water molecule to this intermediate to produce the free 
isocitrate. Isocitrate is then oxidized and decarboxylated to a-ketoglutarate 
by isocitrate dehydrogenase. M. tuberculosis has two isocitrate dehydrogenases 
(IDHs) (icdl, icdl) (Sharma et ah, 1985). Similarly, Ralstonia species encode two 
IDHs and these are functionally redundant (Wang et ah, 2003a). 
The oxidation of a-ketoglutarate to succinyl-CoA is catalyzed by the a-
ketoglutarate dehydrogenase complex (a-KGDH), which is analogous to the PDH 
complex which oxidizes pyruvate to acetyl-CoA. In M. tuberculosis, PDH and a-
KGDH complexes apparently have in common not only the LPD (E3) component, 
but also the lipoate dehydrogenase (E2) component, since the only lipoylated 
protein in the M. tuberculosis proteome is SUCB (E2) (Bryk et ah, 2002). The 
conversion of succinyl-CoA to succinate is catalyzed by succinate thiokinase 
(sucCD) and is accompanied by the generation of an ATP molecule by substrate 
level phosphorylation by taking advantage of the high energy thioester group in 
succinyl-CoA. In E. coli, a-KGDH dehydrogenase genes (sucAB) and the 
succinate thiokinase genes (sucCD) are in an operon (sucABCD); in M. 
tuberculosis, sucCD form an operon, but sucA and sucB do not. 
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Succinate dehydrogenase (SDH, sdhA-D) then oxidizes succinate to fumarate, 
which is subsequently hydrated to malate by fumarase (FUM, fum). In E. coli, an 
NAD-dependent malate dehydrogenase (MDH) is primarily responsible for the 
oxidation of malate to oxaloacetate. Malate:quinone-oxidoreductase (MQO), an 
FAD-dependent membrane-associated protein, which can also catalyse the 
oxidation of malate to oxaloacetate while the electrons are donated to quinones of 
the electron transport chain instead of to NAD+ (Kather et ah, 2000), is only 
required if MDH is missing (Molenaar et ah, 2000; van der Rest et ah, 2000). In 
contrast, MQO is the principal enzyme catalyzing the oxidation of malate to 
oxaloacetate in C. glutamicum, and Amqo mutants of this species cannot grow on 
C2 substrates. In fact, purified C. gltuamicum MDH readily catalyzes the 
reduction of oxaloacetate to malate (Molenaar et ah, 2000). Similarly, in P. 
aeruginosa MQO rather than MDH oxidizes malate to oxaloacetate and is needed 
for growth on acetate; the function of MDH in this species is not known 
(Kretzschmar et ah, 2002). These observations suggest that in at least some 
bacteria, MDH is involved in the reductive branch of the TCA cycle (See Fig. 3.3), 
while MQO functions in TCA cycle and/or the GC during growth on C2 substrates 
(See Fig. 3.2, 3.6). Mycobacteria have both types of malate dehydrogenase. 
Addition of cAMP to low-oxygen cultures of M. bovis (BCG) upregulates 
expression of mdh, which could mean that mycobacteria increase flow of carbon 
through the TCA and glyoxylate cycles under these conditions (Gazdik & 
McDonough, 2005), or, alternatively, that the TCA cycle functions reductively 
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Fig. 3.3. Branched and 'modified' T C A Cycle. The branched (biosynthetic) mode of operation of 
the citric acid cycle is employed by bacteria growing under aerobic conditions in excess glucose or 
anaerobically on any carbon substrate, and by bacteria that lack a-ketoglutarate dehydrogenase, the 
pathway plays a strictly biosynthetic role. A T P is obtained from glycolysis and from acetyl-CoA 
catabolism via the P T A / A C K pathway (not shown). The glyoxylate cycle is needed for anaplerosis. 
In M. tuberculosis the T C A cycle might operate in the branched mode via K G D and G A B D 
replacing a-ketoglutarate dehydrogenase. Abbreviations: CIT, citrate cynthase; ACN,aconitase; 
IDH, isocitrate dehydrogenase; SUC,. succinyl-CoA synthetase; K G D , a-ketoglutarate 
decarboxylase; S S A D H , succinic semialdehyde dehydrogenase; SDH, succinate dehydrogenase; 
FRD, fumarate reductase; F U M , fumarase; M D H , malate dehydrogenase; M Q O , malate:quinone 
oxidoreductase; ICL, isocitrate lyase;MLS, malate synthase. 
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under these conditions, depending on whether mycobacterial M D H is more similar 
in function to the MDH of E.coli or C. glutamicum, respectively. 
All the TCA cycle enzyme activities have been demonstrated in protein 
extracts from animal tissues and many bacteria (Cronan & LaPorte, 1996). 
Mycobacterial genomes have homologs of every step of the cycle. Many of the 
activities including those of ACN, IDH, SDH, FUM and MDH have been 
demonstrated in several fast and slow growing mycobacteria including M. vaccae, 
M. phlei, M. avium, and M. leprae (Sharma et ah, 1985; Katoch et ah, 1987). 
Activities of the TCA cycle enzymes have also been demonstrated in M. 
tuberculosis (Murthy et ah, 1973), except for a-KGDH activity, which was 
extremely low; however, since the TCA cycle is an inducible pathway, several 
growth conditions should be tried before railing out the presence of a particular 
activity (Iuchi & Lin, 1988; 1991; Guest & Russell, 1992; Hayashi et ah, 2002; 
Lorenz et ah, 2004). Recently, it has been reported that M. tuberculosis indeed 
lacks a-KGDH activity, and that instead, an a-ketoglutarate decarboxylase 
converts a-ketoglutarate to succinic semialdehyde, which is then converted to 
succinate (Tian et ah, 2005) (Fig. 3.3). 
The main factors affecting expression of TCA cycle enzymes are oxygen, 
and the type and concentration of carbon source available to the cell (Gray et ah, 
1966; Spencer & Guest, 1987, Lynch & Lin, 1996; Park et ah, 1997). TCA cycle 
enzymes are expressed in low levels in anaerobiosis and in glucose-excess aerobic 
growth, and in high levels during aerobic growth on C2 compounds such as fatty 
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acids or acetate (Amarasingham & Davis, 1965; Ornston & Ornston, 1969; Chin et 
ah, 1989; Holms, 1996; Lynch & Lin, 1996; Peng & Shimizu, 2003). Gene 
expression and carbon flux analyses in C. glutamicum suggest a similar control of 
the TCA cycle (Weindisch et al, 2000; Hayashi et al, 2002). Conditions 
affecting the expression of key enzymes of the TCA cycle also affect the way the 
cycle operates (Gray et al, 1966). As mentioned previously, during anaerobic 
growth on glucose, E. coli obtains energy from glycolysis and utilizes the TCA 
cycle in a bifurcated mode (Fig. 3.3) in which the oxidative branch [citrate 
synthase, aconitase, isocitrate dehydrogenase] produces 2-ketoglutarate, while the 
reductive branch [malate dehydrogenase, fumarase, fumarate reductase (replaces 
succinate dehydrogenase), and succinate thiokinase (a.k.a succinyl-CoA synthase)] 
produces succinyl-CoA (Amarasingham & Davis, 1965). Interestingly, succinyl 
CoA synthase activity is high in leprosy bacilli grown in vivo (Wheeler, 1984). 
In the absence of a suitable electron acceptor, E. coli converts acetyl-CoA 
to a mixture of acetic acid and ethanol via fermentation (Cozzone, 1998). 
Whether fermentative or acetate producing pathways are employed by 
mycobacteria is not known; however, genes putatively encoding fermentative 
enzymes such as formate lyase (pfl) or lactate dehydrogenase (lid), as well as 
acetate producing enzymes (ack, pta) are present in mycobacterial genomes. 
Although much has been learnt about sugar metabolism from model 
organisms such as E. coli, Salmonellae, and B. subtilis over the last century, it is 
becoming apparent that some of the tenets of central metabolic pathways do not 
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apply to bacterial strains/species that are not laboratory-adapted. For instance, 
recent carbon 13C tracer flux analysis experiments with several non-laboratory-
adapted phylogenetically distinct bacteria indicate that unlike E. coli or B. subtilis 
laboratory strains, many bacteria catabolize sugars via the EDP rather than 
glycolysis, and rely on the PPP almost exclusively to fulfill biosynthetic needs. 
Importantly, all aerobes analyzed apparently employed a full respirative TCA 
cycle for oxidation of acetyl-CoA without any significant overflow of carbon in 
the form of acetate when grown in glucose under aerobic conditions (Fuhrer et ah, 
2005). Although these observations are only of a quantitative nature, they suggest 
that the significance and function of a given metabolic route in one species in a 
particular setting is likely to be much less of a generalizable characteristic than 
previously thought, with different bacteria using different routes of carbon 
utilization to different degrees depending on the conditions of growth. 
3.7. Glycerol catabolism 
Glycerol can be used as a carbon source by many bacteria, and in particular the 
cultivation of mycobacteria in vitro is greatly enhanced by addition of this 
carbohydrate (Katoch et ah, 1987; Wheeler, 1984). In E. coli glycerol is first 
phosphorylated to glycerol-3-P by a glycerol kinase (Hayashi & Lin, 1967). 
Glycerol-3-P is then oxidized to dihydroxyacetone phosphate by glycerol-P 
dehydrogenase (Schryvers et ah, 1978). M. tuberculosis has a glycerol kinase 
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(glpK, Rv3696c) and two putative glycerol-P dehydrogenases (glpDl, Rv2249c; 
glpDl, Rv3302c). Glycerol-3-P is an important precursor of phospholipids, and in 
the absence of an exogenous source of glycerol, cells make glycerol-3-P from 
dihydroxyacetone phosphate employing a glycerol-3-P synthase. The proteins 
encoded by the glp regulon can also be used by the cell for recycling the glycerol 
moiety of phospholipids and triglycerides. 
3.8. Fatty acid catabolism 
Cells need to metabolize fatty acids to fulfill several physiologic needs. Fatty 
acids provide the building blocks for phospholipids, glycolipids and lipoproteins, 
and their derivatives act as hormones and messengers in many cell types. 
Furthermore, fatty acids are excellent fuels. It has been estimated that 40% of the 
weight of a mycobacterial cell is made up of lipids (Anderson, 1940; Wheeler, 
1988) and about 8% of the M. tuberculosis genome is made up of genes putatively 
involved in lipid metabolism, including over 100 putative catabolic functions 
(Cole et ah, 1998; Cole, 2002). 
Though a permease that can transport acetate into E. coli cells has recently 
been identified (Gimenez et ah, 2003), little is known about the uptake of other 
short- and medium-chain fatty acids (SCFAs, MCFAs), most of which might get 
into the cell by diffusion. The transport of long-chain fatty acids (LCFAs) into E. 
coli cells is mediated by a carrier mechanism which requires fadD and fadL, which 
97 
encode a fatty acyl-CoA synthase (Kamede and Nunn, 1981) and an outer 
membrane protein (Black et ah, 1985), respectively. The exact function of FADL 
is not known, but it increases binding and uptake of MCFAs and LCFAs. 
Mycobacteria lack an outer membrane and have no homologs of fadL genes; 
nothing is known about how fatty acids cross the thick lipid-rich wall and plasma 
membrane of a mycobacterial cell. 
3.8.1. The cycle of beta-oxidation. Bacteria, like eukaryotes, degrade fatty acids 
primarily via a cyclic oxidation pathway known as P-oxidation (Black & DiRusso, 
1994). Some eukaryotes including plants, fungi, and mammals have a 
mitochondrial as well as a peroxisomal pathway of P-oxidation, the components of 
which differ depending on the type of fatty acid they oxidize (Kunau et ah, 1985). 
Through P-oxidation, even-numbered fatty acids (C2 substrates) are oxidized 
stepwise into acetyl-CoA subunits, while odd-chain fatty acids (C3 substrates) are 
similarly catabolized into acetyl-CoA units and a terminal propionyl-CoA unit. 
Acetyl-CoA and propionyl-CoA then entered central metabolism where they are 
further oxidized or serve as precursors for lipid synthesis (Kolattukudy et ah, 
1997; Campbell & Cronan, 2001). Under aerobic conditions, E. coli can grow on 
LCFAs (>12 carbon-long acyl chains) as sole source of carbon, but growth on 
MCFAs (C6-C12) can take place only after p-oxidation enzymes are induced as a 
result of the transport and activation of LCFAs inside the cell (Overath et ah, 
1969). 
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Each turn of the P-oxidation cycle is accompanied by the reduction of one 
FAD+ (acyl-CoA dehydrogenase reaction) and one NAD+ (3-hydroxyacyl-CoA 
dehydrogenase reaction), and the shortening of the acyl chain by two carbons, 
which are released as an acetyl-CoA (CoA-dependent thiolytic cleavage) (Fig. 
3.4). The shortened fatty-acyl-CoA molecule reenters the degradation cycle. 
The principal enzymatic steps are as follows: 
1. Activation of the free fatty acid to an acyl-CoA thioester by acyl-CoA synthase 
(Fatty acid:CoA ligase; EC 6.2.1.3). This step requires two high-energy phosphate 
equivalents per molecule of free fatty acid activated. Once a fatty acid is thus 
activated, no further energy expenditure is required; thus, the longer a fatty acid 
the more energy it can yield. While E. coli has a single acyl-CoA synthase with 
broad specificity for medium and long chain fatty acids, FADD (Overath et ah, 
1969; Klein et ah, 1971), M. tuberculosis has 36 putative fadDs. At least some of 
these FADDs, particularly those adjacent to lipid biosynthetic genes such as the 
polyketide sythases (PKS), function as long-chain fatty acyl-AMP ligases which 
activate fatty acids as acyl-adenylates which might then be transferred to the PKS 
for further processing (Trivedi et ah, 2004). 
2. Next, the CoA ester is oxidized to an enoyl-CoA by a fatty acyl-CoA 
dehydrogenase (FADE). Again, while E. coli has a single fadE, M. tuberculosis 
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Fig. 3.4. b-oxidation pathway of fatty acid degradation in Mycobacterium tuberculosis. Based on 
homology searches of the M. tuberculosis genome (H37Rv; http://genolist.pasteur.fr/TubercuList/) 
using bacterial, fungal and mammalian b-oxidation genes. Gene names are those used for M. 
tuberculosis. E. coli (ECO) and M. tuberculosis (MTB) enzymes are listed. Gene names are 
italicized. Abbreviations: H A C D H , 3-hydroxyacyl-CoAdehydrogenase; SC-HADH, short-chain 3-
hydroxyacyl-CoA-dehydrogenase. (Modified from Clark and Cronan, 1996). 
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has 34 fadE homologs, resembling eukaryotic cells in which many acyl-CoA 
dehydrogenases with different specificities are present (Kunau et ah, 1995). 
3-5. The remaining steps are catalyzed by enoyl-CoA hydratases (ECHs), which 
hydrate the enoyl-CoA to 3-hydroxy(OH)-acyl-CoAs, 3-hydroxyacyl-CoA 
dehydrogenases (FADBs), which oxidize the 3-OH-acyl-CoA to 3-keto-acyl-CoA, 
and 3-ketoacyl-CoA thiolases (FADAs), which cleave away the terminal acetyl-
CoA, freeing the already activated fatty acyl-CoA, which enters another oxidative 
round. The M. tuberculosis genome contains 22 echA genes putatively encoding 
enoyl-CoA hydratases/isomerases. It also has two short 3-OH-butyryl-CoA 
dehydrogenases (fadBl and fadB3), as well as a putative multifunctional long 
FADB (fadB), which has ECH and hydroxyacyl-CoA dehydrogenase (HADH) 
domains. FADB2 and FADB3 belong to a large family of short chain hydroxy 1-
acyl dehydrogenases (SC-HADH) with members in the mitochondrial P-oxidation 
systems of eukaryotes, belonging to the superfamily of short-chain alcohol 
dehydrogenases (Krozowski, 1994). 
M. tuberculosis has many genes potentially encoding SC-HADHs (Cole et 
ah, 1998), including around 30 or so SC-HADHs with homology to fungal 
peroxisomal p-oxidation SC-HADHs. A. nidulans mutants lacking a peroxisomal 
SC-HADH (AfoxA) are impaired for growth on long chain fatty acids, but grow 
normally on C6 fatty acids relying on a mitochondrial short chain P-oxidation 
system (Maggio-Hall & Keller, 2004), and interestingly, the dehydrogenases of 
these mitochondrial pathways are homologous to the E. coli and M. tuberculosis 
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canonical fadB products. Thus, considerable functional overlap exists between 
FADBs and non-canonical short chain dehydrogenases in fungi; whether this is the 
case in M. tuberculosis remains to be determined. 
3.8.2. Catabolism of short chain fatty acids as carbon substrates. In some 
bacteria, including E. coli, growth on SCFAs (C4-C6) requires, in addition to 
some P-oxidation enzymes, the induction of an additional set of activities encoded 
by the atoA, D, B and C genes (Pauli & Overath, 1972). AtoA and atoD encode 
the subunits of an acetoacetyl-CoA transferase involved in the activation of 
acetoacetate and short-chain fatty acids into acyl-CoAs; atoB encodes a 
ketohydroxylacyl thiolase. In addition to repression by FadR (a regulator of 
LCFA utilization), these genes are subject to transcriptional control by a positive 
regulator encoded by atoC (Overath et ah, 1969). Wild-type E. coli cannot grow 
on SCFAs unless FadR is released by activated LCFAs and the ATO system is 
induced by SCFAs. 
In contrast to enterics, mycobacteria readily grow on SCFAs without 
requiring prior exposure to LCFAs. In fact, both M. smegmatis (Munoz-Elias et 
ah, in preparation) and M. tuberculosis (Munoz-Elias & McKinney, 2005) grow 
comparably well in SCFAs and glucose. M. tuberculosis scoA and scoB genes 
have homology to atoD and atoA genes, respectively, and fadA genes have some 
homology to atoB. Thus, it is possible that scoAlB gene products are involved in 
activating SCFAs to acyl-CoAs. Alternatively, one or more of the FADD acyl-
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C o A synthases could perform this function. After processing by a F A D E and an 
ECH, the 3-OH-acyl-CoA could then be oxidized by a FADB or one of the other 
SC-HADHs, into the keto form, which might then be cleaved by a FADA thiolase. 
Given that the scoB/A genes are in an operon with accAl/accDl genes, which 
putatively encode acetyl-/propionyl-CoA carboxylases, it is also possible that the 
degradation of some SCFAs might be linked to the metabolism of propionyl-CoA 
via the methylmalonyl-CoA pathway. 
3.8.3. Regulation of fatty acid utilization. In E. coli the genes encoding the 
functions involved in the transport and p-oxidation of MCFAs and LCFAs form 
the fad regulon, which is under the transcriptional control of the negative regulator 
FadR, which in the absence of LCFAs, represses oxidation and induces fatty acid 
biosynthesis instead (Cronan & Subrahmanyan, 1998; Black et ah, 2000). In E. 
coli, the fadBA operon has a FadR binding site in its promoter, and binding of 
acyl-CoAs (>11 carbons in length) to FadR, releases it from the fadBA promoter 
and allows the synthesis of P-oxidation enzymes. Utilization of fatty acids 
requires the anaplerotic GC, the expression of which is indirectly controlled by 
FadR through IclR (see below) (Ornston & Ornston, 1969). A homolog of fadR is 
absent in M. tuberculosis and essentially nothing is known about the regulation of 
fatty acid catabolism in mycobacteria. 
3.8.4. Utilization of acetate and propionate. 
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Acetate. Acetate might diffuse freely or be transported into the E. coli cell 
by a permease (Gimenez et ah, 2003), and after activation to acetyl-CoA by an 
inducible acetyl-CoA synthase (ACS) (Brown et ah, 1977), it either enters 
biosynthesis or is oxidized to C02 via the TCA cycle (Fig. 3.5A). In Salmonella, 
the histone deacetylase SIR2 is required for ACS activity, and for growth on 
acetate and propionate (Starai et ah, 2003). Growth on acetate, similarly to 
growth on other C2 substrates, requires the GC for anaplerosis (Romberg & 
Krebs, 1957; Romberg & Sadler, 1960). 
E. coli and C. glutamicum growing in high concentrations of glucose 
employ the PTA/ACK pathway, which is composed of a phosphotransacetylase 
(PTA) that reversibly converts acetyl-CoA and Pi to acetyl-P and CoASH, and 
acetate kinase (ACK), which reversibly converts acetyl-P and ADP to acetate and 
ATP (Rose et ah, 1954) (Fig. 3.5A) to produce acetate from acetyl-CoA (Kakuda 
et ah, 1994). However, the pathway can function in the opposite direction, 
especially during growth in high concentrations of acetate, and allows Aacs 
mutants to grow, though poorly, on low concentrations of acetate (Kumari et ah, 
1995) (Fig. 3.5B); Aacs/Apta/Aack mutants cannot grow on acetate (Kumari et ah, 
1995). In addition to eliminating excess acetyl-CoA in the form of acetate, the 
PTA/ACK pathway also provides acetyl-P, which has been proposed as a 
signaling molecule based on in vitro studies using two-component systems and 
acetyl-P as phosphate donor, though the significance of these observations is not 
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Fig. 3.5. Pathways of acetate and propionate metabolism. (A-B) Acetate metabolism. (A) 
Acetate is assimilated via acetyl-CoA synthase. A C S can also use propionate as a substrate. (B) 
PT A / A C K is used for acetate production and also provides the acetyl-P signaling molecule. Enzyme 
names are indicated next to corresponding reaction. (C) Odd-chain carbon substrate metabolism via 
the methyl citrate cycle (MCC). The M C C pathway essentially converts propionyl-CoA into 
pyruvate. Enzymes involved: acetyl/propionyl-CoA synthase (ACS, acs), 2-methylcitrate synthase 
(prpC, M C S ) , 2-methylcitrate dehydratase (prpD, M C D ) , and 2-methyl-isocitrate lyase (prpB, 
MICL). Aconitase (ACN, acn) is in common with the T C A cycle, as are the enzymes converting 
succinate to oxaloacetate (not shown). Gene/enzyme names are based on the M. tuberculosis genome 
(Tuberculist.org), although not always annotated as such; when missing, the E. coli name is used (in 
parentheses). (C) Adapted from Tabuchi & Uchiyama (1975). 
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not been found to be affected by loss of either ackA or pta (Cleary & Stock, 1994; 
Chamnongpol & Groisman, 2000). More recently, acetyl-P has been implicated in 
glucose-starvation (Chang et ah, 1999), osmoregulation (Bang et ah, 2002), 
biofilm development (Wolfe et ah, 2003), as well as in nitrogen and phosphate 
assimilation (Reviewed in Wolfe, 2005). 
Mycobacteria have homologs encoding functions of both acetate 
metabolism pathways. It appears that similarly to E. coli, in mycobacteria ACS is 
the major pathway involved in acetate utilization as a carbon source, since Aacs 
mutants of M. smegmatis cannot grow on acetate (L. Merkov, personal 
communication). The function of the PTA/ACK pathway and acetyl-P 
intermediate in mycobacteria is unknown. 
Propionate. In mammalian cells, the metabolism of propionate-, branched-
chain amino acids-, and odd-chain fatty acids-derived propionyl-CoA takes place 
via propionyl-CoA carboxylase (PCCA), a mitochondrial enzyme that 
carboxylates propionyl-CoA to d-methylmalonyl-CoA, which is then rearranged to 
succinyl-CoA. Mutations in PPCA are the cause of propionic acidemia, the most 
frequent autosomal recessive disorder of organic acid metabolism in humans 
(Wolf et ah, 1981). This pathway is also used by several bacterial species 
(Halarnkar & Blomquist, 1989) and has been proposed to function in E. coli 
(Evans etal., 1993). 
However, mounting evidence indicates that several bacteria including E. 
coli (Textor et ah, 1997), S. typhimurium (Horswill & Escalante-Semerena, 1997; 
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1999), C. glutamicum (Claes et ah, 2002), and Ralstonia eutropha (Bramer & 
Steinbuchel, 2001), catabolize propionate via a pathway known as the 
methylcitrate cycle (MCC). The role of the MCC in C3 substrate catabolism was 
discovered three decades ago in Candida lipolytica (Tabuchi & Serizawa, 1975; 
Tabuchi & Uchiyama, 1975), and has more recently been demonstrated in two 
other fungi, S. cervisiae (Pronk et at., 1994) and A. nidulans (Brock et ah, 2001). 
In the MCC, a molecule of propionyl-CoA is condensed with oxaloacetate by 
methylcitrate synthase (MCS, prpC) to form methylcitrate, which is then 
isomerized by the combined action of a dehydratase (MCD, prpD) and aconitase 
(ACN, acs) into methylisocitrate, which is cleaved into succinate and pyruvate by 
methylisocitrate lyase (MICL, prpB) (Tabuchi & Uchiyama, 1975) (Fig. 3.5C). 
The M. tuberculosis genome has homologs of prpC (MCS) and prpD (MCD), in 
addition to the other TCA cycle enzymes in common with the MCC; however, a 
prpB (MICL) is apparently missing. 
The first step in propionate utilization is its activation to propionyl-CoA. 
This can occur via a specific propionyl-CoA synthase (PRPE) as in Salmonellae 
(Horswill & Escalante-Semerena, 1999), or by ACS which, in addition to acetate, 
can use propionate as a substrate. However, not all ACS can use propionate; for 
example S. cereviase has 2 ACS, and while one can use both acetate and 
propionate as a substrate, the other can only use acetate (van den Berg et ah, 
1996). Mycobacteria have only one ACS (acs), whose specificity is unknown. 
Alternatively, propionate activation can occur via the PTA/ACK pathway, which 
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usually operates in the reverse orientation (acetate production). The first step can 
be catalyzed by a specific propionate kinase - tdcD gene in E. coli and 
Salmonellae - which produces propionyl-P. The closest homolog to either of these 
kinases in M. tuberculosis is ackA. ACK from E. coli can function as a propionate 
kinase but is less efficient than the canonical propionate kinase. In the second step 
in the activation of propionate, propionyl-P is converted to propionyl-CoA by 
PTA. 
In E. coli and Salmonellae, the prp genes are subject to catabolite 
repression by glucose (Lee et ah, 2005). In M. tuberculosis, transcription of 
prpDC is upregulated after phagocytosis by macrophages and in vivo 
(Schnappinger et ah, 2003). 
3.9. PEP generation and gluconeogenesis 
Regardless of whether carbohydrates are available as carbon sources or not, 
bacteria need to generate several glycolysis intermediates that serve as 
biosynthetic precursors. In the absence of sugars as carbon sources, cells 
accomplish this via gluconeogenesis, which is essentially glycolysis backwards 
since most glycolytic enzymes readily catalyze the reverse reactions (Fig. 3.1). 
Only the conversion of fructose- 1,6-P2 to fructose-6-P requires a non-glycolytic 
enzyme and this is because the PFK-catalyzed reaction is not readily reversible. 
This strictrictly gluconeogenic enzyme is called fructose-1,6-biphosphatase (fbp), 
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and mutants lacking this activity fail to grow on acetate, dicarboxylic acids and 
other gluconeogenic substrates (Fraenkel & Horecker, 1965). In M. tuberculosis, 
this reaction is carried out by a class II fructose 1,6-bisphosphatase encoded by 
glpX (Movahedzadeh et ah, 2004). The transcriptional activator/repressor Cra 
(era) is apparently responsible for controlling the direction of carbon flow in E. 
coli and Salmonellae and mutants of cra cannot grow on glucogeogenic substrates 
(Saier & Ramseier, 1996). No such regulator has been identified in mycobacteria. 
The starting point of gluconeogenesis varies depending on the carbon 
source available for growth but it is usually pyruvate or PEP. The most common 
precursor of PEP is oxaloacetate, but PEP can also be generated by reactions 
around pyruvate (Fig. 3.6). During growth of E. coli on C2 substrates or 
dicarboxylic acids, PEP carboxykinase (PCK) decarboxylates oxaloacetate to PEP. 
PCK-deficient E. coli can grow on glucose or pyruvate, but not on succinate, 
fumarate, or malate (Anderson & Wood, 1969). PEP can also be generated from 
pyruvate by PEP synthase (PPS), and E. coli lacking PPS cannot grow on 
pyruvate, lactate, or alanine (Cooper & Romberg, 1965; Oh et ah, 2002), 
indicating that E. coli cannot use the pyruvate-oxaloacetate-PEP route (via PCA 
and PCK) for PEP generation under these conditions. Growth of E. coli on 
glucose or PEP requires upregulation of the anaplerotic PEP carboxylase (PPC), 
and downregulation of PCK and PPS; PCK is induced by acetyl-CoA, while PPS 
is induced by pyruvate (Cooper & Kornbeg, 1967). M. tuberculosis and M. bovis 
do not have a PPS homolog, but have a putative pyruvate phosphate dikinase 
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(PPDK), which could generate PEP via phosphorylation of pyruvate as in E. coli, 
thus possibly replacing PPS (Cooper & Romberg, 1965). 
An alternative route for generating PEP from C2 substrates is via malic 
enzyme (MEZ), which decarboxylates malate to pyruvate (Fig. 3.6) (Hansen & 
Juni, 1975). During growth of E. coli on dicarboxylic acids, MEZ produces 
pyruvate, which is oxidized to obtain necessary acetyl-CoA (Pertierra & Cooper, 
1977). In B. subtilis, the pyruvate produced by MEZ apparently also serves as as a 
substrate for pyruvate carboxylase (PCA). In this species, MEZ and PCA form a 
"pyruvate shunt" whose function might be to provide pyruvate during growth on 
gluconeogenic substrates and then recycle back the pyruvate left to acetyl-CoA 
(Diesterhaft & Freese, 1973). A recent quantitative carbon flux study found that 
several non-model bacteria substantially (up to ~30% of carbon flow) relied on the 
pyruvate shunt to obtain oxaloacetate during growth on glucose (Fuhrer et ah, 
2005). M. tuberculosis has both pea and mez genes, but while pea transposon 
mutants are impaired for growth on glucose-containing plates, mez mutants are 
not, suggesting that M. tuberculosis might not need to generate pyruvate from 
malate during growth on glucose (Sassetti et ah, 2003). 
In E. coli, both PCK and MEZ/PPS(PPDK) pathways can be used to 
generate PEP from gluconeogenic substrates. While single ApckA or Apps 
mutants grow on acetate, a double mutant cannot. Likewise, deletion of both 
genes encoding malic enzymes (sfcA and maeB) does not abrogate growth on 
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Fig. 3.6. Cellular biosynthesis and anaplerosis. Anaplerotic reactions are essential for maintaining 
the balance between metabolic pathways. Catabolism of carbohydrates through glycolysis and of 
fatty acids through ̂ -oxidation yield acetyl-CoA, which feeds into the T C A cycle and/or glyoxylate 
cycle (GC). Anaplerosis on carbohydrates is via PPC or PCA, growth on C2 substrates is via the GC: 
isocitrate lyase (icll & 2) and malate synthase (glcB). Gluconeogenesis starts with PEP carboxykinase 
(pckA). A ppc homolog is absent in M. tuberculosis. 
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PPS/PPDK makes P C K essential for gluconeogenesis (Velayudhan & Kelly, 
2002). In C. glutamicum, the purified MEZ favors the decarboxylation reaction 
(toward gluconeogenesis), but deletion of malE (MEZ) has no effect on growth on 
C2 substrates, suggesting that the absence of mez might be compensated by PCK 
as in E. coli (Gourdon et ah, 2000). During growth on glucose, C. glutamicum 
generates oxaloacetate from PEP by PPC, making PCA or the MEZ-PCA pyruvate 
shunt dispensable. Though the function of mez has not been investigated in 
mycobacteria, M. smegmatis seems to rely mainly on PCK to generate PEP during 
growth on C2 or gluconeogenic substrates because a Apck mutant could not grow 
on acetate, pyruvate, succinate or malate, but grew normally on dextrose or 
glycerol (A. Upton, personal communication). This indicates that MEZ and PPDK 
cannot compensate for the loss of PCK in gluconeogenesis. Furthermore, a PCK-
deficient mutant of M. bovis grows normally on standard media where glycerol 
and dextrose are the main carbon substrates, suggesting that PCK is not needed for 
anaplerosis during growth on carbohydrates (Liu et ah, 2003b); the mutant was not 
tested for growth in C2 substrates. 
3.10. Anaplerosis: the replenishment of intermediary metabolites 
In addition to its role in energy generation, i.e., ATP production by substrate level 
phosphorylation and reducing power in the form of reduced pyridine and flavine 
nucleotides (NADH, FADH2) which are oxidized through the respiratory chain to 
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generate more ATP, the T C A cycle also provides essential biosynthetic precursors 
and does so in the form of its intermediates such as oxaloacetate and a-
ketoglutarate. If these C4-dicarboxylic acids of the TCA cycle were not 
replenished, the cycle would quickly run out of intermediates and come to a stop. 
Cells avoid such a fate by constantly replenishing such intermediates from the 
outside directly. Reactions of this sort, which allow net carbon gain, are termed 
anaplerotic reactions (Romberg, 1966). The anaplerotic route an organism 
employs depends on the type and concentration of carbon substrates, as well as on 
the electron acceptor(s) available to it (See Fig. 3.6). Some of these anaplerotic 
routes will be discussed in the next sections. 
3.10.1. Anaplerosis during growth on sugars. When E. coli grow on sugars in 
batch culture (standard sugar concentrations ~ 0.1-0.5% w/v), oxaloacetate is 
replenished by carboxylation of PEP by PEP-carboxylase (PPC). PPC-deficient 
Salmonellae grow poorly on glucose unless TCA cycle intermediates are provided 
(Theodore & Englesberg, 1964). Interestingly, the slow growth on glucose of E. 
coli Appc mutants (~20% slower than wild-type bacteria) is facilitated by 
upregulation of the GC, since when PPC-deficient mutants are grown in relatively 
high glucose (0.4-0.5% w/v), they increase carbon flow through the GC in order to 
obtain sufficient oxaloacetate (Peng et ah, 2004). Thus the anaplerotic function of 
PPC on dextrose can be compensated by the GC. During growth on 
carbohydrates, other bacteria, including B. subtilis and C. glutamicum, replenish 
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T C A cycle intermediates via carboxylation of pyruvate to oxaloacetate by 
pyruvate carboxylase (PCA) (Diesterhaft & Freese, 1973; Peters-Wendisch et ah, 
1998;). Inspection of recently published genome sequences from enterics 
indicates that pea is missing in this group of bacteria. M. tuberculosis and M. bovis 
lack a ppc homolog and Apca transposon mutants are impaired for growth on 
standard 7H10 plates (glucose and glycerol) (Sassetti et ah, 2003), suggesting that 
M. tuberculosis employs PCA for anaplerosis on carbohydrates and that 
compensation by the GC may not occur. Other mycobacteria, including M. 
smegmatis, do have homologs of PPC, suggesting that the loss of ppc might have 
been a recent event in the Mycobacterium genus. 
3.10.2. The Glyoxylate Cycle: anaplerosis during growth on fatty acids and 
other substrates metabolized via acetyl-CoA. As discussed above, many 
bacterial species can utilize short, medium and long fatty acids including acetate 
and propionate, as sources of carbon and energy. Acetyl-CoA produced by fi-
oxidation of fatty acids (Fig. 3.4), is further oxidized to C02 via the TCA cycle 
(Fig. 3.2). When fatty acids are the only carbon source available, replenishment of 
TCA cycle intermediates cannot be accomplished via PPC or PCA. Under these 
conditions, an anaplerotic pathway called the GC becomes indispensable 
(Romberg & Krebs, 1957; Romberg, 1966; Omston & Ornston, 1969) (Fig. 3.6). 
In the first step of the GC, isocitrate lyase (ICL) cleaves isocitrate into glyoxylate 
and succinate, and in the second step, malate synthase (MLS) condenses the 
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glyoxylate with another molecule of acetyl-CoA to form malate (Vanni et ah, 
1991). The succinate is oxidized to fumarate by succinate dehydrogenase (SDH), 
or converted to succinyl-CoA by succinyl-CoA synthase (SUCCD). ICL and 
MLS-catalyzed reactions together with the TCA cycle enzymes SDH, fumarase 
(FUM), malate dehydrogenase (MDH), citrate synthase, and aconitase (ACN) 
constitute the cycle (Fig. 3.6). In addition to mediating the incorporation of two 
new molecules of acetyl-CoA per turn of the cycle, the GC also bypasses the 
decarboxylation reactions of the TCA cycle (IDH and aKGDH steps, Fig. 3.3), 
which further contributes to carbon conservation. 
In E. coli, the genes encoding ICL (aceA) and MLS (aceE) are in an operon 
with aceK (aceBAK), which encodes a regulator of IDH (see below). In M. 
tuberculosis ICL and MLS are encoded by aceA (a.k.a. icll) and glcB, 
respectively, and they are not together in the chromosome (Cole et ah, 1998). A 
gene encoding another putative ICL (ic/2) is present in the genome of all 
mycobacteria. Interestingly, in at least one strain of M. tuberculosis icll might be 
a pseudogene (Cole et ah, 1998), while in M. leprae icll is a pseudogene (Cole et 
ah, 2001). Cell-free extracts from in viYra-grown M. tuberculosis, M. smegmatis 
and armadillo-grown M. leprae have both ICL and MLS synthase activities 
(Kannan et ah, 1985; Bharadwaj et ah, 1987). The data on M. leprae indicates 
that the product of icll is expressed in vivo and that it indeed encodes an ICL. 
The control of carbon flow through the GC. Isocitrate can serve as 
substrate for either IDH (TCA cycle) or ICL (GC), and thus constitutes a branch 
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point in central metabolism, where two enzymes are competing for the same 
substrate. Given the kinetic constants of the E. coli enzymes (IDH's Km = 8 [xM; 
ICL's Km = 600 \iM), it is not surprising that during growth in excess glucose 
most of the isocitrate is preferentially oxidized by IDH. Carbon flux into the GC 
is facilitated in two ways: the GC genes are induced and IDH is deactivated 
(Walsh & Koshland, 1984). In E. coli, aceK of the aceBAK operon encodes an 
IDH kinase/phosphatase which can phosphorylate IDH and thereby drastically 
deactivate the enzyme, thus shifting the flow of carbon toward ICL. Addition of 
glucose to a culture of bacteria growing on acetate, despite increasing growth, 
rapidly lowers carbon flow through the TCA cycle (by 5 fold). Simultaneously, 
the IDH kinase/phosphatase dephosphorylates IDH, which rapidly increases its 
activity and almost completely stops carbon flux through the GC (Walsh & 
Koshland, 1985). It is not clear how glucose mediates these effects (Corzone et 
ah, 1998). 
Expression of the GC in enterics is under the indirect transcriptional control 
of FadR (of fatty acid catabolism) and the direct control of IclR, a repressor which 
binds to its own promoter and that of the aceBAK operon, thereby repressing 
expression of the GC (Maloy & Nunn, 1982; Gui et ah, 1996a). This binding is 
inhibited by PEP (Cortay et ah, 1991). Transcription of iclR is positively 
regulated by binding to its promoter by FadR (Gui et ah, 1996b). No homologs of 
either FadR or IclR have been identified in M. tuberculosis. In C. glutamicum, a 
transcriptional repressor called RamB that binds to the promoter of the aceA (ICL) 
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and aceB (MSL) genes and partially prevents their expression has been described 
recently. However, mutation of ramB does not significantly impair growth on 
acetate or glucose, suggesting that other regulators exist (Gerstmeir et ah, 2004). 
Interestingly, M. tuberculosis apparently has two putative transcriptional 
regulators that have homology to RamB. One of these, Rv0465c, is upstream of 
icll, and the promoter of icll has a motif that is a close match to the well 
conserved motif recognized by RamB in C. glutamicum promoters (Gerstmeir et 
al, 2004). The other putative regulator, Rvll29c, is located upstream of 
homologs of prpC and prpD, which are putatively involved in metabolism of C3 
substrates (see above & Chapter 10). A second repressor of the GC has been 
found in C. glutamicum and it is called GlxR. GlxR bears homology to the cAMP 
receptor-binding protein (CRP) regulator from E. coli. In E. coli, cAMP is the 
mediator of catabolite repression: when glucose is low, intracellular cAMP 
increases, binds CRP and cAMP-CRP activates transcription of several genes 
involved in the utilization of alternative sources of carbon (Lin, 1996). To the 
contrary, in C. glutamicum, growth on glucose leads to high cAMP intracellular 
concentrations, and cAMP-GlxR complexes exert transcriptional repression of 
genes encoding enzymes involved in utilization of alternative carbon substrates 
including GC genes. During growth on acetate, cAMP levels are low, and since 
the repressor cannot bind cAMP, it remains inactive (Kim et al, 2004). ORF 
Rv3676 of M. tuberculosis is over 75% homologous to glxR. 
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3.11. Alternative routes of C2/glyoxylate metabolism 
The glyoxylate produced by the GC is most commonly condensed with acetyl-
CoA by malate synthase to generate malate. However, other routes of glyoxylate 
metabolism exist; some of these are discussed below. 
3.11.1. Glycerate Pathway. In the glycerate pathway, glyoxylate carboligase 
catalyzes the condensation of two molecules of glyoxylate into one molecule of 
tartronate semialdehyde (Gupta & Vennesland, 1964), which is then 
phosphorylated to 3-phosphoglycerate by tartronate semialdehyde reductase and 
glycerate kinase; 3-P-glycerate is then catabolized via glycolysis to pyruvate. M. 
smegmatis can grow on glyoxylate, though poorly (unpublished observations). 
Since this pathway results in the net conversion of two molecules of glyoxylate to 
one of PEP/pyruvate, which could then be converted to oxaloacetate by PCA, this 
routing of the carbon could bypass the need for malate synthase during growth on 
C2 substrates. Though the genes of this pathway appear to be present in several 
mycobacteria, they are apparently absent in M. tuberculosis. In E. coli glyoxylate 
can alternatively be reduced to glycolate by a constitutive glyoxylate reductase 
(ycdW) (Ornston & Ornston, 1969; Nunez et al, 2001). 
In E. coli, glycolate can be metabolized by the enzymes encoded by the glc 
operon, which includes glycolate oxidase (GOX) and a glyoxylate-induced malate 
synthase (MLSG, glcB). In this bacterium, either acetate or glyoxylate can induce 
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the glc and ace operons and the glcB- and aceB-encoded malate synthases can 
compensate for each other (Pellicer et al, 1999). M. tuberculosis has a putative 
GOX and its only malate synthase is closer in homology to the glcB-encoded MLS 
than to the aceB encoded enzyme (acetate-induced). 
3.11.2. The Dicarboxylic Acid Cycle. Using a citrate synthase E. coli mutant, 
Romberg & Sadler (1960) demonstrated that oxidation of glyoxylate could take 
place independently of a complete functional TCA cycle as long as glutamate was 
provided. Cells given labeled acetate rapidly labeled oxaloacetate, PEP, and 
pyruvate in the presence of unlabeled glyoxylate indicating that acetyl-CoA was 
preferentially metabolized via the GC to oxaloacetate. Oxaloacetate was then 
decarboxylated (presumably by PCK) to PEP, which was subsequently oxidized 
(via PYK) to pyruvate, which could then be dehydrogenated to acetyl-CoA to keep 
the cycle running. Interestingly, it has been recently shown that in contrast to E. 
coli grown in batch culture in excess glucose (~0.1-0.5 w/v), starving bacteria 
(<0.002% glucose) grown in a chemostat, preferentially metabolize glucose via the 
dicarboxylic acid cycle rather than the TCA cycle (Fischer & Sauer, 2003). 
3.12. Catabolism of amino acids 
Amino acids are often catabolized by converting them to intermediates of central 
intermediates of metabolism. In general, amino acids are first converted to the 
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corresponding amino acid via oxidative deamination reactions catalyzed by amino 
acid specific dehydrogenases (e.g., CH3-CH(NH2)-COOH (alanine) -> CH3-CO-
COOH (pyruvate). The catabolism of certain amino acids, e.g., threonine, 
methionine, valine, and isoleucine results in the generation of propionyl-CoA 
(Hesslinger et al, 1998). 
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C H A P T E R 4 
Bacterial Metabolism during Infection 
INTRODUCTION 
In order to successfully infect, grow, and survive in their hosts, pathogens must be 
able to find appropriate and sufficient sources of carbon and energy (Rhen et al, 
2000). With few exceptions, little is known about the nutrient sources and 
metabolic pathways utilized by pathogens during infection (Smith, 2000). Even 
though the importance of microbial metabolism in vivo might appear self-evident, 
it is an area of research that has received little attention in the past, largely because 
it has been assumed that we know more than we actually do know about microbial 
metabolism and also because interfering with central metabolic pathways was 
deemed unfeasible due to structural conservation of the enzymes involved. 
However, evidence is emerging that pathogens acquire nutrients from the host 
utilizing factors (transporters, enzymes, cofactors, etc.) that are sufficiently 
distinct, and in some cases altogether absent, from those in their mammalian hosts, 
to warrant targeting such factors for chemotherapeutic intervention (Walsh, 2003; 
Fidock et al, 2004; Nathan, 2004). In fact, some of these microbial pathways 
could be viewed as important "virulence" determinants in at least two senses. 
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Firstly, they are almost certainly needed by pathogens to adapt to the specific 
"metabolic niches" they inhabit, and thereby provide the pathogen with the 
constituents and energy required to be able to counteract, evade or deactivate, host 
antimicrobial effectors. Secondly, emerging evidence indicates that at least some 
metabolic enzymes, possibly bifunctional, might be directly involved in chemical 
reactions that deactivate host antimicrobial effector molecules (Bryk et al, 2002; 
Lundberg et ah, 1999). 
Defining the way parallel and opposing metabolic pathways operate is a 
difficult task, especially because, as discussed in the previous chapter, the 
functions of these pathways are highly dependent on environmental conditions, 
e.g. growth parameters and nutrients available. The challenge becomes 
considerably more formidable when the goal is to determine which metabolic 
pathways are relevant in the highly dynamic environment of an infection. The 
following paragraphs review our current, rather scant, understanding of metabolic 
pathways of carbon utilization employed by bacterial pathogens during infection. 
4.1. Escherichia coli 
Even though our knowledge of E. coli metabolism during axenic growth in the 
laboratory is extensive, little is known about nutrient acquisition and metabolism 
of E. coli living in the intestines as a commensal or as a pathogen. The intestinal 
epithelium is covered by mucus, a complex of glycoproteins and glycolipids that 
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includes acetylglucosamine, Af-acetylneuraminic acid, iV-acetylgalactosamine, 
galactose, glucuronate, galacturonate, mannose, fucose, sialic acids, and ribose. 
Accumulating evidence indicates that carbohydrate metabolism is important for 
survival of E. coli in the mammalian large intestine as first suggested by the 
finding that E. coli mutants that cannot grow on mucus fail to colonize the 
intestine of mice (Peekhaus & Conway, 1998). In support of this view, Aeda 
mutants of the Entner-Doudoroff pathway (EDP) are defective in intestinal 
colonization in the streptomycin-treated mouse model, and a gluconate transporter 
(GntP) mutant was also impaired for intestinal growth (Sweeny et ah, 1996b). 
The utilization of glucuronate is suggested by the severe (100 fold < wildtype) 
colonization defect of AuxuA, which lacks a dehydratase involved in the 
catabolism of this compound (Sweeny et ah, 1996b). 
Recently, gene expression studies of E. coli grown in glucose versus mucus 
revealed that during growth in mucus bacteria upregulate, as expected, genes 
involved in the catabolism of amino sugars, pentoses, and amino acids (Chang et 
ah, 2004). Less expectedly, E. coli also upregulates genes involved in 
phospholipid degradation as well as the gluconeogenic genes pckA and ppsA (pps). 
Genes involved in the synthesis of purines, pyrimidines and several amino acids 
are in contrast repressed suggesting E. coli scavenges these from mucin (Chang et 
ah, 2004). These investigators also evaluated several metabolic mutants for their 
ability to colonize the mouse intestine, and their findings largely confirmed the 
importance of the EDP for in vivo growth and survival. However, these studies 
123 
also revealed that mutants differentially deficient in their ability to utilize 
carbohydrates had different in vivo phenotypes. For instance, mutants of the EDP, 
which could not use gluconate, failed to grow and to persist in the host. However, 
those incapable of using fucose, mannose, or ribose were impaired specifically 
during persistence. Mutants of the pentose phosphate pathway (Agnd), TCA cycle 
(AsdhB) and gluconeogenesis (Apps, ApckA) did not show an in vivo phenotype. 
Interestingly, in a separate subsequent study, Apps or ApckA mutants were found 
to be impaired for persistence in the context of a co-infection with wild-type 
bacteria (Miranda et ah, 2004). 
Together these data support the notion that during its sojourn in the 
intestine, E. coli bacteria largely use carbohydrates for growth and survival. 
However, to do so they apparently must be able to use a wide variety of substrates. 
This could be because these different substrates become variably available 
throughout the infection and in particular might become more limiting during the 
persistent phase of the infection and/or in the context of a co-infection. 
4.2. Helicobacter pylori 
A large fraction of the world's population is believed to be persistently infected by 
H. pylori (Blaser & Atherton, 2004). Nothing is known about the type of carbon 
sources used by H. pylori in the stomach of its host. However, the H. pylori 
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genome sequence indicates that it has a modified T C A cycle in which the 
conversion of a-ketoglutarate to succinyl-CoA is carried out via a keto-glutarate 
ferredoxin oxidoreductase instead of via the canonical a-ketoglutarate 
dehydrogenase (Tomb et ah, 1997). Interestingly, the a-ketoglutarate ferredoxin 
oxidoreductase appears to be essential, making this enzyme of central metabolism 
an attractive target for drug discovery (Hugues et ah, 1998). The korA-D genes of 
M. tuberculosis are homologous to those that encode the aforementioned enzyme 
complex in H. pylori. H. pylori lacks the genes encoding the GC, making it 
unlikely that these bacteria use fatty acids or gluconeogenic substrates are carbon 
sources in the stomach. 
4.3. Listeria monocytogenes 
Virulence of L. monocytogenes requires entrance into intestinal epithelial cells, 
escape from the phagosome into the cytoplasm, replication therein, and actin-
based motility which eventually facilitates infection of neighboring cells (Lecuit & 
Cossart, 2002). Some of these events are regulated by the transcriptional activator 
PrfA (Kreft et ah, 2002). Based on the observation that in vitro conditions that 
activated the expression of prfA, and of PrfA-dependent virulence genes, also 
endowed Listeria with the ability to utilize glucose-1-P as a carbon substrate, and 
the fact that glucose-1-P is a breakdown product of glycogen which might be 
readily available in the cytosol of host cells, it was hypothesized that hexose 
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phosphates could be used by Listeria as carbon substrates during infection (Ripio 
et ah, 1997). Indeed, while wild-type Listeria microinjected directly into a 
mammalian cell's cytosol could readily grow and replicate, a mutant in htp, 
encoding a hexose transporter, could not (Goetz et ah, 2001). Furthermore, this 
Ahtp mutant could not utilize several glucose-1-P-related sugars including 
glucose-6-P, fructose-6-P, and manose-6-P in vitro (Chico-Calero et ah, 2002), 
and was attenuated during infection in mice, e.g, mutant bacteria grew more 
slowly and killed infected mice later than wild-type. This adaptation by Listeria to 
the intracytoplasmic niche it inhabits might be shared by other pathogens. An Hpt 
homolog is also found in Shigella, which like Listeria escapes from the 
phagosomal vacuole and grows in the cytoplasm of host cells. 
4.4. Salmonellae 
Our understanding of Salmonella carbon metabolism in vivo is rather rudimentary. 
The Salmonellae vacuole is likely limiting in essential elements such as Mg++ and 
Ca++, since the mtgC gene encoding a Mg++ transporter is required for virulence 
(Buchmeier et al, 2000), and the two-component system PhoP/PhoQ, which 
regulates transcription of genes whose function is required for intracellular 
survival is activated by low concentrations of Mg++ (Miller et al, 1989). Amino 
acids and purines also appear to be limiting since auxotrophs are attenuated for 
intracellular survival (Hoiseth & Stocker, 1981; Fields et al, 1986). 
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Based on a comprehensive examination of Salmonellae gene expression 
isolated from infected macrophages, it has been suggested that these bacteria use 
gluconate, galactone and similar sugars as carbon sources during infection 
(Eriksson et al, 2003). This was based on the finding that although expression of 
genes of the EDP pathway was unchanged, some genes encoding transporters of 
gluconate were upregulated. The fact that both glycolysis and the pentose 
phosphate phosphate pathway were drastically downregulated was interpreted as 
suggesting specificity in the types of sugars metabolized by the bacteria. These 
observations, though informative, are not sufficient to establish the relevance of 
sugar metabolism during infection of Salmonellae. Furthermore, some puzzling 
observations in the same study -that several genes encoding enzymes of amino 
acid biosynthesis were downregulated, some of which are known to be essential 
for Salmonellae survival in the macrophage vacuole (Hoiseth & Stocker, 1981; 
Fields et al, 1986) - need to be clarified. 
Alternatively, it has been suggested that Salmonella may depend on C2 
substrates during infection. An S. typhimurium (SR-11) mutant that could not 
grow on C2 substrates in vitro was found to be attenuated in mice (Utley et al, 
1998), and was later shown to be a mutant of the catabolite activator/repressor cra 
(Allen et al, 2000). Cra positively controls genes involved in the utilization of 
gluconeogenic substrates including the GC and gluconeogenesis (Saier & 
Ramseier, 1996). Suggestively, a mutant of malic enzyme (Amez), which converts 
malate to pyruvate, was also found to be attenuated in vivo (Valentine et al, 
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1998). Recently, an S. typhimurium isocitrate lyase (AaceA) mutant of the G C was 
found to be attenuated "late" in the infection (day 10) in the susceptible mouse 
model, despite growing similarly to wild-type early on in the infection, or during a 
24 hr macrophage infection (Fang et al, 2005). The mutant also showed impaired 
survival during the chronic phase of infection when tested in a recently described 
Salmonellae persistence model in resistant mice (Monack et al, 2004), however, 
for this experiment, the AaceA was combined with an aroA mutation, complicating 
the interpretation of the results. Though clearly the issue merits further 
investigation, considerable evidence supports the idea that C2 substrates might 
play an important role in the metabolism of Salmonellae in vivo, especially in the 
persistence phase of the infection. 
4.5. Mycobacterium tuberculosis 
M. tuberculosis is an intracellular pathogen that chiefly resides within vacuoles in 
macrophages (Armstromg & Hart, 1971; 1975; Clemens et ah, 2002). Although 
some aspects of the mycobacterial vacuole such as its pH in resting and activated 
macrophages or its interaction with other components of the endosomal network 
such as lysosomes have been partially characterized (Clemens & Horwitz, 1995; 
Clemens, 1996; Russell & Sturgill-Koszycki, 1996; Russell, 2001), other aspects 
such as its chemical composition in terms of essential elements and nutrients that 
might be available to the bacterium within it, remain poorly understood. 
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Some lines of evidence indicate the tubercle bacillus resides in a nutrient-
limited environment in vivo. Amino acid and purine auxotrophs isolated in both 
M. tuberculosis and M. bovis are impaired for growth in macrophages and/or 
animal models of infection (Hondalus et ah, 2000; Smith et ah, 2001; Jackson et 
ah, 2003). The fact that AmbtB mutants, which lack the high affinity siderophore 
mycobactin and cannot grow in medium containing low iron in vitro, are also 
incapable of replication in human (THP1) macrophages (De Voss et ah, 2000) 
suggests that M. tuberculosis might also experience some iron-limitation during 
infection. Siminarly, magnesium also appears to be limiting within the 
mycobacterial vacuole (Rodriguez & Smith, 2003, Buchmeier et ah, 2000). 
Some evidence gathered over the years regarding carbon utilization by M. 
tuberculosis suggested a slowing down of metabolism and the prevalence of C2 
(fatty acid) catabolism in vivo. M. tuberculosis and M. bovis bacteria isolated 
from -20 day-infected mouse lungs respired at much lower levels than in vitro-
grown bacteria, which suggested reduced metabolism. Curiously, it was also 
observed that fatty acids but not carbohydrates significantly stimulated the ability 
of these bacteria to reduce a tetrazolium dye; in viYra-grown bacteria readily 
oxidized both (Segal & Bloch, 1956; Kanai & Rondo, 1974). Kondo et ah, (1970) 
also found that mycobacteria harvested from infected lungs appeared to be closely 
associated with lipids, and showed that M. tuberculosis could digest liposomes in 
suspension, releasing fatty acids (Kondo & Kanai, 1976; Kondo et ah, 1985). 
Mycobacteria apparently have extracellular lipases that might have this function 
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(Casal & Linares, 1984; Kannan et ah, 1987) including four partially redundant 
phospholipases C (Raynaud et ah, 2002), which jointly are required for virulence 
of M. tuberculosis. Furthermore, some 20 genes annotated as putative lipases 
(UpC-lipW genes) are also present in the genome. 
The glyoxylate cycle and persistence of M. tuberculosis. As reviewed in 
Chapter 3, many bacteria can utilize fatty acids as sources of carbon and energy, 
and to do so bacteria specifically require the /2-oxidation cycle and the GC (GC). 
Early studies seeking to determine the metabolic capabilities of mycobacteria 
revealed that both fast and slow growing mycobacteria including M. tuberculosis 
and M. leprae encoded activites of the TCA cycle and the GC (Murthy et ah, 
1973; Seshadri et al, 1972; 1976; Kannan et al, 1985; Katoch et al, 1987; 
Bharadwaj et al, 1987). Analysis of M. leprae, M. microti and M. avium grown in 
vivo also revealed the presence of GC enzymes isocitrate lyase and malate 
synthase (Bharadwaj et al, 1987; Wheeler & Ratledge, 1988). These findings 
together with the demonstration that activity of ICL increased in late stationary-
phase M. tuberculosis cultures (Murthy et al, 1973), led some of these early 
investigators to suggest that GC-mediated metabolism might represent a strategy 
employed by pathogenic mycobacteria such as M. leprae and M. tuberculosis to 
persist in the host in such ill-defined states as dormancy (Segal & Bloch, 1956; 
Bharadwaj et al, 1987; Gupta & Ratoch, 1997). This "alternate" (to 
carbohydrates) mode of metabolism based on the GC, it was speculated, could be 
linked to phenotypic drug tolerance and the common failure of antitubercular 
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drugs to kill recalcitrant 'persisters' (Murthy et al, 1973; Kannan et al, 1985; 
Gupta & Katoch, 1997). 
Functional genetic evidence supporting the hypothesis that fatty acids and 
specifically the GC might indeed be relevant to the metabolism of the tubercle 
bacillus during infection was first provided by McKinney and colleagues (2000). 
An M. tuberculosis mutant lacking ICL1 (Aicll) was impaired for survival 
specifically during the persistence phase of the infection in the mouse model of 
chronic tuberculosis, despite growing indistinguishably from the parental strain 
during the acute phase (Fig. 4.1 A). The mutant also elicited less pathology than 
wild-type bacteria (Fig. 4.1B&C). 
The extensive duplication of genes encoding fatty acid P-oxidation 
enzymes in M. tuberculosis (Cole et al, 1998) presents a major obstacle to the 
genetic analysis of the role of fatty acid catabolism in TB pathogenesis due to 
potential functional redundancy between homologs. In contrast, the GC in M. 
tuberculosis apparently comprises a single gene encoding malate synthase and two 
genes encoding isocitrate lyases (icll and icll) (Cole et al, 1998). Thus, we 
decided to focus our efforts on investigating the role of this latter pathway in the 
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Fig. 4.1. iWl is required for persistence and virulence of M . tuberculosis in mice. (A) Bacterial 
loads in the lungs of B6X129F1 mice infected with IO6 j'c/7-deficient (filled circles) or wild-type 
(circles) M T B cells. (B-C) Lung pathology in B6X129F1 mice infected with (B) wild-type or (C) 
Aicll mutant bacteria at 16 weeks post-infection. (Data, courtesy of J. D. McKinney). 
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P A R T II 
C H A P T E R 5 
Mycobacterium tuberculosis Replication D y n a m i c s in vivo 
INTRODUCTION 
In the mouse model of TB a predominantly pulmonary infection is established 
after intravenous inoculation or exposure to aerosolized bacteria (North & Young, 
2004). The acute phase of infection lasts a few wks and is characterized by 
exponential bacterial growth in the lungs. The transition to the chronic phase of 
infection is brought about by the emergence of acquired cell-mediated immunity 
(CMI), which is mediated by antigen-specific T cells and and immune-activated 
macrophage and results in the stabilization of bacterial loads in the infected organs 
(Flynn & Chan, 2001). A long-standing question has been whether this plateau in 
the bacterial growth curve during chronic infection represents a "static" 
equilibrium in which bacterial replication is slow or absent, or a "dynamic" 
equilibrium in which continued rapid bacterial replication is precisely balanced by 
an equally rapid rate of killing by the host immune response (Sever & Youmans, 
1957). This issue has important implications for anti-mycobacterial drug therapy 
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because drugs that are currently used to treat T B are more effective against 
bacteria undergoing rapid growth and cell division (McKinney, 2000; Mitchison, 
2004). 
In a classic study, Rees and Hart (1961) sought to distinguish between 
"static" and "dynamic" models of the host-pathogen equilibrium in persistent TB 
by enumerating "viable counts" (CFU) and "total counts" (microscopically 
detectable acid-fast bacilli (AFB)) in the lungs of chronically infected mice. The 
authors reasoned that if the dynamic model were correct the viable counts and 
total counts should diverge over time due to progressive accumulation of dead 
bacilli, which would contribute to the total counts (AFB) but not to the viable 
counts (CFU). Instead, they found that the viable and total counts were 
remarkably congruent throughout the course of infection, a result that favored the 
static model. They acknowledged, however, that loss of acid-fast staining by dead 
bacilli could result in an underestimate of the true number of total counts. Loss of 
acid-fastness might also explain their observation that the total counts gradually 
declined in animals treated with the anti-mycobacterial drug isoniazid (INH), 
which is known to interfere with acid-fast staining (Middlebrook, 1952). It has 
also been suggested that acid-fast staining might be lost in tubercle bacilli present 
in latently infected human tissues (Seiler et al, 2003). 
In this chapter we describe experiments addressing this important aspect of 
the host-pathogen interface in persistent TB. First, we measured and compared M. 
tuberculosis viable counts (CFU), and total counts, represented by the number of 
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bacterial chromosome equivalents (CEQ), in the lungs of chronically infected 
mice. Our experimentally determined values were then compared with values 
obtained from an in silico model that was used to simulate bacterial growth curves 
(CFU accumulation) and to predict the extent of accompanying bacterial CEQ 
accumulation over time at different rates of bacterial cell division. Alternative 
scenarios were modeled in which the immune response was bacteriostatic, 
bactericidal, or both. Our results support the static equilibrium model, in which 
entry into the chronic phase of infection is accompanied by a marked reduction in 
the bacterial cell division rate. (The results discussed in this chapter are the result 
of a conceited effort by Wai-Tsing Chan, Jim Gomez, John McKinney, Juliano 
Timm, and the author and have been reported [Munoz-Elias et al, 2005]). 
RESULTS 
5.1. Modeling the host-pathogen equilibrium in infected mice 
In the mouse model of TB, the chronic phase of infection is characterized by 
progressive lung pathology despite relatively stable numbers of viable bacteria 
enumerated as colony-forming units (CFU) (Rhoades et ah, 1997). The plateau in 
the bacterial growth curve could represent a "static" equilibrium in which the rate 
of bacterial cell division is very slow, or a "dynamic" equilibrium in which rapid 
bacterial cell division continues unabated, balanced by an equal rate of bacterial 
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death effected by host immune mechanisms (Rees & Hart, 1961). The latter 
scenario would be akin to the highly dynamic equilibrium observed in HIV 
infection prior to the onset of AIDS (Simon and Ho, 2003). We reasoned that the 
two scenarios -static vs. dynamic- could be distinguished by comparing the "viable 
counts" (CFU) and "total counts" (bacterial chromosome equivalents (CEQ)) at 
various stages in chronically infected animals. The static model predicts that CFU 
and CEQ will not diverge over time, whereas the dynamic model predicts that 
bacterial CEQ will accumulate over time while CFU remain stable. 
To illustrate these alternative scenarios, we devised a simple in silico model 
that can be used to generate CFU and CEQ curves representing a static 
equilibrium in which CMI is strictly bacteriostatic (Fig. 5.1 A), or a dynamic 
equilibrium in which CMI is strictly bacteriocidal (Fig. 5.IB). The derivation of 
our model is described in the Materials and Methods. 
In the "static" scenario, the model predicted that both viable counts (CFU) 
and total counts (CEQ) would remain stable and would not diverge over time (Fig. 
5.1 A). In the "dynamic" scenario, the model predicted that although viable counts 
would remain stable over time, the total counts would gradually rise due to the 
accumulation of dead bacteria; in the modeled experiment depicted in Fig. 5.IB, 
the CEQ/CFU ratio increased by ~ 100-fold between 2 wk and 16 wk post-
infection. We also modeled semi-dynamic scenarios where CMI exerted both 
bacteriostatic and bacteriocidal effects resulting in stable numbers of CFU but 

































Fig. 5.1. Modeling static and dynamic scenarios of the host-pathogen equilibrium in chronic 
murine TB. Mice are infected with 200 CFU. Acute-phase infection (0-2 wk) is characterized by an 
exponential increase in viable counts (CFU) with a 24.6 h population doubling time. Chronic phase 
infection (2-16 wk) is characterized by stable viable counts. (A) Static scenario. Acquired immune 
response halts bacterial replication after the acute phase of infection. Viable counts (CFU, dotted 
lines) and total counts (CEQ, solid lines) do not diverge over time. (B) Dynamic scenario. Bacterial 
replication continues at an undiminished rate (24.6 h doubling time) throughout the chronic phase, 
but bactericidal acquired immune response kills 50% of the bacteria after each round of cell division. 
Balanced growth and death results in stable viable counts while total counts accumulate, resulting in 
rapid divergence of CEQ and CFU. (C & D) Semi-dynamic scenarios where the rate of bacterial cell 
division is reduced by (C) 50% or (D) 90% from the acute-phase rate, resulting in a more gradual 
divergence of CFU and CEQ. 
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effect of C M I on the entire bacterial population, or variable efficacy of C M I 
against different bacterial sub-populations (Fig. 5.1C, D); our model cannot 
distinguish between these possibilities. The semi-dynamic scenarios were modeled 
by varying the rate of bacterial cell division and death during the chronic phase, as 
described in the Materials and Methods. When the rate of cell division during the 
chronic phase was reduced by 50% (Fig. 5.1C) or 90% (Fig. 5.ID) as compared to 
the cell division rate during the acute phase, the CEQ/CFU ratio nonetheless rose 
appreciably—by ~ 40-fold (Fig. 5.1C) or ~ 8- fold (Fig. 5.ID), respectively— 
between 2 wk and 16 wk post-infection. Our model will also accommodate more 
complex scenarios, such as fluctuating rates of cell division or cell death during 
the course of infection (see Fig. 5.2). A key assumption is that non-viable bacteria 
(and their chromosomes) are not removed or degraded over time; here we provide 
experimental support for this assumption (see below), in agreement with evidence 
adduced previously by others (Rees & Hart, 1961). 
5.2. Comparison of modeled and experimentally determined CFU and CEQ 
curves in infected mice 
In order to generate experimental values for bacterial CFU and CEQ during the 
course of a murine infection, C57B1/6 mice were aerosol-infected with -200 CFU 
of M. tuberculosis (Erdman) and groups were sacrificed at selected time points for 
quantitative analysis of bacillary loads. Viable counts (CFU) were enumerated by 
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plate-culture of lung homogenates and total counts (CEQ) by quantitative real-
time PCR (QPCR). 
During the acute phase of infection (0-2 wk post-infection), the viable 
counts in the lungs increased exponentially with an average population doubling 
time of 24.6 hr (Fig. 5.2), which is typical in the mouse model of TB. During the 
chronic phase of infection (2-16 wk post-infection), there was a much slower rise 
in the viable counts with an average population doubling time of 1,676 hr (~ 70 d) 
(Fig. 5.2). The CEQ/CFU ratio showed little change during the chronic phase of 
infection (Fig. 5.2; inset numbers indicate CEQ/CFU ratios/time point), indicating 
that there was minimal accumulation of chromosomes from dead bacteria. These 
observations resemble the predicted curves generated by the "static" scenario in 
our model (Fig. 5.1 A), and differ markedly from those of the "dynamic" scenario 
(Fig. 5. IB), and support the idea that the rate of bacterial cell division is very slow 
during the chronic phase of infection. In order to provide a more direct 
comparison between our modeled and experimental results, we modeled the 
"dynamic" and "static" scenarios using the growth rate constants derived from the 
experimental data depicted in Fig. 5.2, taking into account any changes in bacterial 
CFU between time points by varying the growth rates constants (K values) 
appropriately. The experimentally determined CEQ values (Fig. 5.2, open circles) 
diverged sharply from the modeled CEQ values in the "dynamic" scenario (Fig. 
5.2, blue line) or the "semi-dynamic" scenario where replication of bacteria during 
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Fig. 5.2. Comparison of modeled and experimentally determined CFU and C E Q curves in 
mice. (A) Wild-type (C57B1/6) mice were aerosol-infected with M. tuberculosis (-200 CFU/mouse). 
At indicated time points, mice were sacrificed and viable counts (CFU) were quantified by plating 
lung homogenates (closed squares); total counts (CEQ) were quantified by QPCR (open circles). 
Modeled CEQ values were derived using the static (red line) or dynamic (blue line) equilibrium 
scenarios, or semi-dynamic scenarios in which the rate of cell division during chronic infection was 
reduced by 50% (green line) or 90% (orange line) compared to acute infection. Symbols represent 
mean CFU or CEQ values (n = 4 mice/group); inset numbers = CEQ/CFU ratios at time point. P 
values for pairwise comparisons of the experimental and modeled CEQ values at 16 wk: 
experimental vs. dynamic or semi-dynamic (50%) scenarios, P < 0.001; experimental vs. static or 
semi-dynamic (10%) scenarios, P > 0.05. Results are representative of two experiments. (B) 
Standard curve for the fadE15 primer-beacon set used to quantify bacterial CEQ in tissue 
homogenates. Threshold cycle (Ct) values (y-axis) were obtained by QPCR of target D N A (x-axis). 
Symbols (open circles) indicate mean Ct values of three independent experiments; error bars 
indicate STDEV. The trendline drawn through the data points indicates the linear regression curve, 
which was calculated using the least-squares method. 
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modeled C E Q values for the "static" scenario (Fig. 5.2, red line) and the 
"semidynamic" scenario where replication of bacteria during the chronic phase 
was reduced by 90% (Fig. 5.2, orange line). The parallel rise in experimental CFU 
and CEQ values between 2 and 16 wk post-infection indicates that stasis is not 
complete, although the doubling time of the bacterial population during the 
chronic phase is increased nearly 70-fold (1,676 hr) compared to the acute phase 
(24.6 hr). Thus, although it is likely that bacterial growth continues at a reduced 
rate during the chronic phase of infection, our results are not consistent with a 
model in which rapid bacterial cell division is balanced by equally rapid cell death. 
5.3. Large numbers of bacterial chromosomes can be quantified in infected 
mice 
We considered the possibility that our inability to detect a divergence of CFU and 
CEQ during the chronic phase of infection might be due to technical limitations in 
our methods for extraction and quantification of bacterial chromosomes from 
infected lungs. In order to confirm that there was no ceiling on the number of 
chromosomes per lung that we could accurately quantify, we enumerated CFU and 
CEQ in aerosol-infected IFN-y deficient mice, which are unable to control 
replication of M. tuberculosis (Cooper et ah, 1993; Flynn et ah, 1993). By 4 wk 
post-infection, shortly before the IFN-y7" mice became moribund, the bacterial 
load in the lungs had reached ~109 CFU per mouse; the number of CEQ detected 
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by Q P C R corresponded very closely to the number of C F U detected by plate 
culture (not shown). The close correspondence of CFU and CEQ spanning a range 
of > 5 log10 confirms that our inability to detect a divergence of bacterial CFU and 
CEQ trajectories in chronically infected mice (Fig. 5.2) was not due to a technical 
limitation of the QPCR assay. 
5.4. Persistence of dead bacteria in mouse lungs 
We considered the possibility that our inability to detect a substantial 
accumulation of bacterial chromosomes during the chronic phase of infection 
might be due to rapid removal or degradation of killed bacteria. In order to 
address this issue using QPCR to quantify bacterial chromosomes in the lungs, we 
assessed the impact of isoniazid (INH) therapy on the viable (CFU) and total 
(CEQ) bacterial counts in chronically infected C57BL/6 mice. Untreated controls 
showed relatively stable viable and total counts between 4 and 12 wk post-
infection (Fig. 5.3B). In contrast, mice treated with INH for 8 wk (from 4 to 12 
wk post-infection) showed a marked reduction in viable counts (3.6 logio), 
whereas the total counts remained stable (Fig. 5.3A). These observations indicate 
that non-viable tubercle bacilli (and their chromosomes) are not subject to rapid 
removal or degradation, in agreement with previous reports (de Wit et ah, 1995; 
Rees and Hart, 1961). 
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Fig. 5.3. Chromosomes of non-viable M. tuberculosis in mouse lungs are not removed or 
degraded rapidly. C57B1/6 mice were infected i.v. with M. tuberculosis (~1 x IO6 CFU per mouse). 
One group (A) received INH (25 mg kg"1 d'1) for 8 wk starting at 4 wk post-infection; a control 
group (B) was left untreated. At 4 , 8, and 12 wk post-infection, mice from INH-treated and 
untreated groups were sacrificed and viable counts (CFU) were quantified by plating lung 
homogenates (open bars); total counts (CEQ) were quantified by QPCR (shaded bars). Bars 
represent mean CFU or CEQ values (n = 4 mice per group); error bars indicate STDEV from the 
means. In pairwise comparisons of CFU values in the INH-treated group for 4 wk vs. 8 wk or 4 wk 
vs. 12 wk post-infection, differences were highly significant (P < 0.005), while those of CEQ values 
in the INH-treated group for 4 wk vs. 8 wk or 4 wk vs. 12 wk post-infection were not (P > 0.05). 
Results are representative of two experiments. 
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C H A P T E R 6 
A n Investigation into the Role of icll and icll in Carbon 
Metabolism and Pathogenesis of Mycobacterium tuberculosis 
INTRODUCTION 
Microorganisms that invade, replicate, and persist within other host organisms 
must acquire and assimilate carbon substrates from their hosts' tissues. With few 
exceptions, little is known about the sources of nutrients or the metabolic 
pathways utilized by pathogens to use such nutrients during infection (Smith, 
2000). Metabolic adaptations to tissue environments are almost certainly essential 
for the ability of pathogens to survive in the host in spite of acquired immunity. 
These adaptations might also contribute to the difficulty in eradicating microbes in 
the host despite prolonged therapy with drugs to which the pathogen, when tested 
in vitro, is susceptible (McDermott, 1958). In vivo drug tolerance is a major 
reason why tuberculosis (TB) therapy requires administration of multiple drugs for 
at least six months, resulting in high rates of patient non-adherence, treatment 
failure, and acquired drug resistance (Gomez & McKinney, 2004). Elucidation of 
the metabolic pathways required for growth and persistence of M. tuberculosis in 
the mammalian lung could suggest new avenues of intervention against this 
recalcitrant pathogen (Stewart et ah, 2003; Boshoff & Barry, 2005). 
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Several lines of evidence suggest that pathogenic mycobacteria primarily 
utilize fatty acids, rather than carbohydrates, as carbon substrates during infection 
(Chapter 3). Previously we reported that disruption of icll in M. tuberculosis 
impairs the ability of the bacteria to survive at wildtype levels during the chronic 
phase of infection in mice, but has little effect on replication during the first two 
wks of the infection (McKinnney et ah, 2000; Chapter 3). The genome of M. 
tuberculosis has a gene homologous to icll, termed icll (MT1966, Rvl915/16), 
which encodes a second putative isocitrate lyase (ICL2) (Cole et ah, 1998). Here, 
we report that icll and icll provide overlapping and essential functions in growth 
and survival of M. tuberculosis in vivo. Deletion of icll or icll alone had little 
effect on bacterial catabolism of fatty acid substrates or multiplication in 
macrophages and mice. In contrast, bacteria lacking both genes were unable to 
grow in fatty acid-containing media or in macrophages, and were rapidly 
eliminated from the lungs of infected mice. Virulence of the Aicll Aicll strain was 
not restored in mice lacking macrophage activation pathways mediated by 
interferon-y (IFN-y) or tumor necrosis factor-a (TNF-a), indicating that the 
essentiality of the gGC) at the onset of the infection is largely independent of the 
host immune response. Using a dual-specific ICL inhibitor, we adduce evidence 
that chemical inhibition of ICL activity might be a feasible and effective 
therapeutic approach. 
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R E S U L T S 
6.1. ICL isoenzymes of M. tuberculosis 
Previously, we reported that isocitrate lyase (ICL1) facilitates persistence of M. 
tuberculosis in chronically infected mice and macrophages (McKinney et ah, 
2000; Fig. 4.1). The genome sequence of a virulent clinical isolate of M. 
tuberculosis (CDC1551) identified a second id gene (MT1966, Rvl915/16; here 
designated icll) (Fleischmann et ah, 2002) with limited homology to icll 
(MT0483, Rv0467); the predicted gene products are 27% identical overall, and 
differ significantly in size (ICL1 = 428 AA; ICL2 = 766 AA). Recombinant ICL2 
displays isocitrate lyase activity in vitro although it is less active than ICL1 (Honer 
zu Bentrup et al, 1999). Sequence alignments revealed three distinct groups of 
ICL proteins (Fig. 6.1), which differed in length and domain organization (Fig. 
6.2A). Group I ICLs comprised eubacterial short ICLs, including M. tuberculosis 
ICLL Group II ICLs included plant and fungal medium-length ICLs, which 
contained a central domain (Domain II) absent in group I. Group III ICLs, so far 
identified only in Mycobacterium, had a long C-terminal domain absent in groups 
I and II; they also contained a central region with significant homology to the 
central domain of the eukaryotic ICLs and were overall -35% identical to them 
(Fig. 6.1&6.2). In silico modeling of the three-dimensional structure of ICL2, 
based on the X-ray crystal structures of ICL1 from M. tuberculosis (Sharma et al, 
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Fig. 6.1. Isocitrate lyases dendrogram. Sequences were obtained through the B L A S T interface 
and genome databases (NCBI). N a m e is followed by accession number or unique gene identifier in 
parentheses, followed by number indicating distance to nearest neighbor. Tree was built using the 
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Fig. 6.2 I C L 1 and I C L 2 are evolutionarily divergent structurally related proteins . (A) Domain 
organization of isocitrate lyases in eubacteria and eukaryotes. Alignments were generated using the 
Conserved Domain Database ( C D D vl.62, NCBI). Domains I and III are present in all ICLs. 
Domain I contains the conserved catalytic motif K K C G H . Domain II is present in fungal and plant 
ICLs and in mycobacterial ICL2, but absent in mycobacterial I C L L Domain IV is unique to 
mycobacterial ICL2. (B) ICL1 and ICL2 are structurally related isocitrate lyases. Structural 
modeling of M . tuberculosis ICL2. Superimposition of the model of ICL2 monomer (red) and the 
X-ray crystal structure of an ICL1 monomer (blue). Encircled: ICL catalytic signature motif 
K K C G H ( A A 193-203 in ICL1; A A 213-217 in ICL2). The ICL2 model was generated using 
M O D E L L E R , based on the predicted A A sequence of ICL2 (Gl: 50952459) and coordinates from 
the crystal structure of ICL1 (PDB 1F8M, Gl: 15607608) (Sharma et al., 2000). Domain II of ICL2 
( A A 269-365) is absent in ICL1, and was modeled after the crystal structure of ICL from Aspergillus 
nidulans (Gl: 49096622)24. Domain IV (not depicted) had no homology to any known sequences. 
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2000) and ICL from Aspergillus nidulans (Britton et al, 2000), revealed a striking 
level of structural concordance (Fig. 6.2B). Significantly, the active site loops of 
ICL1 and ICL2, containing the conserved catalytic motif (KKCGH), were nearly 
superimposable (Fig. 6.2B, encircled). Thus, despite the limited homology 
between ICL1 and ICL2, conservation of tertiary structure and enzymatic activity 
suggested these enzymes might subsume overlapping biological roles. 
6.2. Generation of Mycobacterium tuberculosis id mutants 
Microorganisms use the GC to replenish TCA cycle intermediates during growth 
on fatty acids because under these conditions the concentrations of PEP and 
pyruvate are insufficient to support anaplerosis via their conversion to 
oxaloacetate by PEP carboxylase (PPC) or pyruvate carboxylase (PCA), 
respectively (Fig. 3.6). To assess the role of the GC in mycobacterial pathogenesis 
and fatty acid metabolism, M. tuberculosis (Erdman) strains were constructed in 
which icll, icll, or both were deleted. The mutants were generated by allelic 
exchange as illustrated (Fig. 6.3A), using a replicative plasmid and sucrose 
counterselection as described previously (Pavelka & Jacobs, 1999). The icll gene 
was disrupted by deletion of two internal MscI fragments and insertion of a 
kanamycin resistance cassette. The same construct was used to disrupt icll in the 
chromosome of wild-type and Aicll mutant bacteria, thereby generating A/c/2 and 
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Fig. 6.3. Disruption of icl2 in the genome of wild-type M . tuberculosis (Erdman and H37Rv) & 
in the icll mutant background (Erdman). (A) Scheme for disruption of icl2 in the chromosome of 
M. tuberculosis (Erdman). (B) Genomic D N A preparations from M. tuberculosis wild-type 
(Erdman) (lane 1), H37Rv (19), plasmid pEM027 carrying wild-type icl2 (lanes 2 & 11), deletion 
construct pEM029 (lanes 3 & 12), mutant candidate clones in Erdman (lanes 4-8), in H37Rv 
(lanes 12-17) and (C) Genomic D N A preparations fromM. tuberculosis wild-type (lane 1), plasmid 
pEM027 carrying wild-type icl2 (lanes 2&8), deletion construct pEM029 (lanes 3&9), Aicll 
(Erdman) (lane 7), Aicl2 (Erdman) (lane 4), Aic/2 (H37Rv) (lane 5), candidate clones for icl2 
disruption on the Aicll (Erdman) background (lanes 10-19) were digested with ApaLI, separated in 
1 % T B E agarose gels, denatured with 0.5 N a O H , transferred to Hybond N membrane, and probed 
with an 610 bp P C R fragment from pEM027 (indicated by diamond-headed marks) labeled with 32P 
using a random priming labeling kit. Hybridization and washings were carried out under stringent 
conditions (65 C); specific hybridization was detected by autoradiography. See materials and 
methods for further details. 
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AicllAicl2 mutants, respectively. Disruptions were confirmed by Southern blot 
(Fig. 6.3B&C). 
Disruption of icll in M. tuberculosis (Erdman) and its complementation 
with an episomal plasmid carrying a wild-type copy of icll gene were previously 
described (McKinney et ah, 2000). In the genome of M. tuberculosis, the ORF 
immediately downstream of icl2 appears to be transcribed in the opposite 
orientation thus making it unlikely that the disruption of icl2 would affect the 
expression of this downstream gene. However, another potential complication in 
the analysis of a mutant is that unintended mutations may be introduced elsewhere 
in the chromosome inadvertently during its construction. Thus, reversal of a 
mutant's phenotype by complementation with a functional copy of the gene that 
was disrupted is always desirable. Since in the AiclllAicU mutant strain we had 
generated icll had been disrupted by deletion of part of the ORF and insertion of a 
hygromycin resistance cassette, while the icl2 gene had been replaced by a 
kanamycin resistance cassette, complementing plasmids carrying a streptomycin 
resistance cassette and either icll (pEM263-4/pICLl) or icl2 (pEM3E4-8/pICL2) 
were constructed and transformed into the AiclllAicU (see Materials & Methods). 
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6.3. Characterization of M . tuberculosis id mutants in standard media 
M. tuberculosis lacking icll, icl2, or both grew equally well and indistinguishably 
from wild-type bacteria in 7H9 broth in either rolling (Fig. 6.4A) or shaking 
bottles (Fig. 6.4B). Rolling bottles afforded better growth presumably because 
they allowed better aereation. The ability to form colonies on standard 7H10 
plates was somewhat different for the different id deficient strains. While the 
single Aicl2 mutant grew like wildtype (CFU in 3 wks), formation of a colony of a 
size comparable to that of wild-type bacteria at 3 wks by Aicll and AiclllAicU 
mutant bacteria required four and six wks of incubation, respectively (not shown). 
6.4. Determining in vitro growth conditions to test utilization of C2 substrates 
In most bacterial species studied so far, the GC is essential for growth solely when 
the only carbon substrates available are ones that enter central metabolism as 
acetyl-CoA (C2 substrates); such carbon sources are primarily fatty acids (Cronan 
& LaPorte, 1996). In order to assess the contribution of ICL 1 and ICL2 to carbon 
metabolism in M. tuberculosis, we set sought to establish culture conditions 
permitting the assessment of the contribution of these enzymes to bacterial carbon 
metabolism. 
Mycobacteria are notoriously slow-growing fastidious organisms (Wheeler, 
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Fig. 6.4. Characterization of M. tuberculosis id mutant strains in standard 7H9 broth, M9-
based and 7H9-based defined liquid media. (A-B) M. tuberculosis (Erdman) bacteria were 
cultured in standard (std.) 7H9 broth: (A) in rolling bottles; (B) in shaking bottles. (C-E) M9-based 
defined media: (C) no carbon; (D) glucose; (E) acetate (C2FA). (F-H) 7H9-based defined media: 
(F) no carbon; (G) glucose; (H) acetate (C2FA). Both M9- & 7H9- based defined media contained 
Tween-80 (0.05%), Albumin fraction V (0.5%), and NaCl (0.08%). Growth was monitored by 
measuring culture turbidity (OD600 nm) at the indicated time points. Results are representative of at 
least two experiments. 
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grown axenically, but its optimal cultivation requires relatively rich media (Dubos 
& Middlebrook, 1947). In liquid, M. tuberculosis is routinely grown in 
Middlebrook 7H9 powder (DIFCO)-based broth supplemented with "ADS" (w/v: 
0.5% albumin, 0.2% glucose, 0.085% saline, 0.05% Tween-80, and 0.5% glycerol. 
On solid media, M. tuberculosis is grown on 7H10 agar (DIFCO)-based media 
supplemented with glycerol (0.5% w/v) and 10% OADC (DIFCO). OADC 
(DIFCO) is a commercial supplement containing oleic acid, albumin, glucose, and 
catalase at the same concentrations used by Middlebrook and Dubos (Dubos & 
Middlebrook, 1947), which are the same as those used in ADS for 
supplementation of 7H9 broth. In order to define conditions that would allow the 
study of carbon utilization of M. tuberculosis on solid media, we repeatedly 
attempted to use non-commercial (home-made) stocks of OADC to culture M. 
tuberculosis, but these media preparations consistently resulted in a drastic delay 
in colony formation (colonies took circa 8 wks to appear, not shown). This fact 
made studies of M. tuberculosis on defined solid media impractical. 
Therefore, we took a two-pronged approach to study carbon utilization in 
mycobacteria. The first approach consisted in generating mutants in the same 
genes we were interested in studying in M. tuberculosis, namely GC genes, in M. 
smegmatis, a fast-growing saprophyte that is readily cultured in minimal media. 
The mutants were then complemented with the homologous M. tuberculosis genes 
to study their function as it pertains to carbon utilization. This work is reported in 
Chapter 9. The second approach was to find growth conditions in which a given 
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carbon substrate was the sole or at least the main carbon substrate present in liquid 
media for M. tuberculosis cultivation. Cultivation of M. tuberculosis in minimal 
M9 salts liquid media supplemented with different single carbon substrates 
resulted in very poor growth, clumping, and attachment of the tubercle bacilli to 
the walls of the culture flask (not shown). We next attempted to grow M. 
tuberculosis in M9 salts liquid media supplemented with albumin, saline and 
Tween-80 (same concentrations used for standard 7H9 broth) and a single carbon 
source at 0.1% (w/v). Encouragingly, M9-based media supplemented with either 
the short chain fatty acid acetate (C2FA) or glucose allowed significant growth 
(Fig. 6.4D&E). Some initial background growth was observed in media 
containing "no carbon;" this we attributed to the presence of Tween-80 (0.05%), 
which at low concentrations can be metabolized by mycobacteria (Saito et ah, 
1983). Nonetheless, the growth obtained in M9-based media was very limited (the 
bacterial doubling time was ~ 5-6 days, compared to ~1 day in standard 7H9 
broth). So we next replaced the M9 salts with 7H9 powder; 7H9 powder 
(DIFCO), in addition to basic salts, contains citrate (0.01%, w/v) and glutamate 
(0.05%, w/v), and traces of other elements that enhance bacterial growth. 7H9-
based media supplemented with glucose (0.1%, w/v) or C2FA (0.1%, w/v) 
supported significantly better and faster growth of M. tuberculosis (doubling time 
3-4 days) than similarly supplemented M9-based defined media (Fig. 6.4G&H). 
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6.5. Functional redundancy of icll and icl2 in fatty acid metabolism in vitro 
Importantly, we observed that while both M9- and 7H9-based defined glucose 
media supported the growth of the AiclllAicU mutant (Fig. 6.4D&G), C2FA-
supplemented media did not (Fig. 6.4E&H). Interestingly, the AiclllAicU mutant 
failed to grow even to background levels in M9- or 7H9-based media without 
added carbon, perhaps reflecting the inability of the mutant to grow on fatty acids 
derived from Tween-80 (Fig. 6.4C&F). These growth conditions were used to 
analyze the ability of the id mutants to grow on different carbon substrates. 
Deletion of icll or icU alone had little effect on bacterial replication 
kinetics in media containing glycerol (Fig. 6.5A), glucose (Fig. 6.5B), short-chain 
fatty acids (Fig. 6.5C-G), or long-chain fatty acids (Fig. 6.6A-E) as carbon 
sources. In contrast, deletion of both icll and icU eliminated growth on fatty acids, 
while having little effect on utilization of carbohydrates (Fig. 6.5&6.7). A slight 
but reproducible lag was observed for growth of the AiclllAicU strain in 
carbohydrate-containing media (Fig. 6.5B), suggesting carbon flux through the GC 
under these conditions in wild-type M. tuberculosis. A similar observation has 
been made in Corynebacterium glutamicum (Wendisch et ah, 2000). In the 
experiments shown in Fig. 6.5 & 6.7, growth was determined by monitoring the 
optical absorbance of the cultures, except for Fig. 6.6D, where the ability of the 
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Fig. 6.5. Overlapping roles of ICL1 and ICL2 in short chain fatty acid metabolism. (A-G) M. 
tuberculosis (Erdman) bacteria were cultured in liquid media containing (0.1% w/v): (A) glycerol; 
(B) glucose; (C) acetate (C2FA); (D) propionate (C3FA); (E) butyrate (C4FA); (F) valerate (C5FA); 
(G) hexanoate (C6FA). Growth was monitored by measuring culture turbidity (OD600 nm) at the 
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Fig. 6.6. Overlapping roles of ICL1 and ICL2 in long-chain fatty acid metabolism. (A-C) M. 
tuberculosis (Erdman) bacteria were cultured in liquid media containing (0.1% w/v): (A) 
polyoxyethylene sorbitan mono-laurate (C12FA); (B) polyoxyethylene sorbitan mono-palmitate 
(C16FA); (C) polyoxyethylene sorbitan mono-stearate (C18FA). Growth was monitored by 
measuring culture turbidity (OD600 nm) at the indicated time points. (D) Growth on palmitate 
(C16FA) was measured by BACTEC, which quantifies [14C]-C02 released by oxidation of [14C]-
palmitate. (E) Growth on dipalmitoyl-phosphatidylcholine (DPPC, C16FA), an abundant 
phospholipid in the lung, was determined by plating for CFU. Results are representative of at least 
two experiments. 
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bacteria to metabolize a C16FA was determined in a B A C T E C apparatus in which 
the evolution of C02 from media containing radiolabeled palmitate is measured, 
and for Fig. 6.6E, where growth was determined by plating for CFU after the 
bacteria had been cultured for 15 days in media supplemented with dipalmitoyl-
phosphatidylcholine (DPPC), a major phospholipid component of pulmonary 
surfactant (pulmonary surfactant is typically 90% lipids, 10% proteins) 
(Santangelo et ah, 1999). 
6.6. ICL activities in vitro and icll and icll mRNA levels during infection 
Next, we determined ICL activities present in extracts from bacteria grown on 
different carbon substrates to get an idea of the relative contribution of each of the 
isoenzymes to the overall ICL activity (Table 6.1). Extracts prepared from 
glucose-grown wild-type bacteria had basal levels of ICL activity, those from the 
single Aicll and A/c/2 mutants each had some activity as well, while Aicll Aicll 
extracts had no activity. The ICL activity in wild-type acetate extracts was about 
10 fold higher compared to glucose, but unexpectedly, the activity in the Aicll 
mutant was barely detectable (similar to ICL levels in glucose), while that in the 
A/c/2 was higher than wild-type. Unexpectedly, growth on the C3 fatty acid 
propionate resulted in ICL activity which was -10 fold higher than on acetate. 
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To get an idea of the regulation of ICL expression during infection, we next 
sought to determine the relative levels of mRNA for each of the id homologs. 
Previously, Timm and colleagues (2003) reported up-regulation of icll in M. 
tuberculosis (strain H37Rv) isolated from mouse lungs relative to bacteria grown 
in vitro. Confirming this previous observation, we found that icll was highly up-
regulated in bacteria isolated from mouse lungs that had been infected with M. 
tuberculosis Erdman, the strain used throughout 
Table 6.1. Isocitrate lyase activity in M. tuberculosis icl mutants 








0.35 +/- 0.16 
1.68+/-0.13 
0.09 +/- 0.31 
Acetate 
26.20 +/- 2.48 
0.54 +/-0.25 
40.07 +/- 5.95 
N D 
Propionate 
406.47 +/- 28.25 
2.35 +/-1.11 
495.44 +/- 65.09 
N D 
Bacteria were grown in defined 7H9 broth at 37 °C with shaking (65 rpm), and 
harvested at late log phase. Carbon substrates were used at 0.2 % w/v, each. 
Values correspond to specific activities (nmol/min/mg) in total cell-free extracts: 
isocitrate-stimulated activity using 1 m M isocitrate, 0.1 m M N A D H at 25 °C. All 
strains are M. tuberculosis (Erdman). N D = not done. Data represent the average 
of 3 measurements from one set of extracts. 
our studies. A peak in expression occurred at around 20 days post-infection, but 














Fig. 6.7. Expression of glyoxylate cycle enzymes during infection. (A) icll and (B) icl2 m R N A 
levels in M. tuberculosis grown in vitro (gray bars), in mouse lungs at 21 d (black bars), 60 d (black 
and white checkered bars) and 180 d (black circles-filled bars). Bars represent ratios of icll or icl2 
levels relative to sigA, a gene whose expression remains relatively unchanged during the infection 
(Timm et al, 2003). Number of transcript copies was determined by QRT-PCR using gene specific 
molecular beacons as detailed in materials and methods. Results are representative of least two 
experiments using samples from the same infection. Mice were infected i.v. with M. tuberculosis 
Erdman (1 x 106 CFU/mouse). 
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points) (Fig. 6.7). Expression of icll was also higher in vivo compared to in vitro, 
but the levels of expression were significantly lower (-10 fold) than those of icll 
at all time points (Fig. 6.7). Together these observations suggest that while ICL1 
is inducible, being upregulated in vitro in response to C2/C3 substrates, and at the 
level of mRNA in the lungs of mice. ICL2 appears to be constitutive in vitro, and 
subjected to some, but relatively low upregulation compared to ICL1 in vivo. 
6.7. Long-term survival of icll -deficient M. tuberculosis 
In order to assess the contribution of ICL1 and ICL2 to growth and survival of M. 
tuberculosis in vivo, we infected wild-type (C57BL/6) mice with bacteria lacking 
icll, icll, or both. Confirming our previous observations (McRinney et ah, 2000), 
by 4 wks post-infection, bacterial loads in the organs of mice infected with Aicll 
M. tuberculosis were 5-10 fold lower than those that had been infected with wild-
type bacteria (Fig. 6.8). However, here, by following the fate of the Aicll mutant 
for much longer than previously, we noted that despite significant prolonged 
attenuation and reduced tissue pathology (Fig. 6.9), Aicll mutant bacteria were 
actually capable of long-term persistence in the lungs of mice (at around 105 
CFU/lung), and late in the infection resumed growth (compare CFU/lung at 16 vs 
52 wk, post-infection), leading to pathology and death of the infected mice at circa 
75 wks post-infection (Fig. 6.10). Mice infected with wild-type bacteria died at 
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Spleen 
Fig. 6.8. Loss of ICL1 attenuates M. tuberculosis in chronically infected mice. Wild-type mice 
(C57BL/6) were infected with M. tuberculosis (Erdman) wild-type or Aicll mutant (IO6 CFU, i.v.). 
Bacteria in the (A) lung, (B) spleen, and (C) liver were enumerated by plating organ homogenates 
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Fig. 6.9. L u n g pathology in mice infected with ICLl-deficient M . tuberculosa. 
L u n g sections ( H & E stain) at 16 w k post-infection in C 5 7 B L / 6 mice infected with M . tuberculosis 
(Erdman) (~5xl05, i.v.) (A-C) wild-type, (D-F) Aicll. N u m b e r s on right margin indicate total 
magnification. 
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about 40 wks post-infection (Fig. 6.10), while uninfected mice lived longer than 
104 wks (not shown). Based on our in vitro carbon utilization experiments 
indicating that the absence of either id was not enough to impair growth on C2 
substrates, we hypothesized that the observed ability of the Aicll mutant to persist 
in the organs of mice and resume growth late in the infection might be due to the 
presence of ICL2. 
6.8. icll is dispensable for M. tuberculosis growth and persistence in mice 
To directly assess the contribution of ICL2 to M. tuberculosis pathogenesis, we 
evaluated the ability of the A/c/2 mutant to grow and persist in mice. Similarly to 
the Aicll mutant, the A/c/2 mutant replicated like wild-type during the first 2 wks 
of infection. However, in contrast to the Aicll mutant, bacteria lacking ICL2 
remained at wild-type levels during the chronic phase of the infection (wk 2-16) 
(Fig. 6.11), and elicited comparable pathology (Fig. 6.12). The fact that deletion 
of each id individually resulted in limited (Aicll) or no phenotype (Az'c/2) is 
consistent with the hypothesis of partial redundancy between the two homologs 
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Fig. 6.10. Survival of mice chronically infected with ICLl-deficient M. tuberculosis. Time-to-
death of wild-type (C57BL/6) mice infected with M. tuberculosis (Erdman) wild-type or Aicll 










Fig. 6.11. ICL2 is dispensable for M. tuberculosis growth and persistence in chronically 
infected mice. Wild-type (C57BL/6) mice were infected with M. tuberculosis (Erdman) wild-type 
or Aicll mutant (5xl05 CFU, i.v.). Bacteria in the (A) lung and (B) spleen were enumerated by 
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Fig. 6.12. L u n g pathology in mice infected with ICL2-deficient M . tuberculosis. 
Lung sections ( H & E stain) at 16 w k post-infection in C57BL/6 mice infected with M . tuberculosis 
(Erdman) (~5xl05, i.v) (A-C) wild-type, (D-F) A/c/2. 
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6.9. Partial functional redundancy between icll and icll in vivo 
Indeed, in contrast to A/c/7 or A/c/2 mutant bacteria, AiclllAicU M. tuberculosis 
mutants failed to replicate in lungs, spleens and livers of mice, and were cleared 
from the lungs by 4 wks post-infection, as seen in two independent experiments 
(Fig. 6.13A-C; Fig. 6.14 A&B). We observed no spontaneous relapse, and no 
bacilli could be recovered from any infected organ 48 wks post-infection (Fig. 
6.13A-C; limit of detection = 2 CFU per organ) suggesting sterilization. Mice 
infected with the AiclllAicll mutant did not show any discemable splenomegaly 
(Fig. 6.15) or lung pathology (Fig. 6.16), and remained healthy until the 
experiment was terminated 2 years post-infection, whereas mice infected with 
wild-type bacteria uniformly succumbed between 8 and 9 months post-infection. 
The experiment was repeated a third time using the aerosol route of infection. 
Mice received 10 CFU/mouse as determined by plating lung homogenates for 
CFU at 24 hours post-infection. By 2 wks post-infection, AiclllAicll mutant 
bacteria had been eradicated from the lungs and had bacteria were unable to 
disseminate to the spleen as indicated by plating organ homogenates at 2 and 4 
wks post-infection (limit of detection = 1 CFU/time-point). Complementation of 
the AiclllAicll mutant with an episomal plasmid carrying a wild-type copy of icll 
restored bacterial growth in both lung and spleen (Fig. 6.17A&B), as well as lung 
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Fig. 6.13. ICL1 and ICL2 are jointly required for growth and survival of M. tuberculosis in 
mice . (A-C) Wild-type (C57BL/6) mice were infected with M. tuberculosis (Erdman) wild-type or 
Aicll/Aicl2 (~106, i.v.). Bacterial loads in the (A) lung, (B) spleen, and (C) liver were enumerated by 
plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each 










Fig. 6.14. ICLl/ICL2-deficient bacteria are eradicated from mouse lungs within 4 weeks of 
infection. (A-B) Wild-type (C57BL/6) mice were infected with M. tuberculosis (Erdman) wild-type 
or Aicll/Aicl2 (5xl05, i.v.). Bacterial loads in the (A) lung and (B) spleen were enumerated by 
plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each 
group (n=4). This experiment only differs from the experiment shown in Fig. 6.13 in that a lower 
infection dose was used in this one. Limit of detection: 2 CFU/lung/mouse. 
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Wild-t\ Aicll Aicl2 Aicl1/Aicl2 
Fig. 6.15. ICLl-/ICL2-deficient M. tuberculosis is avirulent in mice. Spleens of C57BL/6 mice 
collected 2 weeks post-infection (~ IO6 CFU, i.v.) with wild-type (6.11 ± 0.15), Aic/7 (5.92 ± 0.12), 
A/c/2 (6.24 ± 0.08), or AicllAicl2 (3.58 + 0.22) bacteria. Numbers in parentheses indicate Log10CFU 
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Fig. 6.16. Lung pathology in mice infected with ICLl-/ICL2-deficient M. tuberculosis. 
Lung sections (H&E stain) at 16 wk post-infection in C57BL/6 mice infected with M. tuberculosis 
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Fig. 6.17. Growth of ICLl/ICL2-defkient M. tuberculosis in mice is restored by 
complementation with pICLl. Wild-type (C57BL/6) mice were infected with M. tuberculosis 
(Erdman) AiclllAicU, or Aic/i/A/c/2::pICLl (5xl05 CFU, i.v.). Bacteria in the (A) lung and (B) 
spleen were enumerated by plating organ homogenates for C F U at indicated time-points. Error bars 
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Fig. 6.18. Lung pathology in mice infected with ICLl-/ICL2-deficient M. tuberculosis 
complemented with ICLl. Lung sections (H&E stain) at 16 wk post-infection in C57BL/6 mice 
infected withM. tuberculosis (~5xl05, i.v.) (A-C) wild-type, (D-F) A/c///A/c/2::pICLl. 
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completely, restored as well. A n in vivo experiment with the AiclllAicll mutant 
that had been complemented with a plasmid carrying a wild-type copy of icll was 
not performed. 
6.10. AiclllAicll M. tuberculosis mutant is avirulent in immune-deficient mice 
TB case fatality rates are higher in AIDS patients than in HlV-negative individuals 
despite appropriate anti-mycobacterial therapy, suggesting that antimicrobials 
might be less efficacious in immune-compromised hosts (El-Sadr et ah, 2001). 
We asked what effect ICL inactivation would have on growth and survival of M. 
tuberculosis in immuno-deficient hosts by infecting mouse strains lacking 
interferon-y (IFN-y7") or tumor necrosis factor-cc receptor 1 (TNF-a-Rl"7"), which 
are highly susceptible to M. tuberculosis infection (Cooper et ah, 1993; Flynn et 
ah, 1993; Flynn et ah, 1995). Importantly, we found that AiclllAicll bacteria 
were incapable of replicating in IFN-y"7" mice (Fig. 6.19) or TNF-ocRT7" mice (Fig. 
6.20). These experiments suggest that targeting ICLs might be effective even in 
immune-compromised individuals. 
Previously we had seen that the attenuation of Aicll bacteria in C57BL/6 
mice was largely reversed in IFN-y"7" mice as well as in mice deficient in other key 
components of the immune response, suggesting that the in vivo requirement for 
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Fig. 6.19. ICLl/ICL2-deficient M. tuberculosis is avirulent in immune-deficient (IFN-y'-) mice. 
IFN-y-deficient (C57BL/6) mice were infected with M. tuberculosis (Erdman) wild-type or 
Aicll/AicU (IO6 CFU, i.v.). Bacteria in the (A) lung and (B) spleen were enumerated by plating 
organ homogenates for CFU at indicated time-points. Individual symbols represent CFU in the 





























Fig. 6.20. ICLl-/ICL2-deficient M. tuberculosis is avirulent in immune-deficient (TNF-aRT/_) 
mice. TNF-aRI-deficient (C57BL/6) mice were infected with M. tuberculosis (Erdman) (A) wild-
type or (B) Aicll/AicU (5xl05 CFU, i.v.). Bacteria in the lung were enumerated by plating organ 
homogenates for C F U at indicated time-points. Limit of detection at 56 days: 40 CFU/organ 
(indicated by dotted line). Error bars indicate S T D E V for each group (n = 4). 
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(Chapter 7; McRinney et ah, 2000). Our results with AiclllAicll mutant bacteria 
are largely inconsistent with this idea and suggest that dependence of M. 
tuberculosis on ICL activity for early growth in vivo is largely independent of 
these components of the immune response. Nonetheless, even though clearance of 
AiclllAicll bacteria from the infected lungs of IFN-y7" mice (Fig. 6.19A) was 
observed by wk 16 post-infection, the die off occurred more slowly than in 
immune-competent mice (Fig. 6.13 & 6.15) and little evidence of it was observed 
in the spleen (Fig. 6.19B), where AiclllAicll bacteria persisted without growing, 
perhaps reflecting organ specific differences in the environment of the infection. 
6.11. Growth of /c/-deficient M. tuberculosis in macrophages 
We next investigated whether the requirement for ICL-mediated metabolism by 
M. tuberculosis to growth and survive in mice could also be seen at the level of the 
parasitized macrophage. In marked contrast to either Aicll or A/c/2 bacteria, 
which replicated like wild-type, AiclllAicll M. tuberculosis was incapable of 
intracellular replication in resting macrophages (Fig. 6.21). 
Stimulation by mycobacterial products and certain cytokines activates 
macrophage effector mechanisms including phagocyte-oxidase-mediated 
generation of ROI, inducible nitric oxide (NOS2)-mediated generation of RNI, and 
LRG47-mediated phagolysosomal fusion and acidification (Nathan & Shiloh, 
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2000; Russell, 2001; MacMicking, 2005). To determine the impact of host cell 
activation on the survival of ICLl-/ICL2-deficient M. tuberculosis, bone marrow-
derived macrophages were activated with IFN-y (100 U mL") prior to and during 
intracellular infection. While macrophage activation was bacteriostatic to 
intracellular wild-type M. tuberculosis as expected, it was markedly bactericidal to 
AiclllAicll M. tuberculosis (Fig. 6.21). M. tuberculosis lacking icll, but not icll-
deficient bacteria also were slightly attenuated for growth and survival within 
macrophages (Fig. 6.21). Complementation of the AiclllAicll mutant with wild-
type copies of icll (Fig. 6.22 A&B) or icll (Fig. 6.22 C&D) restored replication in 
non-activated macrophages (Fig. 6.22 A&C) and survival in IFN-y-activated 
macrophages (Fig. 6.22 B&D). 
6.12. Growth of /c/-deficient M. tuberculosis in human macrophages 
To extend our observations to human cells, human blood monocyte-derived 
macrophages were infected ex-vivo. Similarly to wild-type, Aicll and A/c/2 M. 
tuberculosis readily replicated in human primary macrophages as determined by 
CFU (Fig. 6.23) and4',6'-diamino-2-phenylindole (DAPI)-staining of intracellular 
bacteria (Fig. 6.24). In contrast, AiclllAicll bacteria were incapable of any 
intracellular replication (Fig. 6.23-6.25). These data suggest that M. tuberculosis 
might depend on the GC during infection of its natural host. 
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Activated Mac 
Fig. 6.21. Replication and survival of icl mutants of M . tuberculosis in murine macrophages. 
Non-activated (A,C,E) and IFN-Y-activated (B,D,F) macrophages were infected with M. 
tuberculosis wild-type, Aicll, A/c/2 or Aicll/AicU as indicated (MOI 2:1). At the indicated time 
points, cells were lysed (n = 4 wells) and plated to enumerate CFU. Symbols represent means; error 
bars indicate STDEV. Results are representative of two experiments. 
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A) 6 Resting Mac B) 6-, Activated Mac 
Fig. 6.22. Replication and survival of M . tuberculosis AiclllAicU complemented with pICLl or 
pICL2 in murine macrophages. Murine bone marrow-derived macrophages, (A,C,) non-activated 
or (B,D) IFN-y-activated were infected with M. tuberculosis wild-type, A/c/7/A/c/2::pICLl or 
A/c/i/A/c/2::pICL2 strains as indicated (MOI 2:1). At indicated time points, cells were lysed (n = 4 
wells) and plated for C F U enumeration. Symbols represent means; error bars indicate STDEV. 
Results are representative of two experiments. 
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Fig. 6.23. Replication and survival of id M. tuberculosis mutants in human macrophages. (A-B) 
Human blood monocyte-derived macrophages were infected with M. tuberculosis wild-type, Aicll, 
AicU, Aicll/AicU or A/c///A/c/2::pICLl strains as indicated (MOI 1:1). At indicated time points, 
cells were lysed (n = 4 wells) and plated to enumerate CFU. Symbols represent means; error bars 
indicate STDEV. Results are representative of two experiments. 
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Fig. 6.24. M . tuberculosis id mutants in human macrophages . (A-D) Human blood monocyte-
derived macrophages seeded on round cover slips were infected with M. tuberculosis (Erdman) (A) 
wild-type, (B) Aicll, (C) A/c/2, (D) AiclllAicU; (MOI 1:1). At 6 days post-infection, bacteria were 
fixed and stained with DAPI. Results are representative of two experiments. 
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Together, these observations suggest that fatty acids might be the principle carbon 
source used by mycobacteria to grow and survive intracellularly. 
6.13. The ICL inhibitor 3-nitropropionate blocks replication of M. 
tuberculosis on fatty acids and in macrophages 
Our demonstration that ICL activity is essential for replication and survival of M. 
tuberculosis in vivo suggested that chemical inhibition of ICL1 and ICL2 might be 
an effective therapeutic strategy. We therefore tested the ability of the prototype 
ICL inhibitor 3-nitropropionate (3-NP) (Schloss & Cleland, 1982; Honer zu 
Bentrup et ah, 1999; Sharma et ah, 2000) to block growth of M. tuberculosis in 
media containing specific carbon substrates (Fig. 6.25) and in macrophages (Fig. 
6.26). 
Growth of M. tuberculosis on glycerol (Fig. 6.25A) or glucose (Fig. 6.25B) 
was only slightly affected by the addition of 0.1 mM 3-NP, comparable to the 
slightly reduced growth kinetics of the AiclllAicll strain under these conditions. 
In contrast, 3-NP prevented growth of M. tuberculosis on fatty acids (Fig. 6.25C-
F). When M. tuberculosis was grown in murine macrophages (Fig. 6.26), addition 
of 3-NP resulted in inhibition of intracellular replication (58-fold reduction in 
CFU at day 7) (Fig. 6.26B), comparable to the growth inhibition resulting from 
deletion of icll and icll (54-fold reduction in CFU at day 7) (Fig. 6.26A). 
Inhibition of mycobacterial growth in macrophages by 3-NP was dose-dependent 
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Fig. 6.25. Chemical inhibition of ICL blocks growth of M . tuberculosis on fatty acids. Wild-type 
M. tuberculosis (Erdman) bacteria were cultured in liquid media containing (0.1% w/v) (A) glycerol; 
(B) glucose; (C) propionate (C3FA); (D) polyoxyethylene sorbitan mono-laurate (C12FA); (E) 
polyoxyethylene sorbitan mono-palmitate (C16FA); (F) polyoxyethylene sorbitan mono-stearate 
(C18FA) with (asterisks) or without (filled squares) the ICL inhibitor 3-NP (0.1 m M ) . Growth was 
monitored by measuring OD600 n m at the indicated time points. Wild-type bacteria: squares; 
ICLl/ICL2-deficient bacteria: diamonds; ICLl/ICL2-deficient bacteria complemented with episomal 
plasmid carrying ICL1: asterisks. Results are representative of three experiments. 
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Fig. 6.26. Chemical inhibition of I C L blocks intracellular growth of M . tuberculosis in 
macrophages. Growth in murine bone marrow-derived macrophages (A-C) and in human blood 
monocyte-derived macrophages (D). Macrophages were infected with wild-type (squares) without 
(filled), with (empty) 3-NP, or AiclllAicU mutant M . tuberculosis (diamonds) After 4 hr, cells were 
washed to remove non-cell-associated bacteria and incubated in fresh medium with or without 3-NP 
(numbers in parentheses indicate m M concentrations). At the indicated time points cells were lysed 
(n = 4 wells) and plated to enumerate C F U . Symbols represent means; error bars indicate S T D E V . 
Results are representative of two experiments. 
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(Fig. 6.26C). Growth of M. tuberculosis in human macrophages was also 
inhibited by 3-NP in a dose-dependent manner (Fig. 6.26D), although inhibition 
was somewhat less effective in human as compared to murine macrophages, 
perhaps due to differences in the uptake or metabolism of the compound. 
Consistent with our interpretation that growth inhibition by 3-NP was due 
to inhibition of ICL per se, bacteria that over-expressed ICL1 from a plasmid (~6 
fold higher expression under in v/fro-inducing growth conditions) were less 
sensitive to growth inhibition by 3-NP than wild-type bacteria in vitro (Fig. 
6.27A&B) and ex-vivo during growth in murine macrophages (Fig. 6.27C). These 
results provide a proof of concept for the potential development of ICL inhibitors 
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Fig. 6.27. M . tuberculosis strain over-expressing ICL is resistant to growth inhibition by 3-
nitropropionate. M. tuberculosis (A) wild-type or (B) ICL 1-over-expressing bacteria were grown 
in liquid media containing (0.1% w/v) propionate (C3FA) in the presence of increasing 
concentrations of 3-NP (as indicated, numbers in m M ) . Growth was monitored by measuring ODfinn 
n m at the indicated time points. (C) Bone marrow-derived mouse macrophages were infected with 
M. tuberculosis wild-type without (filled squares) or with (empty squares) 3-NP (10 m M ) or with an 
ICL 1-over-expressing strain without (x) or with (*) 3-NP (10 m M ) . ( A & B) results are 
representative of two experiments. (C) results of one experiment. 
189 
C H A P T E R 7 
A link between the I m m u n e Response, Bacterial Metabolism, a n d 
Persistence of M. tuberculosis in the Host 
I N T R O D U C T I O N 
The immune system has evolved a number of strategies to curtail the replication 
and survival of intracellular pathogens. One important strategy involves a 
remodeling of the infected area so as to isolate it from healthy tissue as it occurs 
during granuloma formation. As this occurs, the host cells that harbor the 
infecting bacteria are also altered (activated) or even killed in an effort to limit the 
growth of the bacteria within them. Activation of effector mechanisms within 
cells involves the production of noxious molecules such as reactive oxygen and 
nitrogen intermediates (ROI and RNI), which are thought to directly block or kill 
the infecting bacteria. 
In dealing with M. tuberculosis, our immune system engages a number of 
mechanisms of defense (Flynn and Chan, 2001; Nathan & Ehrt, 2003; 
MacMicking 2005). In addition to the production of ROI and RNI, during 
activation of infected cells other changes in the chemical composition of the 
intracellular space the pathogen inhabits take place. Macrophage activation via 
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interferon gamma (IFN-y) leads to increased phagolysosomal fusion and 
acidification, which at least in part is mediated by IFN-y-induced GTPase LRG47 
(MacMicking et ah, 2003; MacMicking, 2005). Although some evidence 
indicates that the mycobacterial vacuole in macrophages is devoid of certain 
amino acids (Smith et ah, 2001; Parish & Stoker, 2002), and limiting in some 
essential elements such as iron and magnesium (Buchmeier et ah, 2000; 
Rodriguez & Smith, 2003), little is known about the carbon substrate vacuolar 
contents or how the concentrations of any of these elements or carbon substrates 
might be influenced by immune-mediated activation of the macrophage. 
We showed previously that M. tuberculosis required ICL to grow and 
survive in mice from the onset of the infection, suggesting that the ability to 
metabolize C2 substrates during infection is essential for this pathogen. Our data 
also showed that either of the two isoenzymes could provide enough activity for 
growth and survival during the acute phase of the infection (~wk 0-2). However, 
during the persistent phase of the infection, Aicll mutant bacteria were unable to 
maintain wild-type levels of bacterial loads in the lung, while A/c/2 mutant 
bacteria behaved like wild-type (Chapter 6; McKinney et ah, 2000; Munoz-Elias 
& McKinney, 2005). Thus, the functional overlap between the two homologs is 
only partial: loss of icll is fully compensated by icll during both acute and 
persistent phases of the infection, while loss of icll is only fully compensated by 
icll during the acute phase of the infection. 
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The fact that the in vivo phenotype of the A/c/7 mutant coincided with the 
time at which acquired immunity to M. tuberculosis normally emerges in the 
mouse model of tuberculosis suggested a causal link. Can acquired immunity 
bring about changes in the infection milieu that prompt M. tuberculosis to rely on 
ICL to a greater degree during the persistent phase of the infection than during the 
acute phase? To shed light on this question, we carried out a series of experiments 
analyzing the ability of ICL 1-deficient M. tuberculosis to grow in mice deficient 
in several known anti-tubercular pathways (Flynn & Chan, 2001; North & Jung, 
2004; MacMicking, 2005). 
Here we show that the host immune response is largely responsible for the 
attenuation phenotype of ICL 1-deficient bacteria during the chronic phase of the 
infection in immune-competent mice. While T cells, IFN-y, and TNF-a played a 
role in bringing about this phenotype, the downstream effectors inducible nitric 
oxide (NOS2) and LRG47 were only partially involved, and phagocyte oxidase 
(PHOX) was completely dispensable. Our results suggest that in an immune-
competent host, the emergence of acquired immunity might cause M. tuberculosis 
to increase its reliance on the GC, implicating carbon restriction as an 
antimycobacterial mechanism specific to persistence. 
RESULTS 
7.1. icll -deficient M. tuberculosis regains virulence in T cell-deficient mice 
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The adaptive immune response to M. tuberculosis infection is largely mediated by 
antigen-specific CD4+ and CD8+ T cells, which exert their protective effects via 
secretion of the macrophage-activating cytokine IFN-y (Flynn & Chan, 2001; 
North & Jung, 2004). Thus, we started evaluating our hypothesis by testing the 
ability of Aicll bacteria to grow in Rag 1-deficient mice (Mombaerts et ah, 1992), 
which were expected to be highly susceptible to M. tuberculosis infection. 
The attenuation of the Aicll mutant seen in wild-type mice was largely 
reversed in Ragl"7" mice. Aicll mutant bacteria replicated similarly to wild-type 
bacteria, and were almost as virulent (Fig. 7.1) (mean time-to-death for Ragl"7" 
mice infected with Aicll mutant and wild-type bacteria were 34 and 19 days, 
respectively). Thus, the persistence-specific attenuation of Aicll mutant bacteria 
appears to be driven by an interaction with components of the host's acquired 
immune response. 
7.2. IFN-y-dependent mechanisms contribute to killing of icll -deficient 
bacteria 
Studies using mice deficient in CD4+ and CD8+ T cells have established that the 
contribution of CD4+ T cells to the protective immune response to M. tuberculosis 
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Fig. 7.1. ICLl-deficient M . tuberculosis regains virulent in T cell-deficient mice. (A-B) Ragl"'~ 
mice are highly susceptible to M. tuberculosis infection. Wild-type mice (dotted lines, empty 
squares) and Ragl"/_ mice (solid lines/filled squares) were infected with M . tuberculosis (Erdman, ~5 
x IO6 C F U , i.v.) . (A-C). Aicll mutant reverts to virulence in Ragl"A mice. Ragl"A mice were 
infected with wild-type (solid lines/filled squares) or Aicll mutant bacteria (solid lines/filled circles). 
Bacteria in the (A) lung and (B) spleen were enumerated by plating for C F U at indicated time-points. 
Error bars indicate S T D E V (n=4). C ) Survival of Ragl_/" mice infected with wild-type (squares) or 
Aicll mutant bacteria (circles) (n=7). 
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Flynn, 1999; Serbina et ah, 2001). CD4+ T cells contribute to anti-tubercular 
immunity largely through the production of IFN-y, which turns on several anti-
mycobacterial defense mechanisms (Flynn & Chan, 2001; North & Jung, 2004; 
MacMicking, 2005). Therefore, we next asked whether A/c/7 bacteira could also 
"revert" to virulence in mice lacking IFN-y. 
Similarly to our observations in Ragl"A mice, A/c/7 bacteria showed a clear 
reversal toward virulence in IFN-y7" mice, growing in all organs analyzed 
similarly to wild-type bacteria (Fig. 7.2A-C), and killing these mice by -33 days 
post infection (Fig. 7.2D). As expected, IFN-y/_ mice infected with wild-type M. 
tuberculosis succumbed by -17 days post-infection (Fig. 7.2D). 
The reversal of the Aicll mutant we saw in both Ragl"A and IFN-yA (Fig. 7.1&7.2) 
was not complete. While wild-type bacteria grew unabated in the organs of both 
of these mice, the A/c/7 mutant noticeably slowed down at about 7-10 days post-
infection (Fig. 7.1&7.2). This difference was underscored by the delayed kinetics 
with which mice infected with A/c/7 bacteria succumbed to infection compared to 
those infected with wild-type bacteria (Fig. 7.1C&7.2D). These observations 
suggest that other host factors which are T cell/IFN-y-independent, likely 
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Fig. 7.2. ICLl-deficient M . tuberculosis regains virulence in IFN-y'" mice. IFN-y"'" mice 
(C57B1/6) were infected with M . tuberculosis (Erdman) wild-type (squares) or Aicll (circles) 
bacteria (0.5-1 x IO6 C F U , i.v.). Bacteria in the (A) lung, (B) spleen, and (C) liver were enumerated 
by plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each 
group (n=4). D ) Survival (n=10). 
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7.3. I m m u n e effector mechanisms that contribute to the control of icll-
deficient M. tuberculosis 
We next turned our attention to effector mechanisms downstream of IFN-y that 
could be responsible for the persistence-specific attenuation of ICL 1-deficient M. 
tuberculosis observed in wild-type mice (McKinney et ah, 2000; Munoz-Elias & 
McKinney, 2005). IFN-y induces expression of Ca++-independent nitric oxide 
synthase (NOS2) through the JAK/STAT pathway (Xie et al, 1992; Nathan & 
Xie, 1994; Darnell, 1997). Nitric oxide and other reactive nitrogen intermediates 
(RNI) are key components in the host's anti-tubercular arsenal (MacMicking et 
al, 1997; Nathan & Shiloh, 2000). To address the contribution of this host 
defense pathway to the attenuation of A/c/7 M. tuberculosis, we infected NOS2"7" 
mice with wild-type or A/c/7 bacteria and monitored bacterial growth and survival 
in their lungs. Unexpectedly, NOS2"A mice were capable of stabilizing A/c/7 
mutant bacterial loads in the lungs at about -106 CFU from day 20-70 post-
infection, only losing control of the infection after -112 days (Fig. 7.3A-C). In 
contrast, wild-type bacteria multiplied to about -109 CFU per lung in only -40 
days in these mice, in accordance with previous results (MacMicking et al, 1997; 
Scanga et al, 2001). Moreover, while NOS2"7" mice infected with A/c/7 mutant 
bacteria survived up to - 135 days, those infected with wild-type bacteria 
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Fig. 7.3. Nitric oxide synthase contributes to the attenuation of ICLl-deficient M. tuberculosis. 
(A-D) NOS2"'" (C57BL/6) mice were infected with M. tuberculosis (Erdman) wild-type or Aicll 
(5xl05 CFU, i.v.). Bacteria in the (A) lung, (B) spleen, and (C) liver were enumerated by plating 
organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each group 
(n=4). (D) Survival (n=8). 
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The fact that A/c/7 mutant bacteria did revert to some degree in NOS2"" 
mice - a slight increase in bacterial loads in both lungs and spleens was observed-
suggests that NOS2, presumably via RNI production, does contribute to the 
phenotype of the A/c/7 mutant during the persistence phase of the infection in 
wild-type mice. However, that the A/c/7 mutant's reversal was not nearly as 
dramatic as that observed in IFN-y-deficient mice suggests that other IFN-y-
dependent mechanisms exist that are capable of inhibiting the growth of the 
mutant, but do not impair wild-type bacteria to the same degree. 
Another IFN-y-dependent mechanism that plays a key role in the control of 
M. tuberculosis infection is the LRG47 GTPase-mediated increase in lysosomal 
fusion and acidification of the M. tuberculosis vacuole (MacMicking et al, 2003). 
When LRG47"7" mice were infected with the A/c/7 mutant, some reversal of the 
mutant's persistence defect was observed. However, similarly to NOS2"/_ mice, 
LRG47"/_ mice were also capable of controlling the growth of the A/c/7 mutant 
and, in fact, did so more efficiently than NOS2"/_ mice (N. Dhar & J.D. 
MacMicking, personal communication). 
Mice lacking phagocyte oxidase (PHOX) are highly susceptible to 
infections by several fungi and bacteria including intracellular Salmonellae spp 
(Nathan & Shiloh, 2000). However, M. tuberculosis is relatively resistant to ROI 
ex vivo (Manca et ah, 1999), and gp91(PH0X"/") mice control M. tuberculosis 
infection as efficiently as their wild-type counterparts (Nathan & Shiloh, 2000; Ng 
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et ah, 2004). Nevertheless, we considered it possible that lower ICL activity in the 
ICL 1-deficient strain might interfere with the bacteria's ability to generate 
effective defenses against ROI, and make them more susceptible to a host-
mediated mechanism to which wild-type bacteria are normally resistant. To test 
this hypothesis, we monitored the growth of A/c/7 mutant bacteria in gp91(PH0X/) 
mice. 
Interestingly, we failed to see any reversal of the A/c/7 mutant's 
attenuation, and instead observed a slight increase in its attenuation. PHOX-
deficient mice killed A/c/7 mutant bacteria more efficiently than wild-type mice 
(Fig. 7.4A-C). The bacterial requirement for ICL1 in these mice might even 
appear earlier on because only 2 wks into the infection, the lung bacterial loads of 
the A/c/7 mutant were about 10X lower than wild-type bacteria (Fig. 7.4A); 
further, the A/c/7 mutant only replicated slightly in the spleen (Fig. 7.4B) and not 
at all in the liver (Fig. 7.4C) during the acute phase. These data argue that the 
phenotype of the A/c/7 mutant in wild-type mice is unlikely to be driven by ROI. 
7.4. TNF-ocRI-mediated immunity contributes to the attenuation of icll-
deficient bacteria 
The cytokine tumor necrosis factor alpha (TNF-a) is a major player in the immune 
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Fig. 7.4. Phagocyte oxidase is dispensable for control of ICLl-deficient M. tuberculosis. (A-C) 
gp91phox-/- (C57B1/6) mice were infected with M. tuberculosis (Erdman) wild-type or Aicll bacteria 
(~5xl05 CFU, i.v.). Bacteria in the (A) lung, (B) spleen, and (C) liver were enumerated by plating 
organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each group 
(n=4). 
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Flynn & Chan, 2001). Together with IFN-y, TNF-a synergistically activates 
macrophages inducing production of higher levels of RNI and ROI, which results 
in higher anti-mycobactericidal activity (Flesch & Kaufman, 1990; Chan et ah, 
1992; Flynn & Chan, 2001). However, TNF-a exerts its antimycobacterial effects 
through both iNOS-dependent and independent mechanisms (Flynn et ah, 1995; 
Adams et ah, 1995; Bean et ah, 1999; Ehlers et ah, 1999; Bekker et ah, 2001). 
Since we had found that NOS2 and LRG47 appeared to be only partially 
responsible for the attenuation of the A/c/7 mutant, we next asked whether TNF-a-
mediated mechanisms might be involved. 
To this end, we evaluated the ability of the A/c/7 mutant to grow in mice 
lacking TNF-aRI. Signaling through this receptor is thought to mediate most of 
the anti-tubercular effects attributed to this cytokine (Algood et ah, 2003). 
Surprisingly, we found that the attenuation of A/c/7 mutant bacteria was almost 
completely reversed in these mice (Fig. 7.5A-C). Growth of the A/c/7 mutant was 
essentially indistinguishable from that of wild-type bacteria, and only a slight 
delay in death in the mice infected with the A/c/7 mutant compared to wild-type 
bacteria was observed (Fig. 7.5D). This experiment was carried out with slightly 
higher dose of bacteria than previous ones (-2-3 x IO6 CFU/mouse versus - 5 to 
10 x 105 CFU/mouse by i.v.), thus it is possible that the high number of bacteria 
overwhelmed the immune response and prevented discerning any residual 
attenuation of the A/c/7 mutant in the experiment shown in Fig. 7.5. In fact, in a 
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Spleen 
Fig. 7.5. TNF-ocRI-deficient mice fail to control the growth of ICLl-deficient M. tuberculosis. 
(A-D) TNF-aRI(p55"'") (C57BL/6) mice were infected with M. tuberculosis (Erdman) wild-type or 
Aicll (~2xl06 CFU, i.v.). Bacteria in the (A) lung, (B) spleen, (C) liver were enumerated by plating 
organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each group 
(n=4). (D) Survival (n=10). 
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second experiment in which bacteria were administered by aerosol (-100 CFU), 
the reversal of the phenotype of the A/c/7 mutant was less dramatic (not shown) 
and was more reminiscent of the pattern of growth we saw in IFN-y-deficient mice 
(Fig. 7.2 & Dahr & MacMicking, personal communication). Nonetheless, these 
data together suggest that TNF-a is a major factor contributing to the immune 
response that causes M. tuberculosis to rely on ICL 1-mediated metabolism during 
infection. 
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C H A P T E R 8 
Assessing the Potential of Inhibiting I C L 1 in Enhancing 
Chemotherapy of Tuberculosis in Mice 
INTRODUCTION 
During the persistent phase of the infection in the mouse model of chronic 
tuberculosis (TB) bacilli are thought to undergo limited replication (Rees and Hart, 
1961; Munoz-Elias et ah, 2005; Chapter 5). Not surprisingly, drugs like isoniazid 
(INH) that preferentially kill replicating bacteria are relatively less efficient when 
administered to infected mice late rather than early in the infection (McCune et ah, 
1956). Nonetheless, even if M. tuberculosis is only replicating slowly during 
infection, it must maintain some metabolic activity in order to support basic cell 
functions, and to counteract the constant onslaught of host immune effectors. The 
type of metabolism characterizing M. tuberculosis during persistence might be 
different from that in periods of rapid bacterial growth, such as during the acute 
phase of the infection. 
Largely based on the fact that antibiotics have dramatically different anti-
tubercular effects depending on when during the infection and in what 
combination they are given when treating TB, it has been proposed that the 
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physiology/metabolism of the tubercle bacillus in the lung might be radically 
different from that of bacteria growing in vitro and that different populations of 
bacteria might exist, which differ metabolically/physiologically from each other as 
well (Mitchison, 1979, 1980). These phenotypic changes might contribute to the 
ability of drug-susceptible bacteria to persist in vivo despite adequate 
chemotherapy, a phenomenon known as in vivo drug tolerance and a major 
obstacle to the eradication of TB (McDermott, 1958). 
Based on our finding that ICL 1-deficient bacteria are specifically attenuated 
during persistence in immuno-competent mice (McKinney et ah, 2000; Chapters 
6&7), and that expression of /c/7 is highly induced throughout the infection in 
mouse lungs (Timm et ah, 2003; Fig. 6.7), we hypothesized that ICLl-mediated 
metabolism might be particularly relevant to the persistent phase of the infection. 
Thus, we set out to test the effect that lack of ICL1 alone would have on the 
treatment of chronically infected mice, and on the ability of ICL 1-deficient 
bacteria to reactivate from "latency" in a chemotherapy-induced model of latency 
in mice. 
R E S U L T S 
8.1. A n additive anti-mycobacterial effect between I N H and lack of ICL1 
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The early anti-tubercular bactericidal activity of isoniazid (INH) is attributed to its 
efficacy in killing actively multiplying bacilli (McKinney, 2000; Mitchison, 2004). 
It is thought that INH's initial rate of killing subsequently declines because 
residual organisms replicate and metabolize more slowly or differently (Mitchison, 
2004; Boshoff & Barry, 2005). Since our results with the A/c/7 mutant suggested 
that the GC might be required during both the acute and chronic phases of the 
infection, we asked whether treatment of INH and lack of ICL1 alone would 
synergize in killing bacteria specifically during the persistent phase of the 
infection. This would be akin to assessing the effect that a potential inhibitor of 
ICL1 would have on TB chemotherapy if co-administered with INH. To this end 
we infected mice (C57BL/6) with A/c/7 mutant or wild-type bacteria and 
compared the in vivo susceptibility of the two strains to INH treatment. Mice were 
inoculated intravenously with wild-type or A/c/7 bacteria and the infection was 
allowed to proceed normally for 4 wks (Fig. 8.1). At that point groups of mice 
infected with either strain were placed in monotherapy with LNH (25 mg/kg/day) 
(Canetti, 1960) for the next 8 wks; every 2 wks, 4 mice from each group (treated 
and untreated, infected with either strain) were sacrificed and the numbers of 
bacteria in their organs were determined by plating for CFU. As expected, by wk 
4 post infection, the counts for the A/c/7 mutant in the lung were already about 5 
fold lower than those of wild-type bacteria and remained between -0.75 and 1 
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log10 lower than wild-type throughout the experiment in lungs, spleens, and livers 
(Fig. 8.1A&Fig. 8.2A&B). 
INH treatment sharply reduced bacterial loads in the lungs (2 log drop/4 
wks) (Fig. 8.1 A), spleens and livers (Fig. 8.2A-B) of mice infected with wild-type 
bacteria during the initial 4 wks of the infection; a similar but more pronounced 
drop in the census of the A/c/7 mutant (2.5 log drop/4 wks) was observed during 
this period. Interestingly, the killing kinetics over this early period of 
chemotherapy indicated an additive bactericidal effect between INH treatment and 
ICL1 deficiency (Fig. 8.1 A&B): By the end of the second wk of INH treatment, 
99% of A/c/7 bacteria had been killed compared to -90 % of wild-type bacteria. 
This enhancement of killing suggests that the eventual use of ICL 1-specific 
inhibitors in the treatment of TB might not interfere with the action of bactericidal 
drugs like INH, an important consideration when evaluating the potential of a 
bacterial target for antibiotic development (Mitchison, 1979; 1980; Nathan, 2004). 
8.2. Lack of ICL1 does not reduce M. tuberculosis in vivo drug tolerance 
That ICL 1-deficiency led to increased susceptibility to killing by INH during the 
early phase of chemotherapy was consistent with the idea that ICL-mediated 
metabolism is essential for M. tuberculosis throughout the infection (Chapter 6). 
However, the increased susceptibility of ICL 1-deficient bacteria to INH we 
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Fig. 8.1. Isoniazid therapy of mice infected with icll -deficient M. tuberculosis. 
Widltype (C57BL/6) mice infected with wild-type or Aicll M. tuberculosis (Erdman) (~106 CFU, i.v.). 
Beginning on week 4 post infection, mice were treated with INH (25 mg/kg/day) for 8 weeks. Bacteria 
in the (A) lung were enumerated by plating organ homogenates for C F U at indicated time-points. (B) 




Fig. 8.2. Isoniazid therapy of mice infected with icll -deficient M . tuberculosis. 
Wild-type (C57BL/6) mice infected with wild-type or Aicll M. tuberculosis (Erdman) (~106 CFU, 
i.v.). Beginning on week 4 post infection, mice were treated with INH (25 mg/kg/day) for 8 weeks. 
Bacteria in the (A) spleen and (B) liver were enumerated by plating organ homogenates for C F U at 
indicated time-points. Error bars indicate S T D E V for each group (n=4). 
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INH treatment during wks 4-8 did not further significantly reduce bacterial loads 
of either wild-type or ICL 1-deficient bacteria (Fig. 8.1&8.2). Importantly, 
bacteria surviving these 8 wks of INH treatment were largely drug susceptible 
because only 0.25% of wild-type and no A/c/7 mutant bacteria found in the lungs 
after the 8 wks of chemotherapy were resistant to INH (INH, 0.5 [xg/mL; limit of 
detection, 1 CFU/lung). Thus, the great majority of these bacteria belonged to the 
category McDermott (1958) termed "in vivo drug tolerant." 
That the lack of ICL1 did not significantly enhance the ability of INH to 
eradicate the bacteria from the organs of mice suggests that if in vivo LNH-tolerant 
bacteria depend on C2-metabolism for persistence, ICL2 is capable of providing 
enough ICL activity to the bacteria so that they can persist on C2 substrates. 
8.3. A Potential role for ICL1 during reactivation from latency 
We next considered the possibility that M. tuberculosis dependence on ICL1 
during persistence might pertain to the bacterial population(s) responsible for 
latency. Latency in humans is the most common outcome of M. tuberculosis 
infection and the result of a partially effective immune response. Since no good 
animal model of such scenario exists apart from the monkey (Capuano et ah, 
2003; Flynn et ah, 2003), we decided to use a modified version of the "Cornell 
model" of drug-induced latency (See Chapter 6) to test the possibility that ICL1-
mediated metabolism might be important for the establishment and/or reactivation 
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from latency. To this end we adapted a recently described aerosol model of drug 
induced latency in which mice are treated with INH and rifampin (RIF) starting at 
2 wks post-infection and then treated with a NOS2 inhibitor to induce reactivation 
(Botha et al, 2002). Since we had observed that IFN-y-dependent/NOS2-
independent factor(s) could, at least transiently, keep A/c/7 bacteria in check 
during the persistent phase of the infection (Chapter 7), we decided to carry out 
the drug-induced latency study in NOS2"7" mice. In preliminary experiments, we 
confirmed that A/c/7 bacteria were attenuated during the persistence phase of the 
infection compared to wild-type bacteria when given via the respiratory route (Fig. 
8.4 C), confirming our previous results via the intravenous route. NOS2"A mice 
were infected by aerosol with either wild-type or A/c/7 bacteria (-30 CFU/mouse, 
aerosol) and at 2 wks post-infection, a group of mice infected with each strain was 
put on an 8-wk long INH-RIF combination. Bacterial counts were determined 
throughout, at 1-wk intervals during the first 4 wks of treatment, and at 2-wk 
intervals from wks 6-10. 8 wks of chemotherapy resulted in drastic reductions in 
wild-type and A/c/7 mutant bacterial loads in the lungs (CFU decreased from 106 
to - 50 CFU, and in some mice, to zero) (Fig. 8.3). The killing rates of wild-type 
and A/c/7 bacteria during antibiotic treatment phase were indistinguishable. This 
observation suggests that NOS2 might contribute to the slightly increased early 
killing of A/c/7 mutant we had observed before (Fig. 8.1 A & B). However, since 
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Fig. 8.3. Evaluating the role of ICL1 in the drug-induced model of latent tuberculosis in mice 
(Modified "Cornell Model"). NOS2"'" (C57BL/6) mice infected by aerosol with wild-type or Aicll 
M. tuberculosis (Erdman, -30 CFU/mouse) received isoniazid plus rifampin (25 mg/kg/day, each) 
from week 2-10 post infection (drugs were given in drinking water and withdrawn 24 hr before each 
time-point). Bacteria in the lungs were enumerated by plating organ homogenates for CFU at 
indicated time-points. Error bars indicate STDEV for each group (n=4). 
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compared directly. 
In the models of drug-induced latency, if one assumes that the bacteria 
remaining after treatment are in a state akin to "latency," then the relapse phase is 
equivalent to reactivation from "latency." If ICLl-mediated metabolism were 
important for the survival of bacteria in this state "latent" state, the A/c/7 mutant 
would be expected to survive less well, perhaps be incapable of reactivating from 
such state. As expected based on previous reports (Botha et ah, 2002; Flynn et ah, 
1998; Scanga et ah, 1999), NOS2-deficiency hasten the kinetics of reactivation 
significantly. Only 4 wks after drug withdrawal, wild-type bacterial numbers had 
bounced back one thousand fold and by 8 wks had climbed to about IO5 CFU per 
lung (Fig. 8.3). Interestingly, growth of wild-type bacteria during this reactivation 
phase was clearly slower than earlier in the acute phase of the infection. During a 
similar time interval in NOS2"/_ mice, wild-type bacterial loads increased from -30 
to about IO9 CFU per lung, which killed the mice within 9 wks of infection (Fig. 
8.4 A&B). These observations suggest the existence of NOS2-independent 
mechanism(s) that may contribute to the control of M. tuberculosis during 
persistent infection and that perhaps together with NOS2 play a role in 
maintaining latency, as proposed before (Flynn et ah, 1998). 
During this initial 8 wks after drug withdrawal, ICL 1-deficient bacteria 
reactivated with indistinguishable kinetics from wild-type (Fig. 8.3). 
Nevertheless, over the ensuing 8 wks (wks 18-26 post infection), while wild-type 
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Fig. 8.4. Comparison of growth of M. tuberculosis ic/7-deficient mutant in wild-type and NOS2" 
'• mice. (A&B) NOS2"'~ and (C) wildtype (C57BL/6) mice were infected by aerosol with wild-type 
(squares) or Aicll (circles) M. tuberculosis (Erdman, -30 CFU/mouse). Bacteria in the lungs were 
enumerated by plating organ homogenates for CFU at indicated time-points. Error bars indicate 
STDEV for each group (n=4). (B) Survival of NOS2"'" mice infected with wild-type or Aicll mutant 
(n=8). 
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bacteria continued to grow, reaching between 107-108 C F U per lung, A/c/7 mutant 
bacteria hovered at around IO5 CFU per lung (Fig. 8.3). In addition, reactivated 
wild-type bacteria killed infected mice between wk 30-34 post-infection, while 
A/c/7 mutant bacteria allowed much longer survival (mice started to die at 38 wks 
post-infection and some mice survived up to 54 wks post-infection) (not shown). 
Bacterial CFU during the survival part of the experiment were not determined. 
These data suggest that NOS2-independent antimycobacterial mechanism(s) exist 
that can more effectively control ICL 1-deficient bacteria compared to wild-type, 
and these might be important during reactivation from "latency." It is unclear if 
this mechanism(s) is the same that transiently controlled the growth of A/c/7 
mutant bacteria in the standard mouse model of chronic TB also using NOS2-
deficient mice (Fig. 8.4A; see also Chapter 7). 
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C H A P T E R 9 
T h e Role of the Glyoxylate Cycle in the G r o w t h of Mycobacteria 
on Fatty Acids & Carbohydrates 
INTRODUCTION 
Previously, we reported that AiclllAicll M. tuberculosis bacteria are unable to 
replicate in vivo and are rapidly cleared from the lungs of mice (Chapter 6; 
Munoz-Elias & McKinney, 2005). As expected based on what is known about the 
canonical role of the GC in carbon metabolism, AiclllAicll bacteria were unable 
to grow on C2 substrates, but unexpectedly, they were also incapable of growth on 
propionate and other C3FAs. (3-oxidation of odd-chain fatty acids generates both 
acetyl-CoA (C2) and propionyl-CoA (C3); the latter can be metabolized via one of 
several possible oxidative pathways (Halarnkar & Blomquist, 1989). Biochemical 
and functional genetic evidence indicates that several bacteria including E. coli 
(Textor et ah, 1997), S. typhimurium (Horswill & Escalante-Semerena, 1997; 
1999) and C. glutamicum (Claes et ah, 2002), catabolize propionate via the 
methylcitrate cycle (MCC), whose role in C3 substrate catabolism was discovered 
in fungi three decades ago (Tabuchi & Uchiyama, 1975) (Chapter 3). 
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The M. tuberculosis genome has homologs of methylcitrate synthase 
(prpC) and methylcitrate dehydratase (prpD), while methylisocitrate lyase (MICL, 
prpB), which catalyzes the breakdown of methylisocitrate into pyruvate and 
succinate, is apparently missing. However, ICLs show limited homology to 
MICLs and can have weak MICL activity, i.e. use methylcitrate as a substrate 
(Luttik et ah, 2000), while MICLs show negligible activity on isocitrate (Brock et 
ah, 2001). These observations led us to consider the possibility that ICL1, ICL2, 
or both might substitute for MICL in the MCC of mycobacteria, thus explaining 
the inability of the Aiclllicll M. tuberculosis mutant to grow on C3 substrates 
(Chapter 6). Alternatively, the mutant's phenotype could be interpreted to mean 
that the GC is required for anaplerosis during growth on C3 substrates, as 
apparently is the case in E. coli (Textor et ah, 2003). 
To differentiate between these two possibilities, we first turned our 
attention to the fast-growing avirulent saprophyte M. smegmatis, which has genes 
putatively encoding both, an intact GC (/c/7, icll, glcB), and an intact MCC, 
including all three prp genes in an operon (prpDBC). Here, we report the 
generation and characterization of M. smegmatis Aicll, Aicll, and AiclllAicll 
mutant strains. In parallel studies, we have directly studied the contributions of 
the prp genes to M. smegmatis (A. Upton, personal communication) and M. 
tuberculosis C3 metabolism and pathogenesis (Chapter 6). 
RESULTS 
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9.1. Cloning and disruption of glyoxylate cycle genes in M. smegmatis 
By performing BLAST database searches of the unfinished genome sequence of 
M. smegmatis (tigr.org) with the amino acid sequences of M. tuberculosis ICL1, 
ICL2 and MLS, we identified contigs encompassing /c/7, icll and glcB putative 
open reading frames. The predicted /c/7 gene product encodes a 428 amino acid 
protein that is 95, 93, 93, 92 and 92 % identical to the predicted sequences of ICL1 
from M. marinum, M. avium, M. avium paratuberculosis, M. bovis, and M. 
tuberculosis, respectively; the predicted product of the icll gene encodes a 769 
amino acid product that is 80, 80, 78, 77, 77, and 77 % identical to ICL2 from M. 
avium, M. avium paratuberculosis, M. marinum, M. leprae, M. bovis, and M. 
tuberculosis, respectively. The amino acid identity between the M. smegmatis 
ICL1 and ICL2 isoenzymes is -27% (over the entire length of the protein), which 
is similar to that between all mycobacterial ICL1 and ICL2 protein sequences (not 
shown). 
9.2. Generation of Aicll, Aicll, AiclllAicll M. smegmatis mutants 
To assess the function of the id genes in M. smegmatis carbon metabolism, we 
constructed in-frame unmarked A/c/7, A/c/2, AiclllAicll deletion mutants. These 
were generated by allelic exchanged delivered via suicide plasmids as described 
(Pavelka & Jabcobs, 1999); see materials and methods for details. The A/c/7 
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mutant was generated and kindly provided by L. Merkov. All chromosomal 
disruptions were confirmed by S. blot analysis (not shown). 
9.3. Carbon utilization of Aicll, Aicll, AiclllAicll M. smegmatis mutants 
Disruption of either /c/7 or icll singly or jointly did not affect the ability of M. 
smegmatis to grow axenically in standard 7H9 broth, 7H10 plates (not shown) or 
minimal M9 liquid media supplemented with either glycerol (not shown) or 
glucose (Fig. 9.1A,D) as sole carbon source. As expected, AiclllAicll M. 
smegmatis bacteria did not grow on even-chain (C2) fatty acids (Fig. 9.1B-D). In 
contrast to the single A/c/2 mutant, which grew similarly to wild-type on all C2 
fatty acids tested, the single A/c/7 mutant did not (Fig. 9.1B&C). Previously, we 
had made a similar observation using a chemical putative /c/7 mutant (McKinney 
et ah, 2000) that has been confirmed to have a point mutation in /c/7 (A. Upton, 
personal communication). The finding that in M. smegmatis deletion of /c/7 alone 
abrogated growth on C2 substrates contrasts with our carbon utilization 
experiments in M. tuberculosis where deletion of /c/7 alone did not abrogate 
growth on C2 substrates (Chapter 6; Munoz-McKinney, 2005). 
One advantage of working with M. smegmatis as opposed to the more 
fastidious M. tuberculosis is that carbon utilization studies can be done under more 
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Fig. 9.1. Non-overlapping roles of ICL1 and ICL2 in M. smegmatis fatty acid metabolism. (A-
D ) Bacteria were cultured in minimal M 9 liquid media containing (0.1% w/v): (A) glucose; (B) 
acetate (C2FA); (C) butyrate (C4FA). (A-C) Growth was monitored by measuring culture turbidity 
(OD600 nm) at the indicated time points. (D) M. smegmatis wild-type (filled columns) or 
AiclllAicU mutant (empty columns) were grown in minimal M 9 liquid media supplemented with 
(0.1% w/v) Glu (glucose) or C2FA (acetate) for 60h and then plated for CFU. Results are 
representative of two experiments. 
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stringent conditions with minimal M 9 salts and single carbon substrates on solid 
media. Echoing our results in liquid media, all id mutants grew on glucose plates 
(Fig. 9.2). However, while wild-type and /c/2-deficient bacteria grew on all C2 
substrates tested, including acetate, butyrate, and palmitate, neither A/c/7 nor 
AiclllAicll mutant bacteria were capable of growth on C2 substrates (Fig. 9.2). 
9.4. Complementation of M. smegmatis id mutants with M. tuberculosis genes 
Both /c/7 and icll genes from M. smegmatis provided separately restored the 
ability of the AiclllAicll M. smegmatis mutant to grow on acetate (Fig. 9.3B&C) 
and other C2 substrates (not shown). Importantly, either /c/7 or icll from M. 
tuberculosis also restored the ability of the M. smegmatis AiclllAicll mutant to 
grow on C2 substrates (Fig. 9.3D&E). That the A/c/7/A/c/2 ::pICL2 strain grew on 
C2 substrates (Fig. 9.3B&E), while the A/c/7 single mutant did not (Fig. 9.1&9.2), 
might be due to higher ICL activity in the complemented strain resulting from the 
fact that the episomal plasmid used to complement it was medium-copy. 
9.5. Dispensability of ids for odd-chain fatty metabolism in M. smegmatis 
The observation that M. tuberculosis AiclllAicll mutant bacteria were unable to 
grow on propionate and that ICL activity was highly up-regulated in total protein 
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Fig. 9.2. Growth of ic/ mutants of M . smegmatis on minimal solid media. M. smegmatis wild-
type, Aicll, AicU or AiclllAicU strains were grown in 7H9 broth to late log phase, serially diluted in 
PBS and plated on minimal M 9 solid media supplemented with 0.1% (w/v) carbon substrates. N C : 
no carbon; Glu: glucose; Ace: acetate; But: butyrate; Pal: methyl-palmitate. Plates were incubated at 











Fig. 9.3. M. tuberculosis icll or icl2 genes restore ability to grow on acetate to ICL-deficient M. 
smegmatis. M. smegmatis AiclllAicU mutant was transformed with (A) empty vector; (B) icll (M. 
smegmatis); (C) icU (M. smegmatis); (D) icll (M. tuberculosis); (E) icU (M. tuberculosis). Bacteria 
were grown in 7H9 broth to late log phase and plated on minimal M 9 solid media supplemented with 
0.1% (w/v) acetate and incubated at 37 °C for 5 days. 
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extracts of M. tuberculosis grown on propionate compared to glucose (Table 6.1), 
suggested that ICLs might play a dual role in mycobacterial metabolism, perhaps 
functioning as methylisocitrate lyases (MICL) in the methyl citrate cycle (MCC), 
in addition to the GC. Alternatively, M. tuberculosis might require ICLs for 
growth on C3 substrates because the anaplerotic function of the GC might be 
needed under such growth conditions. 
Since M. smegmatis has at least one putative prpB gene encoding a 
dedicated MICL, AiclllAicll M. smegmatis mutants should only be impaired for 
growth on C3 substrates if the GC is required for C3 metabolism. Thus, we tested 
the ability of the different M. smegmatis id mutants to grow on C3 substrates as 
sole carbon sources. Wild-type M. smegmatis grew very efficiently on the C3 
fatty acid propionate. In sharp contrast to our findings with M. tuberculosis, id 
genes appeared completely dispensable for growth of M. smegmatis on C3 
substrates. Wild-type, A/c/7, A/c/2 and AiclllAicll M. smegmatis mutants grew 
indistinguishably from each other in glucose (Fig. 9.4A), propionate (Fig. 9.4B) or 
valerate (Fig. 9.4C) liquid media, or propionate plates (Fig. 9.4D). 
These observations suggest that if the MCC is required for C3 utilization by 
M. smegmatis, MICL encoded by prpB is probably sufficient for catalyzing this 
step of the pathway. They could also mean that the GC is not required for C3 
metabolism in mycobacteria, and that replenishment of TCA cycle intermediates 
during growth on C3 substrates likely takes place via conversion of pyruvate, the 
product of the MCC, to oxaloacetate by pyruvate carboxylase (PCA). This 
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Fig. 9.4. id genes are dispensable for odd-chain fatty acid metabolism in M. smegmatis. (A-C) 
Bacteria were cultured in minimal M 9 liquid media containing (0.1% w/v): (A) glucose; (B) 
propionate (C3FA); (C) valerate (C5FA). Growth was monitored by measuring culture turbidity 
(OD600nm) at the indicated time points. (D). M. smegmatis wild-type, Aicll, AicU or AiclllAicU 
strains were grown in 7H9 broth to late log phase and plated on minimal M 9 solid media 
supplemented with (0.1% w/v) propionate (C3FA). Plates were incubated at 37 °C for 5 days. 
Results are representative of three experiments. 
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suggestion is further supported by the finding that a mutant of glcB, encoding 
malate synthase (second step of the GC), grew indistinguishably from M. 
smegmatis wild-type on C3 substrates (L. Merkov, personal communication). 
9.6. ICL activity during growth on C2/C3 substrates 
In M. tuberculosis, id and icll axe separately dispensable but jointly required for 
growth on C2 substrates (Chapter 6). Interestingly, while M. tuberculosis extracts 
from A/c/2 mutant bacteria had ICL activity levels that were comparable or higher 
than those from wild-type, those from A/c/7 bacteria had only very low basal 
levels of activity (Table 6.1). To study the regulation of ICLs in M. smegmatis, 
we grew the different id mutants on different C2 and C3 substrates to late-log 
phase and prepared cell-free extracts for analysis of ICL activity. Extracts from 
wild-type M. smegmatis grown on glucose had considerable levels of ICL activity, 
which increased about 5 fold when the bacteria were grown in glucose plus acetate 
(Table 9.1). Extracts from dextrose-grown A/c/7 mutant had about 14% of the 
activity of extracts from glucose-grown wild-type cells. However, extracts from 
glucose/acetate-grown A/c/7 mutant had almost no activity. Interestingly, and 
reminiscent of our observations in M. tuberculosis, all extracts prepared from the 
A/c/2 mutant had ICL levels that were higher (-2X) than those of wild-type. No 
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Bacteria were grown in minimal M 9 broth at 37 °C with shaking (100 rpm), and 
harvested at late log phase. Carbon substrates (0.1 % w/v, each): Glu = glucose; 
Ace = acetate; Pro = propionate; But = butyrate. Data represent the average of 2 
independent cultures from which 3 measurements were made. Total protein: 
isocitrate stimulated specific activity (nmol/min/mg) using 1 m M isocitrate, 0.1 
m M N A D H at 25 °C (Data were kindly provided by A. Upton). 
ICL activity was detected in extracts from AiclllAicll bacteria grown on glucose 
or glucose plus acetate. Extracts of acetate-, propionate-, or butyrate-grown wild-
type M. smegmatis bacteria had 2-3 fold higher levels of ICL activity than extracts 
from glucose-grown bacteria (Table 9.1). 
9.7. A role for the glyoxylate cycle in carbon utilization in mixed substrates 
Under standard conditions, E. coli requires the GC only when C2 substrates are 
the sole carbon source (Komberg, 1966; Cronan & LaPorte, 1996). However, our 
finding that extracts from M. smegmatis grown on a mixture of glucose and acetate 
had considerably higher ICL activity than extracts from glucose-grown bacteria, 
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and similar observations made in M. avium (Honer zu Bentrup et ah, 1999), 
suggest mycobacteria might employ the GC in mixed substrates. Indeed, we 
found that M. smegmatis AiclllAicll had a significant lag during growth on 1:1 
mixtures of acetate and glucose (not shown). We sought to extent these 
observations to M. tuberculosis by assessing the ability of /c/-deficient M. 
tuberculosis to grow on mixed carbon substrates. While wild-type M. tuberculosis 
grew on C2 substrates alone, glucose alone, or mixtures of the two, unexpectedly, 
the AiclllAicll mutant was unable to grow on glucose plus any C2/C3 substrate 
tested including acetate (Fig. 9.5A), propionate (Fig. 9.5B), C12FA (Fig. 9.5C), 
and C16FA (Fig. 9.5D). These experiments suggest in order to grow on mixed 
substrates M. tuberculosis requires ICL. Thus, the GC requirement by M. 
tuberculosis during infection might not indicate absolute inaccessibility to 
carbohydrates. 
9.8. Inhibition of M. tuberculosis ICL1 or ICL2 in whole cell assays 
The absence of ICL orthologs in mammals should facilitate the eventual 
development of GC inhibitors as drugs for the treatment of TB. Using the ICL 
inhibitor 3-nitropropionate (3-NP) (Schloss and Cleland, 1982; Honer zu Bentrup 
et ah, 1999; Sharma et ah, 2000), we provided evidence suggesting the feasibility 
of blocking ICL1 and ICL2 in M. tuberculosis, and that such inhibition prevented 
bacterial growth on fatty acids and in macrophages (Chapter 6). Screening for 
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C3FA + Glucose 
Fig. 9.5. M . tuberculosis relies on glyoxylate cycle ICL for growth on fatty acid/carbohydrates 
mixed substrates. Bacteria were cultured at in liquid media containing (0.1% w/v each): (A) 
acetate (C2FA) + glucose; (B) propionate (C3FA) + glucose; (C) polyoxyethylene sorbitan mono-
laurate + glucose; (D) polyoxyethylene sorbitan mono-palmitate + glucose. Growth was monitored 
by measuring culture turbidity (OD600nm) at the indicated time points. Results are representative of 
two experiments. 
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ICL inhibitors would be greatly facilitated if initial testing could be done in M. 
smegmatis. Here, we show that AiclllAicll M. smegmatis mutant strains carrying 
the heterologous /c/7 or icll M. tuberculosis paralogs can be used for such 
purpose. Addition of 3-NP to C2FA, but not to glucose minimal liquid media, 
prevented the growth of wild-type M. smegmatis, as well as that of AiclllAicll M. 
smegmatis carrying either /c/7 or icll genes from M. tuberculosis (Fig. 9.6). 
Similarly, addition of 3-NP to M9 plates abrogated bacterial growth on C2FA but 
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Fig. 9.6. Whole cell screening assay for dual inhibitors of M. tuberculosis ICL1 and ICL2 
isoenzymes. (A-D) ICL inhibitor 3-nitropropionate (3-NP) (empty symbols) inhibits growth of M. 
smegmatis (A) wild-type, (B) Aicll A£c/2.vpICLl (M. tuberculosis), C) Aicll/AicU::plCL2 (M. 
tuberculosis) on acetate (circles) but not on glucose (squares), (D) M. smegmatis AiclllAicU mutant. 
Bacteria were cultured in minimal M 9 broth supplemented with (0.1% w/v) glucose (Glu) (filled 
squares), glucose plus 3-NP (empty squares), C2FA (acetate) (filled circles) or C2FA (acetate) plus 
3-NP (empty circles). Growth was monitored by measuring OD600 nm at the indicated time points 
(E-J) Plate assay. Growth inhibition of M. smegmatis (E&H) wild-type, (F&I) Aicll /Aicl2::pICLl 
(M. tuberculosis) (G&J) Aicll /Aicl2::pICL2 (M. tuberculosis) by 3-NP on (0.1% w/v) (E-G) acetate 
but not on (H-J) dextrose, as carbon source in minimal M 9 plates. 3-NP was included in the 
medium at 5 m M . Results are representative of three experiments. 
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C H A P T E R 10 
T h e Methyl Citrate Cycle in M . tuberculosis 
INTRODUCTION 
In the foregoing chapter (Chapter 9), we presented evidence that ICL1 and ICL2 
are dispensable for growth of M. smegmatis on C3 substrates, ruling out an 
essential role for ICLs in the methylcitrate cycle (MCC) in this species (Fig. 
10.1). Since M. smegmatis has a prpB homolog that putatively encodes a 
canonical methylisocitrate lyase (MICL), these findings are not surprising. 
Furthermore, since glcB, encoding malate synthase, is also dispensable for growth 
on C3 substrates (L. Merkov, personal communication), the GC is apparently not 
required for M. smegmatis growth under these conditions either. In contrast, M. 
tuberculosis id genes are jointly required for both C2FA and C3FA metabolism 
(Chapter 6). The M. tuberculosis genome has homologs of methylcitrate synthase 
(prpC) and methylcitrate dehydratase (prpD), while methylisocitrate lyase (MICL, 
prpB), which catalyzes the breakdown of methylisocitrate into pyruvate and 
succinate, is apparently missing. However, ICLs show limited homology to 
MICLs and can have weak MICL activity, i.e. use methylisocitrate as a substrate 
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Fig. 10.1. Methyl citrate cycle ( M C C ) in M. tuberculosis. Even- and odd-chain fatty acids are 
degraded to acetyl-CoA (C2) and propionyl-CoA (C3), respectively, via the beta-oxidation pathway. 
Propionyl-CoA can be metabolized through the methylcitrate cycle. The glyoxylate cycle permits the 
net synthesis of C 4 intermediates, which can serve directly as biosynthetic precursors or can be 
further metabolized to C3 precursors. Glyoxylate cycle specific enzymes: isocitrate lyase 1 (ICL1), 
isocitrate lyase 2 (ICL2) and malate synthase (MLS). ICL1 and ICL2 could function as 
methylisocitrate lyases in the methylcitrate cycle together with the methylcitrate cycle-specific 
enzymes 2-methylcitrate synthase (GLTA1) and 2-methylcitrate dehydratase (MCD). Glyoxylate 
cycle enzymes in common with the T C A cycle: Citrate synthase I (GLTA2); citrate synthase II 
(CITA), aconitase (ACN), succinate dehydrogenase (SDH), fumarate (FUM), malate dehydrogenase 
( M D H ) and malate:quinone oxidoreductase ( M Q O ) . Phosphoenol pyruvate (PEP) can be produced 
by decarboxylation of oxaloacetate by PEP carboxykinase (PCK). Pyruvate can be generated from 
malate by malic enzyme (MEZ), from PEP by pyruvate kinase (PYK), or through the M C C by the 
action of ICL1/ICL2 on 2-methylisocitrate producing succinate and pyruvate. Gene names are in 
italics. 
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ah, 2001). These observations led us to consider the possibility that ICL1, ICL2, 
or both might substitute for MICL in the MCC of mycobacteria, thus explaining 
the inability of the Aiclllicll M. tuberculosis mutant to grow on C3 substrates 
(Chapter 6). Alternatively, the mutant's phenotype could be interpreted to mean 
that the GC is required for anaplerosis during growth on C3 substrates, as 
apparently is the case in E. coli and Ralstonia (Textor et ah, 1997; Wang et ah, 
2003a). 
Here we present evidence indicating that ICLs are induced during growth 
on propionate and are bifunctional enzymes that can use both isocitrate (ICA) and 
methylisocitrate MICA) as substrates. The ability of ICL1 to function as a MICL 
was superior to that of ICL2, since even overexpression of ICL2 resulted in only 
low levels of MICL activity. Furthermore, ICLs appeared to function together 
with methylcitrate synthase and methylcitrate dehydratase encoded by prpC and 
prpD M. tuberculosis genes, respectively, to form a functional MCC, which we is 
required by M. tuberculosis to grow on odd chain fatty acids in vitro. A 
requirement for the MCC by M. tuberculosis during infection was suggested by 
the inability of a AprpDC mutant to grow in murine macrophages, but was not 
supported by in vivo evidence indicating the dispensability of these genes for 
growth and persistence in mice. The work presented in this chapter is the result of 
collaborative work with A. Upton in the laboratory. 
RESULTS 
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10.1. id genes of M. tuberculosis encode isocitrate/methylisocitrate lyases 
To test the hypothesis that one or both of the id genes in M. tuberculosis encoded 
a bifunctional ICL/MICL, we cultured M. tuberculosis (Erdman) wild-type and 
AiclllAicll bacteria in defined media containing glucose or propionate and 
measured ICL and MICL activity in cell-free extracts. MICA was not available 
commercially and was chemically synthesized starting with mesaconic acid by 
modifying previously published methods (Brock et ah, 2001; Plaut et ah, 1975); 
this was done in collaboration with J. Cherian and T. Kapoor at Rockefeller 
University (see materials & methods). 
Extracts prepared from wild-type M. tuberculosis demonstrated ICL and 
MICL activity, both of which where much higher in extracts from bacterial 
cultures grown on propionate (Fig. 10.2A) compared to glucose (not shown). 
Extracts from wild-type bacteria grown on propionate had very high activity on 
ICA and high, though significantly lower (3 fold), activity on MICA (Fig. 10.2A). 
The AiclllAicll mutant grown on glucose had no detectable activity (not shown). 
The finding that propionate extracts prepared from the A/c/7 mutant (which, 
though impaired, grew sufficiently to allow preparation of cell-free extracts) had 
very low levels of activity (Fig. 10.2A&B), while propionate extracts from the 


















Fig. 10.2. I C L and M I C L activities of propionate-grown M . tuberculosis cell-free extracts. (A-
E ) M . tuberculosis (Erdman) bacteria were grown at 37 °C with shaking to late log phase in liquid 
media containing (0.2% w/v) propionate (C3FA). Cell-free extracts were assayed for activity on 
isocitrate (ICA) or methylisocitrate ( M I C A ) as indicated. (A) Wild-type, (B) Aicll, (C) Aicl2, (D) 
Aicll/AicU transformed with an episomal plasmid carrying icll, (E) Aicll/AicU transformed with an 
episomal plasmid carrying icU. Assays were done in triplicates from two set of extracts. Date are 
from one experiment. 
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wild-type (Fig. 10.2A&C) suggested that ICL2 was not as efficient as ICL1 as a 
MICL. In addition, propionate extracts of a strain overexpressing /c/7 from an 
episomal multicopy plasmid on an AicllAicll background had markedly higher 
levels of expression of both ICL (-6.5 fold) and MICL activity (~9 fold) compared 
to wild-type (Fig. 10.2A&D), while overexpression of icll in the same background 
resulted in a large increase in ICL actitvity (10 fold higher than in extracts of the 
A/c/7 mutant) (Fig. 10.2D), but a minimal increase in MICL activity (Fig. 10.2E). 
These data indicate that at least in vitro, ICL1 is a bifunctional ICL/MICL 
enzyme, and suggest that it might function in the MCC cycle of M. tuberculosis in 
that capacity. The ability of ICL2 to function as a MICL is more limited. 
10.2. Cloning and disruption of the putatitve methylcitrate cycle genes in M. 
tuberculosis 
The inability of the AiclllAicll M. tuberculosis mutant to use propionate as 
substrate and the lack of MICL and ICL activities in extracts from this strain 
(grown on glucose), together with the induction of ICL and MICL activities during 
growth on propionate, suggested that M. tuberculosis might require the MCC and 
the MICL function encoded by /c/7 and/or icU genes for propionate metabolism. 
However, the possibility remained that in M. tuberculosis, unlike in M. smegmatis, 
the GC was required for anaplerosis during propionate metabolism either via the 
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M C C or another pathway, and the inability of the AiclllAicll mutant to grow on 
propionate was due to anaplerotic deficiency rather than impairment of propionate 
metabolism per se. To distinguish between these scenarios, we constructed a 
strain of M. tuberculosis (Erdman) in which the genes unique to the MCC, prpD 
and prpC, were deleted. Homologs of prpD and prpC are found together in the M. 
tuberculosis genome such that the final codon of prpD overlaps the first of prpC. 
Although annotated as a 526 amino acid protein in the genome (H37Rv), ORF 
analysis of the prpDC region revealed 3 possible start sites for prpD that would 
give rise to proteins of 526, 505 or 502 amino acids in length. The 3 possible 
peptides, conceptually translated, were aligned using BLASTP to all PRPD 
peptide sequences available in NCBI databases, and the most probable was chosen 
based on similarity to enzymes reported to be functional (Horswill & Escalante-
Semerena, 1999). This ORF, which encoded the shortest PRPD peptide (502AA), 
was defined as the prpD gene sequence for the present study. 
M. tuberculosis with an in-frame unmarked deletion in the prpD and prpC 
ORFs was generated by homologous recombination such that the wild-type prpDC 
locus was replaced with sequence encoding a 9AA peptide. The deletion was 
confirmed by PCR analysis and Southern blot (not shown). For complementation 
studies of the AprpDC mutant, the strain was transformed with an integrating 
plasmid derived from pMV361 (Stover et ah, 1991) carrying a wild-type copy of 
the putative prpDC operon. 
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10.3. The methylcitrate cycle is required for propionate metabolism and 
growth of M. tuberculosis on odd-chain fatty acids 
Deleting prpDC had no effect on bacterial growth on glucose or glycerol (Fig. 
10.3A&B). Unlike the parental strain, the AprpDC mutant was unable to grow 
with propionate or any other odd-chain fatty acid given as substrate (Fig. 10.3). 
Unlike the AiclllAicll mutant (Chapter 6), the AprpDC mutant exhibited growth 
on even chain fatty acids that was comparable to that of the parental strain (Fig. 
10.3). Complementation of the AprpDC mutant with an integrating plasmid 
carrying the wild-type putative prpDC operon largely restored growth on 
propionate media. Thus, the prpDC genes and hence the MCC are required 
specifically for in vitro growth on odd-chain fatty acids by M. tuberculosis. The 
ability of this mutant to grow using C2 carbon sources indicates that the MCC is 
not required for growth on C2 substrates as expected. Together these results 
suggest that ICL1 and perhaps ICL2 might function as MICL in the MCC. 
10.4. The methylcitrate cycle is required for survival and replication of M. 
tuberculosis in resting and activated murine macrophages 
We next investigated whether the requirement by M. tuberculosis for the MCC 
could be seen at the level of the parasitized macrophage. In marked contrast to M. 
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Fig. 10.3. Indispensable role of prpC and prpD in C3 fatty acid metabolism. (A-G) M. 
tuberculosis bacteria were cultured at 37 °C in liquid media containing (0.1% w/v): (A) glycerol; (B) 
glucose; (C) acetate (C2FA); (D) propionate (C3FA); (E) butyrate (C4FA); (F) valerate (C5FA); 
(G) hexanoate (C6FA). Growth was monitored by measuring culture turbidity (OD60 nm) at the 
indicated time points. Results are representative of two experiments with similar results. 
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tuberculosis wild-type bacteria which grew nearly one log over the 7 day time 
course of an infection of bone marrow-derived murine macrophages, AprpDC 
mutant bacteria were incapable of any growth (Fig. 10.4A). To determine the 
impact of host cell activation on the survival of MCC-deficient bacteria, 
macrophages were activated with IFN-y (100 U mL") prior and during intracellular 
infection. While macrophage activation was bacteriostatic to intracellular wild-
type M. tuberculosis, it was slightly bactericidal to AprpDC bacteria (Fig. 10.4B). 
Complementation of the AprpDC mutant strain with a copy of wild-type prpDC 
genes restored growth in resting macrophages and wild-type levels of survival in 
activated macrophages (Fig. 10.4C&D). 
10.5. The methylcitrate cycle is dispensable for growth and persistence of M. 
tuberculosis in the mouse model of chronic tuberculosis. 
Since our data suggested that ICL1 and to a lesser extent ICL2 could function as a 
MICL, we considered the possibility that the in vivo phenotype of the iclllicll or 
single A/c/7 mutants could be due to their function as a MICL instead of or in 
addition to their role as ICLs. To directly address this question and the 
contribution of the MCC to the pathogenesis of M. tuberculosis in vivo, we 
evaluated the ability of the AprpDC mutant to grow and persist in mice. Unlike 
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Fig. 10.4. Methylcitrate cycle genes prpC and prpD are required for intracellular replication of 
M. tuberculosis. (A-D) Murine bone marrow-derived macrophages (A&C) non-activated or (B&D) 
rFN-y-activated (100 U/mL) were infected with (A-D) wild-type, AprpD/AprpC, or (C&D) 
AprpD/AprpC::PprpDC+ M. tuberculosis (Erdman), (MOI 2:1). Monolayers were incubated at 37 °C 
in 5% C02. At indicated time points, cells were lysed (n = 4 wells) and lysates were plated to 
enumerate CFU. Symbols represent means; error bars indicate STDEV. This experiment was done 
twice. 
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AiclllAicll mutant bacteria which are impaired for growth from the onset of the 
infection, or A/c/7 mutant bacteria, which become impaired at around 2-3 wks 
post-infection, AprpDC mutant bacteria replicated and persisted indistinguishably 
from wild-type bacteria throughout the infection in both lungs (Fig. 10.5A) and 
spleens (Fig. 10.5B), and elicited comparable pathology (Fig. 10.6). Thus, the 
requirement for ICL during infection appears to be due to a requirement for a 
functional GC rather than a MCC. 
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Fig. 10.5. prpC and prpD are dispensable for growth and persistence of M. tuberculosis in 
mice. (A&B) Wild-type (C57BL/6) mice were infected with wild-type or AprpDC M. tuberculosis 
(Erdman) (-100 CFU, aerosol). Bacteria in the (A) lung and (B) spleen were enumerated by 
plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each 
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Fig. 10.6. Lung pathology in mice infected with AprpDC M. tuberculosis. (A-F) Histopathology 
of H & E (haematoxylin-eosin)-stained lungs from C57BL/6 mice infected with M. tuberculosis 
(Erdman) (-100 CFU, respiratory route) at 10 weeks post-infection. Bacterial strains: (A-C) wild-
type, (D-F) AprpDC. Corresponding CFUshown in Fig. 10.5. 
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P A R T III 
CHAPTER 11 
Discussion 
I N T R O D U C T I O N 
Some of the most devastating diseases known to man, including syphilis, 
gonorrhea, typhoid fever, and tuberculosis (TB) are caused by bacteria capable of 
persisting in their hosts often for life. To our detriment, we know little about the 
interactions between hosts and pathogens that allow the establishment of such 
persistent infections (Munoz-Elias & McKinney, 2002; Stewart et ah, 2003; 
Monack et ah, 2004). Regardless of whether a persistent infection is clinically 
active or latent, the establishment of such infection means that the pathogen will 
most likely succeed in being transmitted to a new host, even if it must wait, 
sometimes, for a lifetime. Investigation into the nature of bacteria during 
infection, including the bacterial characteristic in vivo physiology and elicited host 
immune responses, and the way pathogens evade and counteract these defenses 
successfully, might provide a foundation on which to base efforts toward 
developing new drugs and vaccines against these foes. 
Persistence of M. tuberculosis in the host is the result of the pathogen's 
interaction with a partially effective immune response, i.e., one that controls 
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bacterial growth but fails to eradicate the infection (Flynn & Chan, 2001; Nathan 
& Ehrt, 2003; North & Jung, 2004). In order to persist, M. tuberculosis must 
adapt to environmental conditions that are complex, and at least in the case of 
chronic active disease, constantly changing as a result of lesion-specific varying 
degrees of ongoing inflammation, cellular infiltration, tissue destruction, and 
further bacterial replication and dissemination (Vandiviere et ah, 1956; Wayne & 
Salkin, 1956; Kaplan et ah, 2003). The bacterial factors involved in survival in 
vivo have begun to be identified through a combination of reverse genetics 
(Glickman & Jacobs, 2001; Gomez & McKinney, 2004; Boshoff & Barry, 2005) 
and differential gene expression in macrophages of murine and human origin 
(Dubnau & Smith., 2003; Schnappinger et ah, 2003; Voskuil et ah, 2003). 
Bacterial gene expression studies of mouse lung-grown bacteria suggest 
that the adaptation of M. tuberculosis to the in vivo environment involves the 
differential expression of genes responsive to iron limitation, specific carbon 
metabolism, and cellular hypoxia (Shi et ah, 2003; Timm et ah, 2003); limited 
studies with infected human samples suggest that some of these adaptations might 
also occur in the human lung (Timm et ah, 2003). 
Despite having preoccupied the mind of early investigators of tuberculosis 
during the first half of the 20th century, two major aspects of the in vivo biology of 
M. tuberculosis are still poorly understood: 1) the replicational status of M. 
tuberculosis during active, and latent infection, and 2) the metabolic activity of M. 
tuberculosis during growth and survival in the host. The work I have carried out 
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over the last few years, and which I have presented in this thesis, was performed 
with the intention of shedding some light on these two major issues. 
11.1. The replication status of M. tuberculosis in experimentally infected mice 
Bacteriologic and pathologic studies of tuberculous human and animal lesions 
indicate that M. tuberculosis in the lung resides in different types of lesions, which 
differ from each other in terms of cellular organization, degree of inflammation 
and necrosis, as well as apparent bacterial burden (Lurie & Zappasodi, 1942; 
Medlar, 1948; Medlar et ah, 1952; Dannenberg & Rook, 1994a; Kaplan et ah, 
2003). The replicational status of the M. tuberculosis in such lesions has not been 
determined, but it is thought to vary between active replication and stasis. 
Replication is believed to occur on the surface of open cavities and to take place 
intracellularly within macrophages there (Kaplan et ah, 2003), and within the 
softened center of liquefied cavities, where bacteria might multiply extracellularly 
(Lurie, 1964; Dannenberg & Rook, 1994a; Grossett, 2003). In Chapter 5, we 
presented data from experiments performed to explore this question in the mouse 
model of chronic TB. It has been established that immediately after M. 
tuberculosis enters the host, robust bacterial multiplication is necessary to ensure 
the establishment of the infection and the steady plateau of viable bacteria that 
characterizes the persistent phase of the infection in lungs of mice (Orme, 1994). 
However, little is known about growth rates during this phase of the infection. As 
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first suggested by Severs and Youmans (1956), fluctuations in bacterial viable 
populations can be readily measured, but these presumably represent the net result 
of multiplication and destruction by host defenses. In a pioneering work, Rees and 
Hart (1961) addressed this question by tallying total bacterial counts determined 
by staining bacterial bodies and comparing these to viable counts (CFU). Based 
on the finding that total and viable bacterial counts overlapped throughout the 
persistent phase of infection in mice, they concluded that persistent bacteria were 
not actively replicating, and favored a model of "static" equilibrium. However, in 
those experiments, the lack of accumulation of bacterial bodies that was observed 
may have been due to loss of acid-fast staining of dead bacterial bodies, a 
phenomenon that has been reported by other investigators (McCune et ah, 1956; 
Middlebrook, 1952). Thus, we revisited this question. 
Viable counts (CFU) obtained from mouse lungs at intervals during the 
chronic phase of a mouse infection were compared with total counts determined 
by quantitative real time PCR. Amplification of chromosome equivalents (CEQ) 
was performed directly from infected lungs by adapting a recently developed real 
time PCR technique used for the precise molecular quantification of mRNA 
(Manganelli et ah, 1999; Timm et ah, 2003). Remarkably, we found that at all 
points analyzed (4, 8, 12 and 16 weeks post-infection) CFU and CEQ curves 
closely matched each other. If constant bacterial turnover during persistence 
occurred, we would have detected the resulting accumulation of bacterial genomes 
(CEQ), assuming that the genomes were not removed/degraded soon after the 
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bacteria were killed. Since we did not observe significant build-up of dead bacilli 
in any of the chronically infected mouse lungs analyzed, we conclude that most 
bacilli in the persistent phase of infection are likely undergoing Utile or no 
replication. 
The assumption that genomes of killed bacteria are relatively stable was 
based on control experiments where genomes from dead bacteria were shown to 
linger in infected lungs (Fig. 5.3). INH therapy started at the onset of the 
persistence phase (4 weeks post-infection) relatively rapidly reduced viable 
bacterial counts (CFU) by ~2 and 4 login by 4 and 8 weeks of treatment, 
respectively. In contrast, CEQ did not diminish after 4 weeks of treatment 
compared to those in lungs of concomitantly infected but untreated mice, and did 
so only slightly after 8 weeks of treatment (Fig. 5.3). The waxy coat of the 
tubercle bacillus, made up of unique glycol-lipids (Brennan, 2003), likely 
contributes to the permanence of bacterial bodies and their DNA content (de Wit 
etal., 1995; Rees and Hart, 1961; Seiler et ah, 2003). 
It is possible that killing of bacilli by immune mechanisms as opposed to 
drugs as done here, may lead to genome degradation. However, this possibility 
could not be tested using the mouse model of chronic TB because the immune 
response against M. tuberculosis infection is not bactericidal, but bacteriostatic. 
Also, our results also do not rule out the possibility that the stable number of 
viable counts in the lungs of chronically infected mice is due to replication in situ 
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balanced by trafficking of organisms out of the lungs, resulting in failure of both 
CFU and CEQ to accumulate over time. 
A key question in the context of any persistent infection is the replication 
status of the pathogen over time. Dynamic pathogens such as the human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV) replicate at very high 
rates throughout the course of infection. In persistently HIV- and HCV-infected 
individuals a dynamic equilibrium is achieved in which a relatively stable viral 
load is maintained by balanced production and immune-mediated destruction of 
virions (Pawlotsky, 2004; Simon & Ho, 2003). Viral persistence is also facilitated 
by antigenic variation, involving sequential emergence of variants that temporarily 
escape surveillance by the adaptive immune response. Antigenic variation is an 
essential persistence strategy of many slower-replicating pathogens as well, 
including parasites and bacteria; well-characterized examples include African 
trypanosomes, Plasmodium falciparum and Borrelia spp. These pathogens 
display oscillating population kinetics in vivo, representing sequential waves of 
antigenic variants that (temporarily) escape destruction by the adaptive immune 
response (Deitsch et ah, 1997; Reviewed in Chapter 1). 
Although antigenic variation is a common feature of many persistent 
pathogens, there is little evidence to support a role for antigenic variation in M. 
tuberculosis persistence in chronically infected individuals (Cole, 2002). We 
propose that M. tuberculosis represents a third persistence strategy, where 
exponential replication of the organism during the acute phase of infection is 
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followed by a relatively static equilibrium, a state of slow- or nonreplicating 
persistence, during the chronic phase. The hypothesis that persistent mycobacteria 
are in a slow- or non-replicating state is consistent with several observations: (i) 
the induction of a gene expression program that is characteristic of non-replicating 
bacilli during the chronic phase of murine infection (Shi et ah, 2003); (ii) the 
relatively poor efficacy of drugs that target cell wall synthesis (such as INH) when 
administered to chronically infected mice as compared to acutely infected mice 
(McCune et ah, 1956); (iii) the increased thermal stress resistance of M. 
tuberculosis (characteristic of stationary-phase cells) in chronically infected mice 
as compared to acutely infected mice (Wallace, 1961); (iv) the lack of 
accumulation of microscopically visible AFB in chronically infected mice (Rees 
and Hart, 1961); (v) the lack of accumulation of bacterial chromosomes in 
chronically infected mice we described here (Mufioz-Elias et ah, 2005). Kanai 
(1966) provided direct proof of the ability of non-replicating M. tuberculosis to 
survive for extended periods in vivo by showing that continued administration of 
streptomycin was not necessary for persistence of a streptomycin-growth 
dependent strain of M. tuberculosis in chronically infected mice. 
The ability of M. tuberculosis to persist without replicating does not imply 
that bacterial replication is entirely absent in chronically infected individuals or 
animals, nor does it imply that persistent bacteria are metabolically inactive. 
Indeed, slow fluctuations in the bacterial load over time, which are typically 
observed in chronically infected mice, presumably reflect slow or intermittent 
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replication of at least some bacilli (Sever & Youmans, 1957), and the dramatic 
increase in bacterial load in late-stage infected mice (Orme, 1988) can only be 
explained in terms of bacterial replication. Evidence from the M. marinum-
leopard frog model also supports the idea that chronic mycobacterial infections 
involve some ongoing bacterial cell division (Bouley et ah, 2001). What seems 
increasingly likely, however, is that M. tuberculosis persistence in chronically 
infected mice does not represent a highly dynamic equilibrium in which rapid 
bacterial growth is balanced by equally rapid immune-mediated killing, but rather 
a relatively static equilibrium in which the rate of bacterial cell division is very 
slow. It is unknown to what extent this conclusion can be extrapolated to humans 
with chronic TB or latent TB infection. Studies on TB lesions in humans suggest 
that the replicative state of the bacteria vary depending on the histopathological 
characteristics of the individual lesions (Kaplan et ah, 2003; Medlar et ah, 1952; 
Vandiviere etah, 1956; Wayne & Salkin, 1956). 
The replicative status of bacilli during persistent infection has important 
implications for the development of more effective interventions against persistent 
M. tuberculosis infections. Treatment of TB is notoriously difficult and 
protracted, requiring a minimum of 6-9 months of multi-drug therapy to prevent 
post-therapy relapse (El-Sadr et ah, 2001). Most of the drugs currently used to 
treat TB are known to target cellular processes involved in cell growth, such as 
cell wall biogenesis and DNA replication; consequently, these drugs are less 
effective against bacteria that are not undergoing rapid cell division (McKinney, 
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2000; Stewart et ah, 2003; Mitchison, 2004; Boshoff and Barry, 2005). 
Elucidation of the mechanisms required for persistence of M. tuberculosis in a 
slow- or non-replicating state in chronically infected individuals with active 
tuberculosis or latent infection might suggest new strategies for targeting 
persistent bacteria. 
11.2. The Glyoxylate Cycle and the Pathogenesis of M. tuberculosis 
All pathogens must acquire nutrients from their hosts in order to replicate and 
survive long enough to ensure their transmission to a new host. Most facultative 
intracellular bacteria grow in specialized phagosome-derived vacuoles (Sinai & 
Joiner, 1997); only a few species can escape the phagosomal compartment and 
grow freely in the cytoplasm. It is not clear whether facultative vacuolar 
pathogens do not grow in the cytosol simply because they lack the machinery to 
break free from their vacuoles. Some evidence suggests that even if they reached 
the cytosol, these pathogens would not be able to grow in it readily, suggesting 
that the cytosol is not a very permissive compartment for growth and that special 
adaptations are required to occupy this niche. By microinjecting several bacterial 
species into the cytosol of host cells, Goetz and colleagues (2001) found that 
pathogens that normally reside in a vacuole, e.g., Salmonella, could not freely 
replicate in the cytosol, while those that infect the cytosol as part of their normal 
life cycles such as Shigella or Listeria could. M. marinum, a mycobacterial 
255 
pathogen of fish, apparently can escape the phagosome and move around in the 
cytosol, however, it is unclear whether it can replicate in this compartment 
(Stamm et ah, 2003). 
The high level of specialization required by a pathogen to successfully 
inhabit a given niche likely involves mechanisms that allow it to acquire and 
metabolize the nutrients available in that environment. With few exceptions, the 
substrates pathogens utilize during infection and the mechanisms involved in their 
acquisition and assimilation are unknown (Reviewed in Chapter 4). 
Carbohydrates comprise the principal carbon source for bacteria occupying 
such diverse niches as the intestinal lumen (Peekhaus & Conway, 1998; Chang et 
ah, 2004), the cytoplasm of infected host cells (Chico-Calero et ah, 2002), and 
perhaps the modified vacuoles within macrophages (Eriksson et ah, 2003). In 
contrast, pathogenic mycobacteria isolated from lung tissues preferred to oxidize 
fatty acids rather than carbohydrates (Segal & Bloch, 1956). Of the activities 
required for fatty acid catabolism, GC enzymes ICL and MLS were demonstrated 
in extracts of both slow and fast growing mycobacteria including M. tuberculosis 
and M. leprae (Murthy et ah, 1973; Kannan et ah, 1985; Bharadwaj et al, 1987; 
Wheeler & Ratledge, 1988). That these activities were found in in vivo grown 
bacteria, as well as upregulated specifically in stationary phase "old" cultures, led 
some of these early investigators to suggest that GC-mediated metabolism might 
be the basis of alternate types of metabolism employed by M. tuberculosis to 
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persist in the host and to avoid eradication by drugs (Murthy et al, 1973; Kannan 
et al, 1985; Bharadwaj et al, 1987; Gupta & Katoch, 1997). 
More recently, mycobacterial genes and enzymes involved in fatty acid 
utilization including the GC and fatty acid P-oxidation have been shown to be up-
regulated during infection of mice (Timm et al, 2003; Dubnau et ah, 2005), and 
macrophages of mouse and human origin (Graham & Clark-Curtiss, 1999; Dubnau 
& Smith, 2003; Schnappinger et ah, 2003). A central role for fatty acid 
metabolism is also suggested by the extensive duplication of genes involved in 
lipid breakdown and assimilation in M. tuberculosis, M. bovis and M. leprae (Cole 
1998; Cole et ah, 2001; Fleischmann et ah, 2002; Gamier et ah, 2003). Induction 
of multiple genes encoding analogous functions in P-oxidation (multiple fadDs, 
fadBs and fadAs) suggests that these might be involved in the degradation of 
different types of C2 substrates, as it occurs in mammalian cells (Kunau et ah, 
1995). 
The M. tuberculosis genome encodes only two homologous genes encoding 
isocitrate lyases which catalyze the first step in the GC required for anaplerosis 
during growth on fatty acid substrates. Previously, we reported that /c/7 is 
dispensable for acute-phase growth but essential for persistence at wild-type levels 
during the chronic phase of infection in M. tuberculosis-infected mice, and 
proposed that M. tuberculosis might switch to fatty acid catabolism at the 
transition from the acute to the chronic phase of infection (McKinney et ah, 2000; 
Chapter 4). 
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O n the essential role of isocitrate lyase (ICL) in M. tuberculosis in vivo 
growth and survival. In Chapter 6, we present evidence that ICL1 and ICL2 
provide overlapping and essential roles in metabolism of M. tuberculosis during 
infection. Deletion of /c/7 or icll alone did not impair replication in macrophages, 
or in the lungs of mice. In contrast, deletion of both /c/7 and icll abrogated 
growth, and led to rapid clearance of the AiclllAicll mutant bacteria from the 
lungs of mice. Our new findings that ICL activity is required from the onset of the 
infection indicate that ICL-mediated metabolism and fatty acid catabolism have a 
more fundamental role during infection than we had previously envisioned. 
Although the essentiality of the GC for growth and survival of M. 
tuberculosis in the host suggests primacy of fatty acid metabolism, this does not 
rule out the possibility that M. tuberculosis might also have access to 
carbohydrates. Irrespective of the carbon source, anaplerosis is necessary to 
replenish intermediates of the TCA cycle, such as oxaloacetate , succinyl-CoA, 
and a-ketoglutarate, which are siphoned off to biosynthetic pathways (Fig. 11.1; 
See also Chapter 3). However, the anaplerotic pathways bacteria employ depend 
on carbon availability and growth conditions (Komberg & Krebs, 1957; Romberg 
& Sadler, 1960; Omston & Ornston, 1969; Cronan & LaPorte, 1996; Holms, 1996; 
Fischer & Sauer, 2003). For instance, in batch culture in excess glucose medium, 
E. coli replenishes oxaloacetate by carboxylation of phosphoenolpyruvate (PEP) 
or pyruvate, via PEP carboxylase (PPC), or pyruvate carboxylase (PCA), 
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Fig. 11.1. Intermediary metabolism in M . tuberculosis. It is proposed that in M . tuberculosis the 
Glyoxylate Cycle ( G C ) plays a central role in intermediary metabolism where it keeps the balance 
between anaplerotic and biosynthetic reactions of central carbon metabolism. 
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2003). However, during slow growth in glucose-limited medium, E. coli employs 
the GC for C4 anaplerosis (Emmerling et ah, 2002; Fischer & Sauer, 2003). 
Likewise, the GC is the predominant anaplerotic pathway during growth of C. 
glutamicum on mixed substrates (glucose and short-chain fatty acid) (Wendisch et 
ah, 2000). Interestingly, A. nidulans growing on carbohydrate and acetate 
mixtures maintains ICL activity comparable to that seen during growth on acetate 
alone, which is much higher than on carbohydrates alone (Arrnitt et ah, 1970). 
Studies of carbon flux in nonmodel bacteria suggest that during growth on 
glucose bacteria rely on shunting of malate, which can be generated by the GC, to 
pyruvate and then to oxaloacetate, as preferred way of replenishing TCA cycle 
intermediates. A potential role the GC in anaplerosis during growth on glucose 
was suggested long ago based on the fact that the slow growth on glucose of a 
Apfk E. coli mutant -likely the result of reduced carbon flow into glycolysis- could 
be compensated by constitutive expression of id (Vinopal & Fraenkel, 1974) 
probably by restoring PEP concentrations to optimal levels (Kornberg & Smith, 
1970). Thus, the GC might be required for M. tuberculosis metabolism in vivo, 
regardless of whether carbohydrate concentrations are limiting or not. 
Carbon utilization studies of Mycobacteria. Though studies of carbon 
metabolism, mostly utilizing 14C-labeled carbon substrates, indicate that M. 
tuberculosis and other mycobacteria readily respire a variety of carbon substrates 
including including glucose, glucose 6-phosphate, 6-phosphogluconate, pyruvate, 
citrate, succinate, glutamate, and palmitate (Wheeler, 1984), few, if any studies 
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have actually documented carbon substrate-specific growth. Carbon 
utilization/metabolic studies in mycobacteria have been greatly limited by our 
inability to grow these slow-growing fastidious bacilli in defined minimal media 
(Kondo & kanai, 1976; Katoch et ah, 1987). Even in the standard relatively rich 
Middlebrook/Dubos media the tubercle bacillus has a doubling time of ~ 20 hours. 
Our initial experiments on defined media supplemented with different 
C2/C3 fatty acid substrates indicate that deletion of the first step of the GC results 
in an inability to grow on C2 substrates. Unexpectedly, however, the mutants are 
also impaired on combinations of carbohydrates and fatty acids (Chapter 9), 
indicating that in vitro M. tuberculosis relies on the GC for fatty acid metabolism 
even in the presence of carbohydrates. That M. tuberculosis lacking both ICL1 
and ICL2 shows a slight lag during growth on glucose suggests that some carbon 
might flow through the GC even when glucose is the major carbon substrate 
present (Chapter 6). We cannot rule out that the slight phenotype of the 
AiclllAicll mutant observed is due to the presence of Tween-80 (0.05 w/v) in the 
media, which is included to prevent clumping. However, we see no such lag 
during growth of the AiclllAicll on glycerol media. Furthermore, we have 
observed that the AiclllAicll M. smegmatis mutant is also impaired for growth on 
mixed substrates where it shows a lag phase compared to dextrose or glycerol 
media (not shown). 
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The central role of the G C in M. tuberculosis metabolism is further 
suggested by the apparent absence of PEP carboxylase (PPC) (Cole et ah, 1998; 
Fleischman et ah, 2002). PPC is the canonical enzyme used for C4 anaplerosis 
from sugars in prokaryotes (Anderson & Wood, 1969; Peng et ah, 2004) (Fig. 
11.1). Adaptation to low concentrations of glycolytic substrates might also 
involve reduced flux of carbon through glycolysis to conserve glucose-6-P and its 
derivatives for biosynthetic pathways (Fig. 11.1). In agreement, genes encoding a 
putative high-affinity carbohydrate transporter (IpqY, sugA-C) and a glucokinase 
(ppgK) are important for in vivo growth of M. tuberculosis (Sassetti & Rubin, 
2003), whereas the glycolytic steps catalyzed by triosephosphate isomerase (tpi), 
glyceraldehyde 3-phosphate dehydrogenase (gap), and phosphoglycerate kinase 
(pgk), which are important for in vitro growth on standard 7H10 plates 
supplemented with glucose (Sassetti et ah, 2003), might be dispensable in vivo 
(Sassetti & Rubin, 2003). These observations suggest that during infection, PEP, 
which is required for the biosynthesis of aromatic amino acids and the 
peptidoglycan precursor UDP-N-acetylmuramic acid, might be generated not by 
glycolysis but by conversion of oxaloacetate to PEP by PEP carboxykinase (PCK) 
(Fig. 11.1). Consistent with this idea, expression of pckA encoding PCK (Fig. 
11.1) is upregulated in the lungs of M. tuberculosis-infected mice (Timm et ah, 
2003). Further, M. bovis pckA mutants are highly attenuated in guinea pigs 
(Collins et ah, 2002), and an M. bovis BCG pckA mutant is attenuated in SCID 
mice and in murine macrophages (Liu et al, 2003b). 
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PEP not consumed in biosynthesis could flow into gluconeogenesis to 
provide essential precursors such as glucose-6-P. Alternatively, it could be further 
oxidized to C02 through the PEP-glyoxylate cycle (Fischer & Sauer, 2003) (Fig. 
11.2A), a pathway described similar to one described long ago as the dicarboxylic 
acid cycle (Romberg & Sadler, 1960). The PEP-GC has been shown to operate in 
E. coli cells when these bacteria are shifted to slow growth in very low levels of 
glucose (<0.002%) - below concentrations that exert cAMP-mediated catabolite 
repression (Notley-McRobb et al, 1997; Matin & Matin, 1982). Under these 
conditions, up to 80% of the cell's oxaloacetate is provided by the GC. During 
this shift, E. coli cells drastically downregulate PPC (-12 fold) and IDH (-4 fold), 
while upregulating ICL (-15 fold) and PCK (-10 fold). Other than the TCA 
cycle, the PEP-GC cycle is the only known energy-yielding pathway capable of 
complete oxidation of PEP to C02 (Fischer & Sauer, 2003) (Fig. 11.2A). If the 
major carbon substrate available to the cell is acetyl-CoA (as during growth on 
fatty acids), this routing of carbon would allow the oxidation of acetyl-CoA to 
C02, while also providing PEP and pyruvate for biosynthesis. Under these 
conditions reactions of the TCA cycle might be needed mostly to supply 
glutamtate (Romberg & Sadler, 1960). Alternatively, the pyruvate produced from 
PEP might instead be recycled back to oxaloacetate, as it occurs during the 
operation of the pyruvate shunt in B. subtilis (Diesterhaft & Freese, 1973) and 




~ ^ % 
Acetyl-CoA 7* synthase 























V I Succinate 
#  dehydrogenase 






















if y y -.••GCL 









/c/7, /c/2 5'ce 
COOH 
NrV,NADH\l ^ „ 






Fig. 11.2. The PEP-GC cycle and the metabolism of glyoxylate. (A) PEP-GC cycle. Catabolism of 
carbohydrates and fatty acids yields acetyl-CoA that feeds into the PEP-GC cycle and or the T C A cycle 
(not shown). G C cycle reactions ICL and M L S together with phosphoenol pyruvate carboxykinase 
(PCK), pyruvate kinase (PYK) and the pyruvate dehydrogenase complex (PDHC) together allow the 
oxidation of acetyl-CoA/glyoxylate to C02. (B) Reactions converging on glyoxylate (Glx). Glx can be 
a substrate for M L S , glycine dehydrogenase (GCV), or Glx carboligase (GCL). Dotted lines indicate 
reactions which based on B L A S T P searches are probably absent in M. tuberculosis. 
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Potential sources of fatty acids for M . tuberculosis during infection. 
The sources and chain-lengths of fatty acids utilized by M. tuberculosis during 
infection are unknown. A possible supply is long-chain phospholipids freed from 
cell (phagosomal) membranes by phospholipases. In C. neoformans, extracellular 
phospholipases, which avidly digest naturally occurring phospholipids of the lung 
surfactant such as dipalmitoyl phosphatidylcholine and phosphatidyl glycerol 
(Santangelo et al, 1999), are required for virulence (Cox et al, 2001). In accord 
with this idea, four M. tuberculosis genes encoding cell wall-associated 
phospholipase C isoforms are up-regulated during infection of macrophages and 
are jointly essential for normal growth in the lungs of mice (Raynaud et al, 2002). 
In addition to phospholipids, Triacylglycerols (TAGs) present in most 
mammalian cells are also a potential exogenous source of carbon that could be 
used by M. tuberculosis during infection. TAGs are highly reduced molecules 
with very high energy content, e.g., 1 gram of triacylglycerol can provide as much 
as 6 times the energy found in 1 gram of glycogen, and are well suited for energy 
storage. TAGs could also constitute an internal lipid reserve which M. 
tuberculosis might draw upon when external supplies of carbon become limiting. 
Though TAGs are common in eukaryotes, their occurrence in prokaryotes is rare. 
In fact, the only bacteria known to produce and store large amounts of TAGs are 
members of the actynomycete family which includes Mycobacterium, 
Rhodococcus and Nocardia, among other genera (Alvarez & Steinbuchel, 2002). 
Remarkably, fatty acids from endogenous TAGs can make up to 78% of the dry 
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weight of a Rhodococcus cell (Alvarez et al, 1996). Recent evidence suggests 
that M. tuberculosis encodes several functional TAG synthases (tgs) (Daniel et al, 
2004). These synthases are upregulated when M. tuberculosis bacteria are 
subjected to an in vitro model of persistence in which bacteria enter a 
nonreplicative state induced by slow oxygen reduction and exposure to low nitric 
oxide (Daniel et al, 2004). Interestingly, Nocardia species initiate synthesis and 
accumulation of TAGs during late log phase and continue accumulating the 
compounds throughout stationary phase for as long as carbon sources are 
available. The in vitro model used by Daniel and colleagues (Voskuil et al, 2003) 
and stationary phase in vitro growth conditions are known to elicit M. tuberculosis 
gene expression patterns that significantly overlap (Muttucumaru et ah, 2004; 
Voskuil et ah, 2004). Thus, the stimulus for TAG synthesis might be carbon 
substrate availability and/or replication rates rather than levels of oxygen in the 
flasks of the "non-replicational persistence" model (Wayne & Sohaskey, 2001) 
used by Daniel and colleagues (2004). 
When external carbon sources become unavailable, Rhodococcus species 
readily begin to mobilize their internal reserves of TAGs, eventually breaking 
down up to 90% of such reserves (Alvarez et ah, 2000). The initial breakdown of 
TAGs requires serine hydrolases known as lipases (Gupta et ah, 2004), and M. 
tuberculosis has circa twenty genes that could encode such functions (UpC-lipW). 
Although these genes are not induced during the initial 24-48 hr of infection in 
macrophages (Schnappinger et ah, 2003), this might be expected if TAGs are 
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needed only during the persistent phase of the infection after external carbon 
substrates become unavailable. Fatty acids released from TAGs are likely 
oxidized via P-oxidation, in much the same way it occurs during early 
development of some plant seedlings. For instance, A. thaliana seedlings lacking 
a peroximal 3-ketoacyl-thiolase do not grow normally because they cannot oxidize 
TAG-derived long chain fatty acids, which end up accumulating in their cells. 
Interestingly, postgerminative growth and seedling establishment in oilseed plants 
is dependent not only on p-oxidation but also on the GC. Seedlings lacking ICL 
are impaired during seedling establishment (Eastmond et ah, 2000), and ICL is 
upregulated specifically during the first days of seedling development (Runquist & 
Kruger, 1999). Thus, utilization of fatty acids resulting from TAG hydrolysis 
might well require a functional GC regardless of whether glycerol or other 
carbohydrates are present. 
It is tempting to speculate that the phenotype of A/c/7 M. tuberculosis 
mutant might result from an increased bacterial reliance on these stored sources of 
fatty acids during the persistence phase of the infection. At the beginning of the 
infection mixed substrates might be available requiring limited carbon flux 
through the GC, which our data suggests could be provided by either ICL1 or 
ICL2. Later on, as the bacteria switch entirely to fatty acids, their reliance on ICL 
might increase accordingly. That M. tuberculosis experiences nutritional stress 
during persistence is suggested by the finding that a mutant lacking relA - a gene 
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of the stringent response to starvation - is severely impaired for persistence (Dahl 
et ah, 2003). 
The methylcitrate cycle of M. tuberculosis, p-oxidation of odd-chain 
fatty acids generates both acetyl-CoA (C2) and propionyl-CoA (C3). Propionyl-
CoA can be metabolized via several routes including the citramalate, 
methylmalonyl-CoA, and methylcitrate pathways (Halarnkar & Blomquist, 1989). 
Mounting evidence indicates that the methylcitric acid cycle (MCC) (Fig. 10.1) is 
required for propionate catabolism in several eubacteria and fungi (Tabuchi & 
Uchiyama, 1975; Horswill & Escalante-Semerena, 1999; Brock et ah, 2001). In 
all these species, a dedicated MICL is present, which cannot function as an ICL 
(e.g. has no activity on isocitrate) (Luttik et ah, 2000; Brock et ah, 2001). The M. 
tuberculosis genome contains homologs of the enzymes catalyzing the first two 
steps of the MCC. These are methylcitrate synthase (prpC, Rvll31) and 
methylcitrate dehydratase (prpD, Rvll30), and they are up-regulated during 
infection of macrophages and in vivo (Schnappinger et ah, 2003). 
Since a methylisocitrate lyase (MICL, prpB) homolog is apparently absent 
from M. tuberculosis, and ICL1 and ICL2 are essential for growth of M. 
tuberculosis on propionate as the sole carbon source (Chapter 6), we postulated 
that ICL1 and ICL2 might subsume this function. ICLs and MICLs share -25% 
sequence homology and while all predicted ICLs have the catalytic site residues 
K[KQ]CGH, which constitute a signature motif , methylisocitrate lyase enzymes 
(prpB) have the signature sequence KRCGH at their catalytic site; mycobacterial 
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ICL1 and ICL2 predicted proteins have the motif K K C G H . Nonetheless, ICL 
from S. cerevisiae has weak MICL (Luttik et ah, 2000). Here, we provide 
evidence that ICLs and in particular ICL1 can function as MICL (Chapter 10). 
The idea that prpB is indeed missing, and that ICL1 and/or ICL2 substitute for this 
enzyme in M. tuberculosis is suggested by the lack of MICL activity in extracts 
from the AiclllAicll mutant. Furthermore, an Aicll mutant and a strain 
overexpressing ICL1 had normal and elevated levels of MICL, respectively, while 
a A/c/7 mutant extracts had negligible activity on methylisocitrate. 
Some bacteria, including E. coli and Ralstonia eutropha, which require the 
MCC for propionate metabolism and have a dedicated MICL (prpB), depend on 
the GC presumably for anaplerosis (Textor et ah, 1997; Bramer & Steinbuchel, 
2001). However, Salmonella mutants lacking ICL or MLS are not impaired for 
growth on propionate media (Horswill & Escalante-Semerena, 1999). In these 
cases, anaplerosis during MCC-mediated propionate metabolism is probably 
carried out by PCA, or perhaps via PPS together with PPC, rather than the GC. 
Data presented in Chapter 9 indicating that the GC is dispensable for growth on 
propionate by M. smegmatis, which unlike M. tuberculosis encodes a dedicated 
MICL (prpB), suggest that mycobacteria, similarly to Salmonella, does not require 
the GC for anaplerosis on propionate, and instead likely carry out anaplerosis via 
PCA (Mukhopadhyay & Purwantini, 2000) during growth on C3 subtrates. 
Experiments directly assessing the role of the MCC in M. tuberculosis 
C3FA utilization and pathogenesis are presented in Chapter 10. Here we provide 
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evidence that metabolism and growth on C3 substrates such as propionate and 
valerate by M. tuberculosis requires the genes putatively encoding methylcitrate 
synthase (PRPC) and methylcitrate hydratase (PRPD). The requirement for this 
pathway in vivo is less clear. In an ongoing experiment, the AprpDC M. 
tuberculosis mutant showed no difference compared to wild-type up until wk 10 
post-infection in both bacterial burden and pathology (Chapter 10). However, the 
AprpDC mutant was impaired for growth intracellularly in mouse primary 
macrophages. These contrasting findings underscore the fact that significant 
differences exist between the metabolic requirements of bacteria depending on 
whether they are grown in vitro, ex-vivo, or in vivo. 
It is possible that C3FAs are used as carbon sources during growth in 
macrophages in tissue culture, but that in vivo other substrates become available, 
thus lessening bacterial dependence on C3 substrates. Alternatively, during 
infection M. tuberculosis might be able to turn on alternative pathways of C3 
metabolism, which it fails to engage during growth in the macrophage model. M. 
tuberculosis has several putative propionyl-CoA carboxylases (accD genes), and 
methylmalonyl-CoA mutase genes (mutA and mutB), which may allow propionyl-
CoA utilization via the methyl-malonate-CoA pathway. Several of these putative 
propionyl-CoA carboxylases are found in the vicinity of fadD and fadE genes, 
suggesting they might be involved in C2/C3 catabolic pathways. 
Potential of ICL1 and ICL2 as drug targets. The complete reliance on 
ICL for replication of M. tuberculosis in vivo suggests that inhibiting both ICLs 
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might have potent therapeutic activity. Experiments presented in Chapter 8 in 
which the effect of blocking only one ICL (ICL1) in the context of chemotherapy 
with isoniazid, in the mouse model of chronic TB, and with isoniazid and 
rifampin, in a modified Cornell model of drug-induced latency, indicate that 
inhibition of ICL1 alone would not significantly improve currently available drug 
regimens. Thus, both ICL1 and ICL2 will likely need to be blocked by any future 
ICL-inhibiting drug for it to be effective. The feasibility of blocking ICL during 
infection as a therapeutic approach is supported by our demonstration that the 
prototype ICL inhibitor 3-nitropropionate (Schloss & Cleland, 1982; Sharma et 
ah, 2000), which inhibits both ICL1 and ICL2 in the tube (Honer zu Bentrup et ah, 
1999), effectively impedes replication of M. tuberculosis on fatty acids and in 
macrophages (Chapter 6). M. smegmatis Aicll/AicU mutant bacteria expressing 
wildtype M. tuberculosis icll and icll genes have been constructed and their 
usefulness as tools for testing potential inhibitors of ICLs is supported by data 
presented in Chapter 9. These strains are currently being employed to test lead 
compounds identified in high-through put screens that are being conducted by 
collaborators in industry (GlaxoSmithKline). 
The importance of ICL and the GC as a target for therapeutics development 
is enhanced by findings implicating the GC in the pathogenesis of several other 
microorganisms including the bacteria Rhodococcus fascians (Vereecke et ah, 
2002), S. typhimurium (Fang et ah, 2005) and the fungi Leptosphaeria maculans 
(Idnurm & Howlett,, 2002); Magnaporthe grisea (Wang et ah, 2003b), and 
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Candida albicans (Lorenz & Fink, 2001). Thus, although the G C is probably not 
universally required for pathogens' survival in the host, as suggested by findings 
in C. neoformans (Rude et ah, 2002) and Y. pestis (Sebbane et ah, 2004), a 
growing number of organisms are being identified which at some point in their 
infection cycle require the GC for growth or survival during infection. 
11.3. Future Studies 
The role of ICL in M. tuberculosis persistence in vivo. The fact that 
either ICL1 or ICL2 can sustain the metabolism of M. tuberculosis early in the 
infection, even though ICL2 is likely providing considerably less activity than 
ICL1, together with our previous observation that A/c/7 mutant bacteria are 
attenuated specifically during the persistent phase of the infection (McKinney et 
ah, 2000), and, in particular, that this attenuation results from an interaction with 
the immune response (Chapter 7), suggest that at the onset of persistence, the 
infection milieu changes in a way that forces M. tuberculosis to increase its 
reliance on ICL-mediated metabolism. One way in which this could happen is by 
immune-mediated restriction in access to carbohydrates. However, the phenotype 
of the A/c/7 mutant, though stage-specific in appearance, is not a demonstration 
that the function of ICL1 is specifically required during persistence. The function 
of ICLs could be performed early in the infection but the effect of lacking such 
function may not manifest itself until later. The possibility that ICLs are 
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dispensable for M. tuberculosis remains and ought to be explored. To address this 
issue, conditionally ICL-expressing strains of M. tuberculosis are being built using 
AiclllAicll mutant bacteria and recently developed methods of conditional 
expression of M. tuberculosis genes (Blokpoel et ah, 2205; Ehrt et ah, 2005). 
The role of the fatty acid p-oxidation cycle in M. tuberculosis 
metabolism in vivo. If lipid-derived fatty acids are indeed the main carbon 
substrates employed by M. tuberculosis in the host, regardless of the source, the 
pathways involved in their oxidation should be essential for the growth and 
survival of the bacteria during infection. As discussed in detail in Chapters 3 and 
4, testing this prediction might be difficult because of the potential for redundancy 
in many of the steps of P-oxidation. A survey of these putative homologous genes 
indicates that the group with the lowest number of homologues is that of the 
ketoacyl thiolases encoded by the fadA genes, of which there are six. Though the 
oxidation of 3-hydroxyacyl-CoAs might only involve the products of 3 annotated 
fadBs, the presence of some 30 or so, other short-chain hydroxyacyl 
dehydrogenases, which though closer in homology to eukaryotic enzymes, might 
nevertheless functionally overlap with the canonical FADBs (Maggio-Hall & 
Keller, 2004), makes this group a less attractive target. 
The role of malate synthase in M. tuberculosis metabolism in vivo. 
We hypothesize that the joint essentiality of ICL1/ICL2 in vivo is attributable to 
their canonical function in the GC. However, it is possible that ICL-mediated 
cleavage of isocitrate into succinate and glyoxylate functions together with other 
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pathways capable of oxidizing the generated glyoxylate. In bacteria such as P. 
denitrificans, glyoxylate is converted to oxaloacetate via the beta-hydroxy 
aspartate pathway in which glyoxylate is first converted to glycine through a 
reductive amination reaction catalyzed by glycine dehydrogenase (GCV), 
followed by condensation with another glyoxylate to form erythro-beta-hydroxy 
aspartate, which is then dehydrated to oxaloacetate (Liu et ah, 2003a). Another 
route for the metabolism of glyoxylate through a glycine intermediate could 
involve a serine-glyoxylate aminotransferase pathway, which would lead to 
formation of glycerate and sugars. This routing of carbon occurs in MLS-deficient 
seedlings (Cornath et ah, 2004) and is analogous to the glycerate pathway (See 
Chapter 3). In this pathway, two glyoxylates are condensed by glyoxylate 
carboligase (GCL) to form tartronate, ultimately generating glycerate (Fig. 11.2B). 
It is not known whether any of these pathways operate in M. tuberculosis since no 
clear homologs of the enzymes involved can be found in its genome. However, 
the reductive amination of glyoxylate to glycine catalyzed by glycine 
dehydrogenase has been demonstrated in extracts of M. tuberculosis H37Ra 
(Goldman & Wagner, 1962). This reaction not only would allow the metabolism 
of glyoxylate but would also aid in the regeneration of NAD+, which might be 
important if bacteria experience hypoxic conditions in vivo (Wayne et al, 1982; 
Boshoff & Barry, 2005). 
In E. coli, the genes encoding ICL (aceA) and MLS (glcB) are in an operon 
(aceBAK). In contrast, in M. tuberculosis they are not in the proximity of each 
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other in the chromosome, and while /c/7 is upregulated in vivo, glcB is not (Timm 
et al, 2003; Fig. 6.7); furthermore while ICL is massively upregulated in vitro on 
C2 substrates, MLS is not. Though these differences might not be important, and 
constitutive levels of MLS might be sufficient for the function of the GC, they 
could also be a hint that other pathways involved in the metabolism of glyoxylate 
might be operative. Two types of malate synthase enzymes have been described: 
type A and type G. Most micro-organisms have only one type but it is not 
uncommon to find species that have both. In E. coli, which has both, MLS-A is 
induced by acetate, while MLS-G is induced by glycolate (Molina et al, 1994). 
However, there is cross-induction of the two enzymes by acetate and glycolate 
(Pellicer et al, 1999). Mycobacteria have only one MLS and it is closer to the 
MLS-G type, encoded by glcB. 
To study the role of MLS in M. tuberculosis, deletion of the single-copy 
gene glcB in M. tuberculosis was attempted. Two different strategies for gene 
disruption in M. tuberculosis - plasmid-mediated (Pavelka & Jacobs, 1999) and 
phage-mediated (Bardarov et al, 1997) homologous recombination - were used in 
separate attempts to make marked deletions in glcB in both Erdman and H37Rv M. 
tuberculosis strains. All of these attempts were unsuccessful. We considered the 
possibility that disruption of glcB could have polar effects on downstream genes, 
and therefore, tried to generate the mutant using unmarked in-frame deletion 
constructs with different flanking lengths (pEM304-306 series). In all cases, 
homologous recombination was obtained, but resolution of the plasmid after 
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sucrose counterselection always resulted in regeneration of the wild-type locus. 
These results suggest that glcB might be essential. If this is the case, this could be 
formally shown by obtaining the mutation in a merodiploid strain in which the 
chromosomal deletion is facilitated by the presence of a second wild-type copy 
either episomally or integrated into the chromosome. Efforts are ongoing to do 
just that. If glcB indeed proves to be essential in vitro, determining the role of 
MLS in the biology of M. tuberculosis might still be feasible by adapting 
methodologies used for conditional gene expression (Blokpoel et al, 2205; Ehrt et 
al, 2005). 
Determining the contributions of glycolysis and gluconeogenesis to M. 
tuberculosis metabolism during infection. Based on our data, we hypothesize 
that carbohydrates are not available, or available in only in low concentrations to 
M. tuberculosis during infection, and furthermore suggest that their availability 
might change overtime, decreasing during the chronic phase of the infection. 
However, several alternative scenarios are possible, and thus it will be important 
to evaluate the role of sugar metabolism-specific pathways in infection. 
If carbohydrates are completely inaccessible, then the ability to catabolize 
carbohydrates (glycolysis) should be dispensable, while the ability to synthesize 
carbohydrates de novo (gluconeogenesis) should be essential. If this scenario is 
correct, then the functions of PCK and GLPX ought to be essential, while those of 
PPGK/GLK and PFK1/2 ought to be dispensable for bacterial growth in vivo. 
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Alternatively, if some carbohydrate is available, perhaps enough to provide 
glucose-6-P and related biosynthetic precursors, but not enough to be used for 
energy, and most of the carbon and energy is derived from fatty acid breakdown, 
then it is possible that the upper and lower branches of glycolysis/gluconeogenesis 
are 'disconnected'. In this scenario, only enzymes in the upper part of glycolysis 
would be required (PGI, PFKs, FBA, GLPX) as well as sugar transporters 
(PPGK), but not enzymes that connect the upper part of glycolysis to PEP (TPI, 
GAP, PGK, GPMs). PCK would be needed to provide PEP. It is possible that 
both scenarios hold true at different times during the infection. Early on, 
glycolysis might play a role while carbohydrates are available, but as the bacteria 
lose access to them, bacteria might have to switch to split C2/carbohydrate 
metabolism (no connection between GC/TCA and upper part of glycolysis). Later 
still, they may become strictly lypolytic and gluconeogenic. 
Lastly, M. tuberculosis could have access unimpeded access to sugars, 
perhaps low levels, and similarly to E. coli growing on very low levels of 
glucose/carbohydrates rely on the GC to do so. In this scenario, the requirement 
for ICL would be due to its role in oxidation of sugar- instead of fatty acid-derived 
acetyl-CoA. PCK would still be needed for PEP generation (Fischer & Sauer, 
2003), but GLPX ought to be dispensable. Furthermore, PPGK/GLK and all 
glycolytic activities ought to be needed as well. 
The finding that M. bovis lacks a functional PYK (Garnier et al, 2003; 
Keating et al, 2005) has been cited as evidence that glycolysis is likely 
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dispensable in pathogenic mycobacteria for growth in vivo since M. bovis causes 
disease in bovines and humans. However, it is possible that in this species the loss 
of PYK has been compensated by upregulation of either MEZ or PCA, or both. In 
order to evaluate the role of glycolysis in mycobacterial metabolism both PFK and 
PYK need to be lacking because PYK could be needed for the metabolism of PEP 
that has been produced via PCK. 
As detailed in Chapter 3, bacteria have enormous metabolic flexibility. In 
E. coli, deletion of ppc results in the upregulation of the GC for anaplerosis during 
growth on glucose, and a mutation on PFK can be compensated by a mutation that 
upregulates the GC as well. Examples of this sort abound. Studies of gene 
expression in different carbon sources have now been carried out on a global scale 
in E. coli and C. glutamicum grown in specific carbon sources (acetate vs 
dextrose); similar studies in M. tuberculosis ought to be feasible using the growth 
conditions we have established (See Chapter 6 and Chapter 12 (Materials & 
Methods)), and might be informative in aiding our understanding of carbon flux in 
M. tuberculosis. Carbon flux analysis with radiolabeled carbon substrates would 
also greatly enhance our understanding of mycobacterial metabolism. As we have 
learned, metabolism is less well understood than sometimes assumed. 
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11.4. Conclusions 
We ignore much about the metabolic pathways specifically employed by 
microorganisms to use the nutrients available in the environment of the infection, 
a prerequisite for pathogenesis. Uniquely, mycobacterial genomes encode an 
unprecedented number of putative fatty acid metabolism genes including several 
paralogs of fatty acid P-oxidation and two genes encoding isocitrate lyases (ICL) -
an enzyme generally needed when fatty acids are the principle sources of carbon 
and energy available to bacteria. While single A/c/7 and A/c/2 mutants are capable 
of growth on C2 substrates, intracellularly in both mouse and human macrophages, 
and in the lungs of mice during the acute phase of infection, a Aicll/Aicll mutant 
is incapable of growth on C2 substrates, or in macrophages, and is avirulent, being 
cleared from lungs within 2 weeks of infection. This functional overlap uncovered 
between ICL1 and ICL2 makes developing dual specificity inhibitors a desirable 
goal. That this is feasible is suggested by the high conservation between the 
proteins' active sites revealed by in silico structural modeling of ICL2, and by the 
abrogation of wild-type M. tuberculosis growth on C2 substrates and in 
macrophages by an ICL inhibitor. These findings establish an essential 
requirement for ICL from the onset of infection. A role for the GC during 
persistence of M. tuberculosis remains an attractive possibility that is supported by 
the phenotype of the single /c/7 mutant and gene expression data, as well as by a 
considerable body of data from other groups. The potential of the GC as a novel 
279 
target for drug development is enhanced by its apparent absence in mammalian 
cells, and by emerging evidence that the pathway is important for virulence in 
various bacterial and fungal pathogens. These include major causes of human 
morbidity, such as Candida albicans, for which the existing therapeutic options 
are suboptimal. The lengthy chemotherapeutic regimens prescribed to treat TB 
and the emergence of rapidly spreading multiple-drug resistant M. tuberculosis 
makes finding more effective drugs an imperative. A novel drug targeting both 
rapidly dividing bacteria and slow growing or non-replicating 'persisters' would 
likely reduce the number of antibiotics prescribed, shorten duration of treatment, 
improve compliance, and contribute to controlling the current TB epidemic. 
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P A R T I V 
CHAPTER 12 
Materials and Methods 
12.1. Bacterial strains and growth conditions 
Standard media. M. tuberculosis Erdman and M. smegmatis mc2155 were 
stored at -80°C in 15% glycerol. Bacteria were grown with aeration at 37°C in 
Middlebrook 7H9 broth (DIFCO) containing 10% OADC (DIFCO), 0.5% 
glycerol, and 0.05% Tween-80, or on Middlebrook 7H10 agar (DIFCO) 
containing 10% OADC and 0.5% glycerol. Antibiotics (Sigma) were hygromycin 
(50 [xg ml"1), kanamycin (25 u.g ml"1) and streptomycin (20 [xg ml"1). 
Defined media. Carbon-source defined media (CDM) contained (w/v): 
0.47% Middlebrook 7H9 powder (DIFCO), 0.5% albumin, 0.085% NaCl, and 
0.05% Tween-80. Carbon substrates were used at 0.1% (w/v) or as indicated. 
pH was adjusted to 6.8. Growth curves were done as follows: bacteria were 
inoculated into standard 7H9 media and grown to late log phase (OD600 1-2). 
These cultures were used to inoculate dextrose-CDM cultures at an initial OD600 
~ 0.025; these were grown for 7-10 days till late log phase (OD600 0.8-1) and then 
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used to inoculate "experimental" C D M supplemented with the desired carbon 
substrates. 
In one set of experiments, M9 salts (DIFCO) supplemented with (0.1 mM) 
CaC12, (2mM) MgS04, 0.5% albumin, 0.085% NaCl and 0.05% Tween-80 were 
used. However, CDM supplemented with glucose (0.1%, w/v) or C2FA (0.1%, 
w/v) supported significantly better and faster growth of M. tuberculosis (doubling 
time 3-4 days) than similarly supplemented M9-based defined media (~6 day 
dobling time). M. tuberculosis extracts were prepared from CDM (7H9-based) 
where carbon substrates were used at (w/v) 0.2%. 
Minimal media for carbon utilization experiments with M. smegmatis: M9 
salts (DIFCO), (0.1 mM) CaC12, (2mM) MgS04 without (liquid) or with (solid) 
agar (15 g L"1). Carbon substrates were used at 0.1% (w/v). M. smegmatis 
extracts were made from minimal M9 liquid media where carbon substrate 
concentrations were (w/v) 0.1%. Distilled water was used in all cases. Media 
were sterilized by either by autoclaving (solid) or filtering (0.2 micron) (liquid). 
BACTEC. Degradation of [14C]-palmitate to [14CJ-C02 was measured 
using the BACTEC system (Becton Dickenson) per the manufacturer's 
instructions. 
12.2. Mouse infections/animal models 
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Mouse strains. All mice used were either male or female (3-5 wks of age) 
on the C57BL/6 background and were purchased from Jackson Laboratories. Mice 
were housed under specific pathogen free conditions at Rockefeller University, 
and were routinely tested and found to be free of common mouse pathogens. All 
experiments with live mice were performed in accordance with the National 
Institutes of Health Guidelines for the Care and Use of Laboratory Animals, and 
were approved by Rockefeller University's Institutional Animal Care and Use 
Committee. 
Mouse infections. Bacteria were grown to mid-log phase (OD60o ~ 0.5) in 
7H9 broth, collected by centrifugation, washed with PBST, adjusted to ~ 1 x IO7 
CFU ml"1, and sonicated briefly in a cup-horn sonicator to disrupt aggregates. 
Mice were infected by injection of 0.1 ml (~ 1 x 106 CFU) of the bacterial 
suspension into a lateral tail vein. 
For respiratory infections, bacteria were grown in 7H9 broth to mid-log 
phase (OD600 ~0.5), collected by centrifugation, washed once with PBST, 
centrifuged at low speed for 5 min to remove clumps and the supernatant was 
suspended at -106-108 CFU ml-1 (adjusted by OD600), depending on the dosage 
required (101-103 CFU per mouse); aerosol exposure of mice was carried out for 
15 min, followed by a 20 min purge with room air, using a custom-built aerosol 
exposure chamber (University of Wisconsin, Madison), as described (MacMicking 
et al, 2003) 
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Chemotherapy of mice. Where appropriate, M. tuberculosis-infected mice 
received isoniazid (0.1 mg/mL - 25 mg per kg body weight per day) or isoniazid 
plus rifampin (0.1 mg/mL - 25mg/kg/day) delivered ad libitum in the drinking 
water. Drugs were replaced by fresh water 24 h before mice were sacrificed at 
each time-point. 
12.3. Bacterial quantification 
Quantification of M. tuberculosis colony forming units (CFU) in organs 
from infected mice. Infected mice were euthanized by C02 overdose (n = 4-5 per 
group). M. tuberculosis CFU were enumerated by homogenizing the left lung of 
each mouse in 5 ml PBST using a Polytron tissue homogenizer, plating the diluted 
homogenates on 7H10 agar, and scoring colonies after 3-4 wk (or 6-8 wk, in the 
case of A/c/7 A/c/2 bacteria) at 37°C. Portions of tissue were fixed in phosphate-
buffered formalin (10%) for histopathology. Histopathology staining was 
performed at Cornell University Pathology Laboratory (New York, NY). 
Quantification of M. tuberculosis CEQ in lungs of infected mice. M. 
tuberculosis chromosomal DNA was prepared by homogenizing the right lung of 
each mouse in 5 mL PBST, collecting the bacteria by centrifugation at 3000 g for 
10 min at 4 °C, resuspending the bacterial pellet in 1 mL TE, adding 0.25 ml warm 
(70 °C) phenol/chloroform/isoamyl alcohol (25:24:1) (Sigma) and 0.25 mL 
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zirconia-silica beads (Biospec Products), and breaking the bacteria in a bead-
beater (Biospec Products). Cell debris was removed by centrifugation at 12,000 g 
for 10 min, 50 jo.1 5 M NaCl was added to the clarified supernatant, extraction with 
phenol/chloroform/isoamyl alcohol was repeated, and genomic DNA was 
precipitated by addition of isopropanol. The precipitated genomic DNA from a 
single infected mouse was ethanol-washed, air-dried, resuspended in 300 [xL of 
water, and stored at -20 °C. Quantitative PCR (QPCR) reactions were carried out 
as described (Timm et ah, 2003). Each reaction was in a volume of 50 [xL 
containing lx Taqman buffer A (Perkin Elmer), 4 mM MgC12, 0.25 mM dNTPs, 
2.5 units of AmpliTaq Gold polymerase (Perkin-Elmer), 0.5 \iM of the fadE15 
primers, 0.3 [xM of the fadE15 molecular beacon, and the template DNA. 
Typically, 1-2 [xl of template DNA (representing 0.33-0.67% of the total genomic 
DNA extracted from a single mouse) was used per reaction. In some cases (where 
bacterial loads were very high), template DNAs were diluted before amplification 
in order to obtain QPCR threshold cycle (Ct) values in the range 25-35; control 
reactions confirmed that dilution of the template had no effect on the linearity of 
amplification (data not shown). The set of primers and the molecular beacon used 
to quantify bacterial chromosomes had the following sequences (hybridizing to 
sequences in the fadE15 gene): FAM-5'-GCAGCC 
CGCATGACCATCGGAGTTAAGT GGCTGC-3' (molecular beacon); 5'-
GATTGCGCAGATGTTCACGG-3' (forward primer); 5'-
GCCCTGCACCCGCTCCTTGG-3' (reverse primer). Real-time QPCR reactions 
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were run and analyzed on an ABI 7900 machine per the manufacturer's 
instructions. PCR conditions were: Amplitaq Gold activation step 95 °C (10 m), 
followed by 40 cycles of 95 °C (30 s), 57 °C (30 s, data collection), 72 °C (30 s). 
Standard curves were generated using serial dilutions of M. tuberculosis genomic 
DNA of known concentration. Quantitative analysis of the data was carried out as 
described (Timm et ah, 2003). 
12.4. Tissue culture. 
12.4.1. Infection of bone-marrow-derived murine macrophages with M. 
tuberculosis. 
Isolation of cells. Bone marrow cells were flushed from mouse femurs and 
cultured for 7 days in DMEM (Cellgro) containing 0.58 g l"1 L-glutamine, 1 mM 
sodium pyruvate, 10% heat-inactivated fetal bovine serum (HIFBS; Hyclone), 10 
mM Hepes 7.55, 100 U ml"1 penicillin G, 100 [xg ml"1 streptomycin, and 20% L929 
cell-conditioned medium (Ehrt et ah, 2001). Adherent cells were harvested, 
seeded in 12-well plates (2 x IO5 cells per well), and incubated at 37 °C, 5% C02. 
Where indicated, macrophages were activated by addition of 50 U ml"1 rlFN-y 
(R&D) to the medium 16 h prior to infection and thereafter. 
Bacterial Infection. Bacteria were grown to mid-log phase (OD60o ~ 0.5) in 
7H9 broth, washed in PBS containing 0.05% Tween-80 (PBST), and centrifuged 5 
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min at low speed to remove aggregates. Macrophage monolayers were infected at 
an MOI of 2:1 in DMEM containing 0.58 g l"1 L-glutamine, 1 mM sodium 
pyruvate, 5% HIFBS, and 5% horse serum (Gibco); after 4 h monolayers were 
washed to remove non-cell-associated bacteria, and incubated (37°C, 5% C02) 
with medium changes every 36 h. Where indicated, 3-NP was included in the 
medium from 4 h post-infection onwards; addition of 3-NP had no detectable 
effect on adherence or viability (trypan blue exclusion) of macrophages. At the 
indicated time points, infected monolayers were washed, lysed with 0.5% Triton 
X-100, and cell-associated bacteria were enumerated by plating lysates on 7H10 
agar and scoring CFU after 3-4 wks incubation at 37 °C. 
12.4.2. Infection of human blood monocyte-derived macrophages with M. 
tuberculosis. Monocyte/lymphocytes were purified from whole human blood 
(New York, Blood Center) by the Ficoll-plaque differential centrifugation method 
as per manufacturer's instructions (Pharmacia Biotech). Cells were seeded in 
tissue culture 12- well plates (Corning) at a density of 2.4 million cells/well and 
cultured for 2 h in 10% PHS-RPMI = RPMI-1640 (Life Technologies) containing 
10% heat inactivated pool human serum (Labquib, Ltd.), 10 mM Hepes, and 
gentamicin (20 ug/mL). Non-adherent cells were removed by 4 washes with plain 
RPMI (37 °C). Adherent monocytes were cultured for 1 wk in 10% PHS-RPMI. 
Before bacterial infections, monolayers were washed 3X with 37 °C PBS. 
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Infections of human cells with M. tuberculosis were carried out identically to 
those in murine macrophages, except that 10% PHS-RPMI was used throughout 
the experiments. 
12.4.3. DAPI Staining of macrophages and intracellular Bacteria. Human 
primary monocytes derived as described above were seeded on round cover slips 
fitted in the bottom of 24-well plates. At desired-time points, monolayers were 
washed 3X with cold PBS, and 500 |xL of 4% paraformaldehyde in IX PBS was 
added per well. After fixing for , wells were washed 3X with PBS and 300 [xL of 
4',6'-diamino-2-phenylindole (DAPI stain (l[xg/mL final concentration in PBS) 
were added per well. The wells were then incubated in the dark for -30 min at 4 
°C. Wells were then washed 3X with PBS and the cover slip was mounted on a 
microscope slide for observation using a fluorescent microscope. 
12.5. Molecular microbiology 
12.5.1. Construction and complementation of id mutants in M. tuberculosis. 
For disruption of icll, a Kpnl fragment containing icll was sub-cloned into 
pBSKS- (Stratagene) to generate pEM027-14. A 1.8 kbp MscI fragment internal 
to icll was replaced with an oph kanamycin resistance (Kmr) cassette (1.3 kbp 
BamHI fragment from pUC4) to generate pEM028; the deletion encompassed AA 
2-612 including the catalytic motif KKCGH (AA 213-217). The Kpnl fragment 
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containing the icllr.aph allele was cloned into the unique Sail site of pEM025, an 
E. coli-Mycobacterium episomal shuttle vector containing the pAL5000 
replication origin (Ranes et ah 1990), aadA streptomycin resistance (SmR) marker 
(1.9 kb Dral fragment from pHP4547), and sacB counter-selection marker to 
generate pEM029-l. The icllr.aph allele was recombined into the M. tuberculosis 
chromosome by selection of pEM029-l (KmR) transformants followed by counter-
selection on 5% sucrose as described (Pavelka & Jacobs 1999). The AiclllAicll 
mutant was generated by disrupting icll in the chromosome of the previously 
generated A/c/7 (icllrhpt) strain (McKinney et ah, 2000). Replacement of the 
wild-type icll gene with the icllr.aph allele was confirmed by PCR analysis and 
Southern blot (Fig. 6.3). pICLl (pEM263-4) was constructed by sub-cloning a 1.6 
kb Spel fragment containing /c/7 into the Hpal site of pEM262, an episomal vector 
derived from the shuttle vector pMV261 (Stover et ah, 1991) by replacing the 
KmR cassette with the aadA SmR cassette. pICL2 (pEM3E4-8) was constructed by 
inserting a 6.1 kbp Kpnl fragment (from an M. tuberculosis Erdman genomic 
library cosmid, gift of M. Glickman, Sloan Kettering Institute) containing icll into 
the Hpal site of pEM262. 
12.5.2. Construction and complementation of id M. smegmatis mutants. M. 
smegmatis (strain mc2155) mutant strains with in-frame unmarked deletions in /c/7 
or icll or both ORFs were generated by homologous recombination using suicide 
constructs based on vectors pJGHOO and pJGlOOl, respectively (gift of J. 
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Gomez). For disruption of /c/7 (carried out by L. Merkov), a 2.3kb fragment 
containing the entire icll gene of M. smegmatis was amplified by PCR from 
genomic DNA using primers smicllupxhol: 5-
CTCGAGCTTCGACCACATGAACAACG-3; smiclldnxhol: 5-
CTCGAGGATCTTCATGATCGGGATGC-3. The PCR product was subcloned 
into pCR2.1 (to give pLM217s) and sequenced. A 2.3kb EcoRI fragment 
containing the PCR product was subcloned into EcoRI digested pBSKS 
(pBluescript) to give pLM218s. pLM218s was digested with Sfol to remove an 
855 bp fragment internal to the /c/7 gene (removes 285 AAs from the ICL protein, 
including the catalytic site, and results in an in frame deletion). The other (5.4kb) 
Sfol fragment from pLM218s was religated to give pLM219s, which was then 
digested with Xhol to excise the 1.5kb band containing the truncated icll gene. 
This 1.5kb fragment was subcloned into Xhol digested pJGHOO vector to create 
pLM220s, which was electroporated into smegmatis. 
For disruption of icll, a 3.9kb Agel fragment from cosmid pEM353 (M. 
smegmatis cosmid genomic library was a gift of B. Subramanian) carrying icll 
was cloned into pSL301 to generate pEM701, which was EcoRV-digested to 
obtain a 3.5kb fragment carrying icll, which was then cloned into the Pmel site of 
pJGlOOl to generate pEM902. pEM902 was BstEII-digested to remove a 660-bp 
fragment, which generated an unmarked in-frame deletion after relegation into 
pEM903; The deletion encompasses AA 307 to 526 of the icll ORF. pEM903 
was electroporated into wild-type M. smegmatis. Counter selection was performed 
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as described (Pavelka & Jacobs, 1999). A AiclllAicll M. smegmatis mutant was 
generated by transforming the A/c/2 mutant with pML220s (described above). 
12.5.3. Construction and complementation of AprpDC M. tuberculosis 
mutants. 
Disruption of the prpdc ORFs. M. tuberculosis (strain Erdman) with an 
in-frame unmarked deletion in the prpd and prpc ORFs was generated by 
homologous recombination using a suicide construct based on the vector pJGl111. 
This vector was derived from pJG1004, a derivative of the kanamycin and 
ampicillin resistant pMV261 (Stover et ah, 1991) into which hygromycin 
resistance and sucrose sensitivity cassettes had been inserted (Gomez & Bishai, 
2000). Additional restriction sites (Spel, BstBI, Sspl, Avrll, Ndel, Xhol, and 
AflU) were added between the pJG1004 Pad and AscI sites via a PCR-generated 
polylinker, to generate pJGHOO. A 39894 bp Smal/Nral fragment excised from 
pGOAL19 (Parish & Stoker, 2000) containing the E. coli lacZ gene under the 
control of the M. tuberculosis Antigen 85 promoter was cloned into the unique 
Pmel site of pJGl 100 to generate pJGl 111 by L. Merkov. 1 kb regions upstream 
and downstream of the putative prpDC ORFs were PCR-amplified (with a M. 
tuberculosis genomic library cosmid as template), using primers designed to 
introduce the restriction sites Pacl/Avrll into the 573' termini of the upstream 
region (primers used were ttaattaactgctctgcggcacggtg and cctaggatgcatcaacat 
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aatccg) and Avrll/AscI sites into the 573' termini of the downstream region (using 
primers cctaggggcaccttctagtcttat and ggcgcgccagcagaccatgatcgtcg). The resulting 
PCR products were subjected to restriction digestion and cloned together into the 
Pad and AscI sites of pJGllll such that the 2 insert fragments were ligated to 
each other at their Avrll sites (the 3' terminus of the upstream region to the 5' 
terminus of the downstream region). Homologous recombination into the M. 
tuberculosis chromosome would result in the replacement prpDC with an ORF 
encoding a fusion protein consisting 9 AA. This construct was recombined into 
the M. tuberculosis genome by selection of white, hygromycin and kanamycin 
resistant transformants followed by counter-selection on 5% sucrose as described 
(Pavelka & Jacobs, 1999). Replacement of prpDC with the sequence encoding the 
9aa peptide was confirmed by PCR analysis and Southern blot (not shown). 
12.6. Gene expression analysis by real time RT-PCR 
RNA preparation from infected tissues was done as described (Timm et ah, 
2003). Bacteria were from mouse lungs of wild-type (C57BL/6) mice infected 
with M. tuberculosis Erdman (1 x IO6 CFU/mouse, i.v.) or from cultures grown in 
7H9 following standard conditions and harvested at mid-log phase. 
12.6.1. Primers and Molecular Beacons. Primers with similar melting 
temperatures (60-66°C) were designed by using PRIMER 3 software (Rozen & 
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Skaletsky, 2000). Primers were tested in PCRs with 100 Erdman genome 
equivalents as template and the amplification products were evaluated by gel 
electrophoresis. Molecular beacons (Tyagi & Kramer, 1996) were designed as 
described (www.molecular-beacons.org); The beacon for icll was purified by J. 
Timm at PHRI, NY. Standard curves were generated by using serial dilutions of 
Erdman genomic DNA as template. The sequences of the beacon and primers for 
icll gene expression analysis were the following: 
Beacon: 5' -GCAGGCTGACGATGCCGCGGTGCTGGGCCTGC-3' 
RT primer: 5'-CGGATCAGGTTGCGTACGTG-3' 
Primerl: 5'-GCTCCAGCACCGAAGATCC-3' 
Primer 2: 5' CTGTCGCTCGCTCATCTGC-3' 
(Those for /c/7 have been reported before (Timm et ah, 2003)). 
12.6.2. Reverse Transcription (RT) and QRT-PCR. QRT-PCRs were as 
described (Manganelli et ah, 2001). Mock reactions (no RT) were done on each 
RNA sample to rule out DNA contamination. Control reactions with uninfected 
murine and human tissues were performed to rule out cross-hybridization. RT 
reactions were performed with Klenow DNA polymerase from Carboxydothermus 
hydrogenoformans (Roche Applied Science): annealing, 95°C (1 min), 65 °C (3 
min), and 57 °C (3 min); polymerization, 60 °C (30 min); RT inactivation, 95°C (5 
min). Real-time PCRs were run and were analyzed on an ABI7900 real-time PCR 
machine. PCR conditions: AmpliTaq Gold activation, 95 °C (10 min); 15 cycles of 
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95 °C (30 sec), 65 °C (0.5° stepdown each cycle, 30 sec), and 72°C (30 sec); 25 
cycles of 95°C (30 sec), 57°C (30 sec), and 72°C (30 sec). 
12.6.3. Normalization of Transcripts. For each RNA sample, the control 
transcripts (sigA mRNA) and target mRNAs were reverse-transcribed together in 
one reaction, and the resulting cDNAs were quantified by real-time PCR. The 
target cDNA was normalized internally to the sigA cDNA levels in the same 
sample and expressed as (Target rnRNA)/(.s/gA). 
12.7. Biochemical procedures 
12.7.1. Preparation of total cell extracts from mycobacterial cultures Cultures 
of the different strains of M. tuberculosis (100-150 mL in roller bottles; OD600 = 
0.7-1) or M. smegmatis (30 mL in shaking flasks; OD600 = 0.7-1.2) were grown to 
late-log phase in 7H9-based CLDM broth (M. tuberculosis) or M9-broth (M. 
smegmatis) supplemented as indicated above. Bacteria were washed three times in 
PBS-Tween80 (0.05%) and resuspended in MOPS buffer (50mM 
morpholinepropane sulfonate, 5mM MgC12, pH 6.8, supplemented with a protease 
inhibitor cocktail (Sigma P-8465)) in 1/75* vol. of culture (M. tuberculosis) or 
l/20th vol. of culture (M. smegmatis). Bacterial cells were disrupted by bead 
beating (high power) for 3 cycles of 1 min pulses followed by 30 seconds of rest 
(on ice). The cell-debris was removed by centrifugation, the extracts were filtered 
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(M. tuberculosis) (0.45 micron low-protein binding SpinX", Corning) and the 
concentration of protein in the supernatants was measured using a Biorad (M . 
smegmatis) or BCA (M .tuberculosis) protein assay kit (Pharmacia). 
12.7.2. Isocitrate lyase assay. ICL activity was measured by following the lactate 
dehydrogenase (LDH) mediated reduction of glyoxylate to glycolate, with 
concomitant oxidation of NADH (Warren et ah, 1970). Reactions were performed 
at room temperature in a 1ml assay volume containing: cell-free extract (10-100 
Ug total protein in 5-50 |iL), 0.1 mM NADH and 7U LDH (Roche), in 50 mM 
MOPS/5 mM MgC12 buffer. Reactions were preincubated for 5 min at room 
temperature before being started by the addition of ImM threo-D-L-isocitrate 
(Sigma). Isocitrate-stimulated NADH oxidation was determined 
spectrophotometrically at 340nm using the standard extinction coefficient 6.22 
mM-1 for a path length of 1cm. 
12.7.3. Methylisocitrate lyase assay. Me-ICL activity was measured in 
analogous fashion by following LDH mediated reduction of pyruvate to lactate, 
with concomitant oxidation of NADH in a 1 mL reaction containing: cell-free 
extract (10-100 [xg total protein in 5-50 u.L), 2 mM DTT, 0.2 mM NADH and 7U 
LDH (Roche) in 50 mM MOPS/5mM MgC12 buffer. Reactions were started by 
addition of 1 mM threo-D-L-2-methylisocitrate. 
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12.7.4. Synthesis of threo-D-L-2-methylisocitrate. The following procedure is 
based on those described in Plaut et ah, 1975 and Brock et ah, 2001, with 
modifications. 
Step 1. Trans-epoxymethylsuccinic acid. Mesaconic acid (10.0 gm, 76.8 
mmol) was suspended in water (40 mL) and NaOH (6.1 g, 153.7 mmol) was added 
portionwise. The resulting solution was cooled to 0 °C and Na2W04.2H20 (0.760 
g, 2.3 mmol) was added, followed by dropwise addition of H202 (30% aqueous 
solution, 9.6 mL, 84.55 mmol). After stirring at 0 °C for 1 h, the mixture was 
heated at 65 °C. After 8 h, the reaction mixture was allowed to cool to RT and 
evaporated to dryness. The residue was partitioned between water (10 mL), ethyl 
acetate (100 mL) and ether (100 mL). Cone. H2S04 (8 mL) dissolved in ether (70 
mL) was added and the mixture stirred at RT for 3 h. The organic layer was 
separated, dried (Na2S04) and evaporated to obtain the epoxide as a white powder 
(9.0 g). 
lR NMR (Acetone-d6, 400 MHz): 5 1.58 (s, 3 H), 3.84 (s, 1 H). 
Step 2. Dimethyl trans-epoxymethylsuccinate. S02C12 (5.6 mL, 75.3 
mmol) was added to a solution of the epoxide (5 g, 34.2 mmol) in anhydrous 
MeOH (50 mL) at 0 °C and the mixture stirred at RT for 8 h. The reaction mixture 
was concentrated in vaccuo and the residue partitioned between ether and sat. aq. 
NaHC03. The ether layer was separated, dried and evaporated to afford the 
dimethyl ester (5.2 g) which was used directly for the next reaction. 
XH NMR (CDC13, 400 MHz): 8 1.63 (s, 3 H), 3.79, (s, 3 H), 3.83 (m, 4 H). 
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Step 3. 2-Methyl-5-oxo-tetrahydrofuran-2,3,4-tricarbomethoxytetra-
hydrofuran. Sodium metal (0.69 g, 28.7 mmol) was added to previously cooled 
anhydrous MeOH (15 mL) under argon atmosphere at 0 °C stirring until the metal 
had dissolved. Dimethyl malonate (3.2 mL, 28.7 mmol) was added to the sodium 
methoxide thus formed and the resulting mixture stirred at RT until a white 
precipitate formed (20-30 min). Epoxide obtained in step II (5.0 g, 28.7mmol) 
was added and the mixture stirred for 3 days at RT. Cone. HC1 was added and the 
stirring continued for another 2 h. The solid formed (NaCl) was filtered, the 
filtrate concentrated to afford crude lactone which was direcly used for the next 
reaction. 
Step 4. 2-Methyl-5-oxo-tetrahydrofuran-2,3-dicarboxylic acid. To the 
crude furan obtained (1.5 g) was added 6 N HC1 (50 mL) and the mixture refluxed 
for 3 h. The reaction mixture was concentrated and to remove traces of HC1 the 
residue was redissolved in water and evaporated. The brown residue thus obtained 
was dissolved in water and treated with activated charcoal at 60 °C. After 30 min, 
the mixture was filtered and the filtrate evaporated to afford colourless crude 
lactone. 
lH NMR (Acetone-d6, 400 MHz): 8 1.78 (s, 3 H), 2.78 - 2.84 (m, 1 H), 3.02 -
3.08 (m, 1 H), 3.60-3.63 (m, 1 H), 11.61 (S, 2H). 
Step 5. Methyl Isocitrate. Water (10 mL) and NaOH (0.95g, 23.9 mmol) 
were added to the compound obtained in the previous step (1.5 g) and the mixture 
heated at 80 °C. At the end of 12 h, the solution was neutralised with Amberlite 
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H + resin at p H 7. After the removal of the solvent, the residue was redissolved in 
10 mL of water and treated with activated charcoal. The mixture was filtered and 
the filtrate evaporated to afford the methyl isocitrate. 
!H NMR (D20, 400 MHz): 8 1.32 (s, 3 H), 2.55-2.67 (m, 2 H), 3.14-3.16 (m, 1 H). 
12.7.5. Southern Blots. -2 |ig of genomic DNA from the different strains 
analyzed were digested with restriction enzymes (NEB), separated in 1% TBE 
agarose gels, denatured with 0.5 NaOH, transferred to Hybond N membrane 
(Amersham Labs.), and probed with inserts/PCR products from appropriate 
plasmids/genomic DNA, labeled with 32P using a random priming labeling kit 
(Boehringer Mannheim). Stringent conditions were used for hybridization (2 h at 
65° C) and washings (20 min in 2X SSC, 0.1%(w/v) SDS at RT; 2X 15 min in IX 
(1st) and 0.1X (2nd) SSC, 0.1% (w/v) SDS at 65° in rolling in oven). Specific 
hybridization was detected by autoradiography. 
12.8. Computer modeling and bioinformatics 
12.8.1. Sequence Alignments. Guide tree of isocitrate lyases amino acid 
sequences generated using Vector NTI Advance 9.0 AlignX, which uses the 
Clustal W algorithm (Thompson et ah, 1994) to create an alignment from which a 
tree is generated using the Neighbor Joining method (Saitou & Nei, 1987). 
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12.8.2. Bioinformatics and modeling. Nucleotide sequences of /c/7 (MT0483) 
and icll (MT1966) ('http://www.tigr.org) were conceptually translated; protein 
domains were identified with Pfam (http://www.sanger.ac.uk/Software/Pfam/) and 
domain alignments were generated with CDD vl.62 (NCBI). Protein sequences 
were aligned with PSI-BLAST (NCBI), and an ICL2 structure model.was 
generated with MODELLER (http://salilab.org/modeller/modeller.html) by 
threading on the structures of ICL1 (Sharma et al. 2000) and A. nidulans ICL 
(Britton et al. 2000). 
12.8.3. Static and dynamic models of host-pathogen equilibrium. A simple in 
silico model of in vivo bacterial growth dynamics and host-pathogen equilibrium 
was generated using Microsoft Excel (spreadsheet available upon request). 
Figures referred to in this section are those in chapter 5. The following input 
parameters were selected for generating the curves depicted in Fig. 5.1: inoculum 
= 200 CFU; acute phase = 0-2 wk post-infection; chronic phase = 2-16 wk post-
infection; replication rate (population doubling time) during acute phase growth = 
24.6 h. These input parameters were selected in order to match the experimentally 
determined parameters shown in Fig. 5.2A, but the model will accommodate any 
set of input parameters. In our model (Fig. 5.1), the curves depicting viable CFU 
incorporate the potentially bactericidal impact of the immune response by 
calculating pre- and post-killing CFU values on a daily basis. Different types of 
equilibria (from fully static to fully dynamic or semi-dynamic scenarios) can be 
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modeled by varying the growth rate and the killing rate during the chronic phase 
of infection; in our specific case, the chronic phase was defined as 2-16 wk post-
infection, although these parameters can also be varied as appropriate. "Pre-
killing" CFU values (CFUpre) on each successive day were calculated according 
to the formula CFUpre = CFUi«eK-T, where CFUi is the number of CFU on the 
preceding day (postkilling), K is the growth rate constant (in d-1) before 
adjustment for host-mediated killing, and T = 1 d. "Post-killing" CFU values 
(CFUpost) on each successive day were calculated according to the formula 
CFUpost = CFUi»eK'«T, where CFUi is the number of CFU on the preceding day 
(postkilling), K' is the growth rate constant (in d-1) after adjustment for immune-
mediated killing, and T = 1 d. The "static" scenario (Fig. 5.1 A) was modeled by 
setting K at 0 d-1 (^doubling time) during the chronic phase of infection (2-16 w). 
The "dynamic" scenario (Fig. 5.IB) was modeled by setting K at 0.6764 d-1 (24.6 
h doubling time, identical to the acute-phase rate). The "partially dynamic" 
scenarios, with bacterial cell division rates reduced by 50% (Fig. 5.1C) or 90% 
(Fig. 5.ID) compared to the acute-phase rate, were modeled by setting K at 0.3382 
d-1 (49.2 h) or 0.0676 d6 (246.0 h), respectively. For illustrative purposes, the 
curves in Fig. 5.1 were generated by setting K' = 0 during the chronic phase of 
infection (2-16 w) in order to maintain a stable plateau in CFU numbers; more 
complex scenarios (rising or falling CFU over time) can be modeled by 
independently varying K and K' (as in Fig. 5.2A). Numbers of total chromosome 
equivalents (tCEQ) on each successive day were calculated by summing the CEQ 
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from viable bacteria (vCEQ) with those from dead bacteria (dCEQ), according to 
the formula tCEQ = vCEQ + dCEQ, where vCEQ = CFUpost, and dCEQ = Sum 
of (CFUpre - CFUpost) for each successive day inclusive of the current day. The 
chromosomal ploidy of M. tuberculosis under different growth conditions is 
unknown; in M. tuberculosis-infected mice the experimentally determined 
bacterial CEQ/CFU ratio at 2 wk post-infection is typically 1-3 (Fig. 5.2, 5.3, and 
5.4; our unpublished results). For illustrative purposes, a ploidy value of 2 was 
arbitrarily used to generate the curves in Fig. 5.1 in order to avoid overlap of the 
CFU and CEQ curves in Fig. 5.1 A. The ploidy value was conservatively set at 1 
for the modeled curves depicted in Fig. 5.2A; higher ploidy values would lead to a 
more rapid divergence of the CEQ and CFU curves. 
12.9. Statistical analysis 
Data are represented as means; error bars indicate standard deviations from 
the means. Student's Mest (two-tailed) was used to evaluate differences in 
bacterial CFU and CEQ obtained from infected mouse lungs or from in silico 
modeling. Trendlines were computed using the least-squares method. 
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